Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 1 of 131 
 
 1 TITLE  
 
A Phase 3, Twelve -week, Multi -Center, Multinational, 
Randomized, Double -Blind, Double -Dummy, Parallel Group 
Study to Determine the Efficacy , Safety and Tolerability of 
P2B001 Once Daily Compared to its Individual Components 
in Subjects With Early Parkinson’ s Disease and to a 
Calibration Arm of Pramipexole ER.  
 
 
 
 
Protocol Number  P2B001/00 3 
Version  3.0 
Version Date   18 November  2020  
Clinical Phase  Phase 3 
Sponsor  Pharma Two B, 3 Pek eris st. Weizmann 
Science Park Rehovot 7 670203  Israel .  
Tel: +972 -8-9472672  
Sponsor representative  David S. Tierney  M.D, CEO , 3 Pek eris st. 
Weizmann Science Park Rehovot 7670203  
Israel  
CRO  PRA Health Science , 4130 ParkLake 
Avenue - Suite 400 , Raleigh, North Carolina 
27612, USA  
 
 
 
CONFIDENTIAL  
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 2 of 131 
 
 The information in this document is considered privileged and confidential, and may not be 
disclosed to others except to the extent necessary to obtain Institutional Review 
Board/Ethics Committee approval, informed consent and the approval of local regulatory 
authorities as required by local law.  
 
 
 
PROTOCOL SIGNATURE SHEET  
 
 
 
 
 
 
  

Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 3 of 131 
 
 Study sites and I nvestigators  
 
Site #  PI Site name  Site location  
101 David Kreitzman  Parkinson's Disease and Movement 
Disorders Center of Long Island  Commack NY  
USA 102 Ramon Gil  Parkinson's Disease Treatment Center 
of South West Florida  Port Charlotte FL  
103 J. Antonelle de Marcaida  David and Rhoda Chase Family 
Movement Disorders Center  Vernon CT  
106 Marie Saint -Hilaire  Boston University Medical Center  Boston MA  
107 Stuart Isaacson  Parkinson's Disease and Movement 
Disorders Center of Boca Raton  Boca Raton FL  
111 Rajesh Pahwa  University of Kansas Medical Center -
Landon Center on Aging  Kansas City KS  
113 Robert Hauser  University of South Florida  Tampa FL  
115 John Morgan  Augusta University  Augusta GA  
120 Lawrence Elmer  University of Toledo, Gardner -
McMaster Parkinson Center  Toledo OH  
123 Aikaterini Kompoliti  Rush University Medical Center  Chicago IL  
124 Andrew Duker  University of Cincinnati  Cincinnati OH  
125 Sotirios Parashos  Struthers Parkinson's Center  Golden Valley MN  
127 Mark Lew  Keck School of Medicine  Los Angeles CA  
128 Andrew McGarry  Cooper University Health Care  Camden NJ  
129 John Goudreau  Michigan State University  East Lansing  
130 Rebecca Thompson  Dartmouth -Hitchcock Medical Center  Lebanon NH  
131 George Ross  VA Pacific Islands Health Care System  Honololu HI  
132 Padraig O'Suilleabhain  University of Texas Southwestern 
Medical Center - Neurology Clinic  Dallas TX  
133 Susan Criswell  Washington University School of 
Medicine  St. Louis MO              
134 Shyamal Mehta  Mayo Clinic, Scottsdale Arizona  Scottsdale AZ  
135 Virgilio Evidente  Movement Disorders Center of Arizona  Scottsdale AZ  
136 Martha McGraw  Central DuPage Hospital  Winfield IL  
137 Henry Moore  University of Miami Health System at 
Boca Raton  Boca Raton FL  
138 Carlos Singer  University Of Miami  Miami FL  
140 Zain Guduru  University of Kentucky Health Care  Lexington KY  
141 Philip Hanna  JFK Medical Center - The Neuroscience 
Institute  Edison NJ  
142 Rohit Dhall  University of Arkansas for Mediclal 
Sciences  Little Rock AR  
143 Sulada Kanchana  / 
Dragos Mihaila  State University of New York Upstate 
Medical University  Syracuse NY  
144 Thyagarajan 
Subramanian  Penn State Health Milton S. Hershey 
Medical Center  Hershey PA  
145 Madhavi Thomas  North Texas Movement Disorders 
Institute  Bedford TX  
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 4 of 131 
 
 Site #  PI Site name  Site location  
146 David Charles  Vanderbilt Neuroscience Institute  Nashville TN  
148 Thomas Guttuso, Jr.  University at Buffalo Neurology  Williamsville NY  
149 Gerald Calegan  The NeuroMedical Center  Baton Rouge LA  
150 Rajeev Kumar  Rocky Mountain Movement Disorders 
Center  Englewood CO  
152 James Patton  Asheville Neurology Specialists  Asheville NC  
153 Mark Baron  Hunter Holmes McGuire Veterans 
Affairs Medical Center  Richmond VA  
154 Andrew Keegan  Roskamp Institute  Sarasota FL  
155 Fredy Revilla  Greenville Health System  Greenville SC  
156 Winona Tse  Icahn School of Medicine at Mount 
Sinai  New York NY  
157 Daniel Burdick  Booth Gardner Parkinson's Care Center  Kirkland WA  
158 Ramsey Falconer  Inova Neuroscience Research  Falls Church VA  
160 Ivan Bodis -Wollner / 
Daphne Robakis  SUNY Downstate Medical Center  Brooklyn NY  
161 Odinachi Oguh / Natalya 
Schneyder  UF Health Neurology – Jacksonville  Jacksonville FL  
162 Peter LeWitt  Henry Ford West Bloomfield Hospital  West Bloomfield MI  
163 Sarah Pirio Richardson  Raymond G. Murphy VA Medical Center  Albuquerque NM  
164 Mark LeDoux  Wesley Neurology Clinic  / Veracity 
Neuroscience  Memphis TN  
202 Susan Fox  Movement Disorders Centre Toronto 
Western Hospital  Toronto, Ontario  
Canada  
203 Barbara Connolly  Hamilton General Hospital  Hamilton, Ontario  
401 Heinz Reichmann  Universitätsklinikum Dresden  Dresden, Sachsen  
Germany  402 Jost-Julian Rumpf  Universitätsklinikum Leipzig  Leipzig, Sachsen  
403 Reinhard Ehret  Praxis für Neurologie und Psychiatrie  Berlin, Berlin  
404 Siegfried Muhlack  Sankt Josef -Hospital  Bochum, Nordrhein -
Westfalen  
405 Johannes Schwarz  Klinik Haag  Haag, Bayern  
406 Tobias Warnecke  Universitätsklinikum Münster  Münster, Nordrhein -
westfalen  
407 Bernhard Haslinger  Technischen Universität München  München, Bayern  
408 Michel Rijntjes  Universitätsklinikum Freiburg  Freiburg, Baden -
Wuerttemberg  
409 Sven Thonke  Klinik für Neurologie  Hanau, Hesse  
410 Jan Kassubek  Universitätsklinikum Ulm  Ulm,  Baden -
Wuerttemberg  
412 Christian Oehlwein  Praxis für Bewegungsstörungen und 
Parkinson  Gera, Thueringen  
455 Bettina Wieder  Curiositas ad sanum  München , Bayern   
501 Alvaro Sanchez Ferro  HM Centro Integral de Neurociencias 
(CINAC)  Mostoles, MD  Spain  
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 5 of 131 
 
 Site #  PI Site name  Site location  
503 Jaime Kulisevsky Bojarski  Private Foundation Hospital de la Santa 
Cruz and San Pablo  Barcelona, CT  
504 Maria Cruz Rodríguez 
Oroz  
  Clinica Universidad de Navarra  Pamplona, Navarra  
544 Clinica Universidad de Navarra Madrid  Madrid, MD  
505 Ernest  Balaguer  Hospital Universitari General de 
Catalunya  Sant Cugat del 
Vallés, Barcelona  
506 Pedro García -Ruíz  Hospital Universitario Fundación 
Jiménez Díaz  Madrid, MD  
507 Joan Carlos Martínez 
Castrillo  Hospital Universitario Ramon y Cajal 
Farmacia  Madrid, MD  
509 Gurutz Linazasoro 
Cristobal  Policlinica Gipuzkoa  Donostia, Guipuzcoa  
510 Jorge Hernandez -Vara  Hospital Universitari Vall d'Hebrón  Barcelona, CT  
511 Exuperio Diez -Tejedor  Hospital Universitario La Paz  Madrid, MD  
512 Pilar Sánchez Alonso  Hospital Universitario Puerta de Hierro 
- Majadahonda  Majadahonda, MD  
 
 
 
  
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 6 of 131 
 
 TABLE OF CONTENTS  
1 TITLE  ................................ ................................ ................................ ................................ ...............................  1 
2 SYNOPSIS  ................................ ................................ ................................ ................................ ......................  14 
3 INTRODUCTION  ................................ ................................ ................................ ................................ .........  27 
3.1 BACKGROUND  ................................ ................................ ................................ ................................ ............  27 
3.2 PRECLINICAL PHARMACOLOGY STUDIES  ................................ ................................ ................................ .... 29 
3.3 TOXICOLOGY STUDIES  ................................ ................................ ................................ ................................  29 
3.4 CLINICAL STUDIES  ................................ ................................ ................................ ................................ ...... 29 
3.5 SUMMARY OF NON-CLINICAL AND CLINICAL STUDIES  ................................ ................................ ...............  31 
4 STUDY OBJECTIVES  ................................ ................................ ................................ ................................ . 32 
4.1 PRIMARY OBJECTIVE  ................................ ................................ ................................ ................................ .. 32 
4.2 SECONDARY OBJECTIVES  ................................ ................................ ................................ ...........................  33 
4.3 EXPLORATORY OBJECTIVES : ................................ ................................ ................................ ......................  33 
4.4 SAFETY & TOLERABILITY OBJECTIVES  ................................ ................................ ................................ ....... 34 
5 INVESTIGATIONAL PRODUCT ................................ ................................ ................................ ...............  34 
5.1 DOSAGE  ................................ ................................ ................................ ................................ ......................  35 
5.2 DOSE MODIFICATION  ................................ ................................ ................................ ................................ .. 35 
5.3 METHOD OF ADMINISTRATION & MEALS  ................................ ................................ ................................ ... 36 
6 STUDY DESIGN  ................................ ................................ ................................ ................................ ...........  36 
6.1 OVERALL STUDY DESIGN AND PLAN DESCRIPTION  ................................ ................................ ....................  36 
6.2 RATIONALE FOR STUDY DESIGN , STUDY POPULATION AND DOSES  ................................ .............................  39 
7 STUDY POPULATION  ................................ ................................ ................................ ................................  40 
7.1 NUMBER OF SUBJECTS  ................................ ................................ ................................ ................................  40 
7.2 SUBJECTS ENROLMENT  ................................ ................................ ................................ ...............................  40 
7.3 INCLUSION CRITERIA  ................................ ................................ ................................ ................................ .. 40 
7.4 EXCLUSION CRITERIA  ................................ ................................ ................................ ................................ . 41 
7.5 EARLY DISCONTINUATION SUBJECTS  ................................ ................................ ................................ .........  43 
7.6 SUBJECT REPLACEMENT  ................................ ................................ ................................ .............................  45 
8 ASSESSMENTS  ................................ ................................ ................................ ................................ .............  45 
8.1 SCHEDULE OF ACTIVITIES  ................................ ................................ ................................ ...........................  45 
8.2 EVALUATION OF PRAMIPEXOLE ER (OR PLACEBO ) DOSE ................................ ................................ ...........  45 
8.3 SAFETY AND TOLERABILITY  ................................ ................................ ................................ .......................  45 
8.3.1  Physical and Neurological Exams  ................................ ................................ ................................ .........  45 
8.3.2  Safety Laboratory Tests – see Appendix II  ................................ ................................ ............................  45 
8.3.3  ECG  ................................ ................................ ................................ ................................ .......................  46 
8.3.4  Vital Signs  ................................ ................................ ................................ ................................ ..............  46 
8.3.5  Concomitant Medications  ................................ ................................ ................................ ......................  46 
8.3.6  Adverse Events  ................................ ................................ ................................ ................................ ....... 46 
8.3.7  Sleepiness  ................................ ................................ ................................ ................................ ..............  46 
8.3.8  Impulsive -Compulsive Disorders  ................................ ................................ ................................ ...........  46 
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 7 of 131 
 
 8.3.9  Suicidality  ................................ ................................ ................................ ................................ ..............  47 
8.4 EFFICACY  ................................ ................................ ................................ ................................ ...................  47 
8.4.1  UPDRS – see Appendix IX  ................................ ................................ ................................ .....................  47 
8.4.2  Clinical Global Impression - severity (CGI -S) - Appendix IV  ................................ ...............................  47 
8.4.3  Clinical Global Impression of Improvement (CGI -I) – Appendix XIV  ................................ ..................  48 
8.4.4  Quality of Life PDQ39 – Appendix X  ................................ ................................ ................................ .... 48 
8.4.5  Health -Related Quality of Life (HRQOL) SF -12v2 questionnaire  – Appendix VII  ...............................  48 
8.5 COMPLIANCE  ................................ ................................ ................................ ................................ ..............  49 
8.5.1  Study Compliance  ................................ ................................ ................................ ................................ .. 49 
8.6 SCREENING EVALUATIONS  ................................ ................................ ................................ .........................  49 
9 STUDY CONDUCT ................................ ................................ ................................ ................................ ....... 50 
9.1 STUDY PERIOD  ................................ ................................ ................................ ................................ ............  50 
9.2 STUDY PROCEDURES  ................................ ................................ ................................ ................................ .. 50 
9.2.1  Detailed Study Plan  ................................ ................................ ................................ ...............................  50 
9.2.2  Visit 1 - Screening Visit  ................................ ................................ ................................ .........................  50 
9.2.3 Visit 2 - Baseline  ................................ ................................ ................................ ................................ .... 51 
9.2.4  Visit 3  ................................ ................................ ................................ ................................ .....................  52 
9.2.5  Week 4 Phone Call  ................................ ................................ ................................ ................................  52 
9.2.6  Visit 4  ................................ ................................ ................................ ................................ .....................  52 
9.2.7  Visit 5  ................................ ................................ ................................ ................................ .....................  53 
9.2.8  Visit 6 – Treatment Termination  ................................ ................................ ................................ ............  53 
9.2.9  Visit 7 – Safety Follow Up  ................................ ................................ ................................ .....................  54 
9.2.10  Unscheduled Visits  ................................ ................................ ................................ ............................  54 
9.2.11  Early Treatment/Study Termination Visit  ................................ ................................ ..........................  55 
10 CONCOMITANT MEDICATIONS  ................................ ................................ ................................ ............  55 
10.1 PROHIBITED MEDICATION  ................................ ................................ ................................ ..........................  56 
10.2 DIETARY RESTRICTIONS  ................................ ................................ ................................ .............................  57 
10.3 RESCUE THERAPY  ................................ ................................ ................................ ................................ ....... 57 
11 LABORATORIES  ................................ ................................ ................................ ................................ .........  57 
11.1 SAFETY LABORATORY TESTS ................................ ................................ ................................ .....................  57 
11.2 VITAL SIGNS, HEIGHT AND WEIGHT  ................................ ................................ ................................ ...........  58 
11.3 ELECTROCARDIOGRAMS (ECG)  ................................ ................................ ................................ ..................  59 
12 STUDY DRUGS SUPPLY  ................................ ................................ ................................ ............................  59 
12.1 DRUG MANUFACTURING  ................................ ................................ ................................ ............................  59 
12.2 TREATMENT ASSIGNMENT AND RANDOMIZATION  ................................ ................................ ......................  59 
12.3 PACKAGING AND LABELING  ................................ ................................ ................................ .......................  60 
12.4 DISTRIBUTION AND SHIPMENT  ................................ ................................ ................................ ....................  64 
12.5 STORAGE , DISPENSING AND RETURN  ................................ ................................ ................................ ..........  64 
12.6 VERIFICATION OF COMPLIANCE WITH TREATMENT REGIMEN  ................................ ................................ .... 65 
12.7 ACCOUNTABILITY  ................................ ................................ ................................ ................................ ....... 65 
12.8 STUDY END ................................ ................................ ................................ ................................ ................  66 
12.9 BLINDING  ................................ ................................ ................................ ................................ ...................  66 
12.9.1  Emergency Code Breaking  ................................ ................................ ................................ ................  66 
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 8 of 131 
 
 13 SAFETY/ADVERSE EVENTS  ................................ ................................ ................................ ....................  66 
13.1 ADVERSE EVENTS DEFINITION  ................................ ................................ ................................ ....................  66 
13.2 AE CAUSALITY DEFINITIONS  ................................ ................................ ................................ ......................  67 
13.3 REPORTING ORTHOSTATIC HYPOTENSION AS AE ................................ ................................ .......................  68 
13.4 SERIOUS ADVERSE EVENT (SAE)  ................................ ................................ ................................ ...............  69 
13.5 SAE  REPORTING  ................................ ................................ ................................ ................................ .........  69 
13.6 PREGNANCY  ................................ ................................ ................................ ................................ ...............  71 
13.7 SUSPECTED UNEXPECTED SERIOUS ADVERSE REACTION (SUSAR)  ................................ ...........................  71 
14 DATA MANAGEMENT AND QUALITY ASSURANCE  ................................ ................................ ........  71 
14.1 HANDLING OF DATA ................................ ................................ ................................ ................................ ... 71 
14.2 CODING OF ADVERSE EVENTS , DRUGS AND DISEASES  ................................ ................................ ...............  72 
14.3 DATA QUALITY ASSURANCE  ................................ ................................ ................................ ......................  72 
15 STATISTICAL METHODOLOGY ................................ ................................ ................................ .............  72 
15.1 SAMPLE SIZE RATIONALE  ................................ ................................ ................................ ...........................  72 
15.2 SAMPLE SIZE RE-ASSESSMENT  ................................ ................................ ................................ ...................  73 
15.3 RANDOMIZATION  ................................ ................................ ................................ ................................ ........  74 
15.4 DATA ANALYSES SETS ................................ ................................ ................................ ...............................  74 
15.5 OVERALL SIGNIFICANCE LEVEL  AND MULTIPLICITY ADJUSTMENT : ................................ ...........................  75 
15.6 STUDY POPULATION SUMMARY  ................................ ................................ ................................ .................  76 
15.6.1  Subject Disposition  ................................ ................................ ................................ ............................  76 
15.6.2  Study Inclusion and Exclusion Criteria  ................................ ................................ .............................  76 
15.6.3  Demographics an d Baseline Characteristics  ................................ ................................ ....................  76 
15.6.4  Medical History  ................................ ................................ ................................ ................................ . 76 
15.6.5  Prior and Concomitant Medications  ................................ ................................ ................................ . 77 
15.6.6  Protocol Violations/Deviations  ................................ ................................ ................................ .........  78 
15.6.7  Efficacy Endpoints and Analyses  ................................ ................................ ................................ ...... 78 
15.6.8  Primary Efficacy Endpoint and Principal Statistical Analysis  ................................ ..........................  78 
15.6.9  Sensitivity Analyses for the Primary Endpoint  ................................ ................................ ..................  79 
15.6.10  Key Secondary Efficacy Endpoints and Analyses ................................ ................................ ..............  81 
15.6.11  The exploratory endpoints to be analyzed are:  ................................ ................................ .................  83 
15.7 SAFETY ASSESSMENTS  ................................ ................................ ................................ ...............................  84 
15.7.1  Adverse Events  ................................ ................................ ................................ ................................ .. 84 
15.7.2  Laboratory Tests  ................................ ................................ ................................ ...............................  85 
15.7.3  Vital Signs  ................................ ................................ ................................ ................................ .........  86 
15.8 ECG  ................................ ................................ ................................ ................................ ...........................  86 
15.9 COLUMBIA SUICIDE SEVERITY RATING SCALE (CSSRS)  ................................ ................................ ............  86 
15.10  TOLERABILITY ASSESSMENTS  ................................ ................................ ................................ ................  87 
15.11  EXPLORATORY SAFETY ENDPOINT  ................................ ................................ ................................ .........  87 
15.12  SAFETY ASSESSMENT SCALES  ................................ ................................ ................................ .................  87 
15.13  STATISTICAL ANALYSIS PLAN (SAP ) ................................ ................................ ................................ ..... 87 
16 STUDY PERSONNEL  ................................ ................................ ................................ ................................ .. 88 
16.1 STUDY SITE ................................ ................................ ................................ ................................ ................  88 
16.1.1  The Principal Investigator  ................................ ................................ ................................ ................  88 
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 9 of 131 
 
 16.1.2  The Clinical Coordinator or designee  ................................ ................................ ...............................  88 
16.2 THE SPONSOR  ................................ ................................ ................................ ................................ .............  89 
16.3 CRO  ................................ ................................ ................................ ................................ ...........................  89 
16.3.1  CRO Clinical Trials Manager  ................................ ................................ ................................ ...........  90 
16.3.2  Statistics and Data Management Centers (S&DM)  ................................ ................................ ..........  90 
16.3.3  Medical Monitor  ................................ ................................ ................................ ................................  90 
16.3.4  Local Clinical Trial Manager (LCTM)  ................................ ................................ .............................  90 
16.3.5  Clinical Research Associate  ................................ ................................ ................................ ..............  90 
16.4 STUDY COMMITTEES  ................................ ................................ ................................ ................................ .. 91 
16.4.1  Data & Safety Monitoring Board (DSMB)  ................................ ................................ ........................  91 
16.4.2  Subject Central Eligibility Monitoring Committee (EMC)  ................................ ................................  91 
17 REGULATORY AND ETHICAL ISSUES  ................................ ................................ ................................ . 91 
17.1 COMPLIANCE WITH REGULATIONS APPLICABLE TO CLINICAL TRIALS  ................................ .......................  91 
17.2 INFORMED CONSENT  ................................ ................................ ................................ ................................ .. 91 
17.3 ETHICS COMMITTEE (EC)  / INSTITUTIONAL REVIEW BOARD (IRB)  ................................ ............................  92 
17.4 PROTOCOL AMENDMENTS  ................................ ................................ ................................ ..........................  92 
17.5 SUBJECT CONFIDENTIALITY ................................ ................................ ................................ ........................  92 
17.6 LIABILITY AND INSURANCE  ................................ ................................ ................................ ........................  93 
18 DOCUMENTATION  ................................ ................................ ................................ ................................ .... 93 
18.1 STUDY FILE AND SITE DOCUMENTS  ................................ ................................ ................................ ............  93 
18.2 SITE DOCUMENTS /EQUIPMENT SUPPLIED BY THE SPONSOR  ................................ ................................ ....... 93 
18.3 MAINTENANCE AND RETENTION OF RECORDS  ................................ ................................ ............................  94 
18.4 DATA HANDLING  ................................ ................................ ................................ ................................ ........  95 
18.4.1  Source Documents  ................................ ................................ ................................ .............................  95 
19 STUDY MONITORING  ................................ ................................ ................................ ...............................  96 
19.1 MONITORS AND MONITORING VISITS  ................................ ................................ ................................ .........  96 
19.2 PRIMARY SOURCE DOCUMENTS  ................................ ................................ ................................ .................  96 
20 USE  OF INFORMATION AND PUBLICATION  ................................ ................................ .....................  97 
20.1 CONFIDENTIAL INFORMATION  ................................ ................................ ................................ ....................  97 
21 INVESTIGATOR AGREEMENT  ................................ ................................ ................................ ...............  98 
22 APPENDICES  ................................ ................................ ................................ ................................ ................  99 
22.1 APPENDIX I: SCHEDULE OF ACTIVITIES : ................................ ................................ ................................ ..... 99 
22.2 APPENDIX II: LABORATORY TESTS  ................................ ................................ ................................ ...........  102 
22.3 APPENDIX III: THE EPWORTH SLEEPINESS SCALE (ESS)  ................................ ................................ ..........  103 
22.4 APPENDIX IV: CLINICAL GLOBAL IMPRESSION - SEVERITY  ................................ ................................ ...... 104 
22.5 APPENDIX V: OHAS  QUESTION 1 (KAUFMANN H, 2012)  ................................ ................................ .........  105 
22.6 APPENDIX VI: QUESTIONNAIRE FOR IMPULSIVE -COMPULSIVE DISORDERS IN PARKINSON ’S DISEASE 
RATING SCALE (QUIP -RS) ................................ ................................ ................................ ................................ .... 106 
22.7 APPENDIX VII:  HEALTH -RELATED QUALITY OF LIFE (HRQOL)  SF-12V2 ................................ ...............  108 
22.8 APPENDIX VIII:  COLUMBIA SUICIDE SEVERITY RATING SCALE (CSSRS)  ................................ ................  111 
22.9 APPENDIX IX: UPDRS   (FAHN S, 1987)  ................................ ................................ ................................ ... 115 
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 10 of 131 
 
 22.10  APPENDIX X: QUALITY OF LIFE - PDQ39  ................................ ................................ .............................  124 
22.11  APPENDIX XI : UK PARKINSON 'S DISEASE SOCIETY BRAIN BANK CLINICAL DIAGNOSTIC CRITERIA   
(HUGHES AJ, 1992)  ................................ ................................ ................................ ................................ ...............  126 
22.12  APPENDIX XII:  MODIFIED HOEHN & YAHR SCALE  ................................ ................................ ...............  126 
22.13  APPENDIX XIII:  MINI-MENTAL STATE EXAMINATION (MMSE)  ................................ ..........................  128 
22.14  APPENDIX XIV:  CLINICAL GLOBAL IMPRESSION - IMPROVEMENT  ................................ .......................  129 
23 REFERENCES  ................................ ................................ ................................ ................................ ............  130 
  
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 11 of 131 
 
 LIST OF ABBREVIATIONS  
Abbreviation  Description  
6-OHDA  6-hydroxydopamine  
UPDRS ADL  Activities of Daily Living  
ADR  Adverse Drug Reaction  
AE Adverse Event  
AR Autoregressive  
AUC  Area under the plasma concentration versus time curve  
Bid Twice per day  
BP Blood Pressure  
CBC  Complete Blood Count  
CGI-S Clinical Global Impression  - Severity  
CGI-S Clinical Global Impression - Improvement  
CGR  Country or Geographical Region  
Cmax  Maximum plasma concentration  
CNS  Central Nervous System  
CO Complete Analysis Set  
CR Controlled Release  
CRA  Clinical Research Associate  
CRF  Case Report Form  
CRO  Clinical Research Organization  
CS Compound Symmetry  
CSH  Heterogeneous Compound Symmetry  
CSSRS  Columbia Suicide Severity Rating Scale  
DSMB  Data Safety Monitoring Board  
EC Ethics Committee  
ECG  Electrocardiogram  
EDC  Electronic Data Capture  
EMC  Eligibility Monitoring Committee  
ER Extended Release  
ESS Epworth Sleepiness Scale  
EST Early Study Termination  
ETT Early Treatment Termination  
FDA  Food and Drug Administration  
G Gram  
GCP  Good Clinical Practice  
GDNF  Glial cell -line derived neurotrophic factor  
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 12 of 131 
 
 Abbreviation  Description  
DSMC  Data & safety Monitoring Committee  
GI Gastrointestinal  
GLP  Good Laboratory Practice  
H&Y  Hoehn and Yahr  
HR Heart Rate  
hr(s)  Hour(s)  
ICH International Conference on Harmonization  
IMP Investigational Medicinal Product  
IR Immediate Release  
IRB Institutional Review Board  
ITT Intent to Treat  
kel Elimination rate constant  
Kg Kilogram  
LCTM  Local Clinical Trial Manager  
L-DOPA  Levodopa  
LSM  Least Square Means  
M Meter  
MAO  Mono Amine Oxidase  
max Maximum  
MedDRA  Medical Dictionary for Regulatory Activities  
Mg Milligram  
min Minute or Minimum  
mITT  Modified Intent to Treat  
Ml Milliliter  
ML Maximum -Likelihood  
MMSE  Mini Mental State Exam  
MPTP  (1-methyl -4-phenyl -1,2,3,6 -tetrahydropyridine  
Ms Millisecond  
N/A Not Applicable  
ºC Degrees centigrade  
PD Parkinson’s Disease  
PDQ39  Parkinson’s Disease Questionnaire 39  
PI Principle Invest igator  
PK Pharmacokinetics  
PP Per Protocol  
 PT Preferred Term   
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 13 of 131 
 
 Abbreviation  Description  
PPX Pramipexole  
QA Quality Assurance  
Qid Four times per day  
QUIP -RS Questionnaire for Impulsive -Compulsive Disorders in 
Parkinson's Disease  – Rating Scale  
RAF  Randomization Authorization Form  
RAS  Rasagiline  
REML  Restricted ML  
RR Respiratory Rate  
RTSM  Randomization Trial Supply Management  
SAE  Serious Adverse Event  
SD Standard Deviation  
SOC  System Organ Class  
SUSAR  Suspected Unexpected Serious Adverse Reaction  
T½ Elimination half -life 
TEAEs  Treatment Emergent Adverse Events  
Tid Three times daily  
Tmax  Time at which Cmax occurs  
TMF  Trial Master File  
U Unit 
UK United Kingdom  
UPDRS  Unified Parkinson's Disease Rating Scale  
WHO  World Health Organization  
 
  
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 14 of 131 
 
 2 SYNOPSIS  
 
Name of Sponsor/Company: Pharma Two B 
Name of Product: P2B001, Pramipexole  0.6 mg /Rasagiline 0.75 mg Once Daily (P2B 001 
0.6/0.75 mg)  
Name of Active Ingredient:  Pramipexole, Rasagiline  
Title of study: A Phase 3, Twelve -week, Multi -Center, Multinational, Randomized, Double -
Blind, Double -Dummy, Parallel Group Study to Determine the  Efficacy , Safety  and Tolerability 
of P2B001 Once Daily Compared to its Individual Components in Subjects with Early 
Parkinson’s Disease and to a Calibration Arm of  Pramipexole ER.  
Study  Sites:  
Approximately 70 sites in the United States, Canada, and Europe  will be participa ting in the 
study.  
Planned Study Duration  
16 – 22 months  from first patient in until database lock.  
Planned first patient in: December  2017  Development Phase:  
Phase 3  
Objectives:  
Primary objective:  
To determine the superiority  of P2B 001 0.6/0.75 mg as compared to its individual components in 
the change  of total UPDRS score (defined as sum of parts II and III, scores (0 -160).  
Secondary objectives:  
• To determine the superiority of P2B 001 0.6/0.75  mg as compared to pramipexole ER  in the 
change  of Epworth Sleepiness Scale (ESS)  score .  
• To determine the efficacy of P2B 001 0.6/0.75 mg as compared to its individual components in 
the c hange of Total PDQ39  score . 
• To determine the efficacy of P2B 001 0.6/0.75 mg as compared to its individual components in 
the c hange of ADL UPDRS (part II) score.  
• To determine th e efficacy of P2B 001 0.6/0.75 mg as compared to its individual components in 
the c hange of motor UPDRS (part III) score.  
• To determine the efficacy of P2B 001 0.6/0.75 mg as compared to its individual components in 
the CGI-S responder ’s analysis  (change from  baseline ≥1 CGI -S points).  
Exploratory objective:  
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 15 of 131 
 
 • To evaluate the superiority  of P2B 001 0.6/0.75 mg compared to its individual components in 
the following endpoints:  
- Change  in each of the 8 PDQ39 subscales scores.  
- Change in  the score of  Health -Related Quality of Life (HRQOL) SF -12v2 questionnaire.  
- Clinical  Global Impression of Improvement (CGI -I). 
 
• To evaluate the superiority of P2B 001 0.6/0.75 mg over pramipexole ER with respect to the 
following outcome measures:  
- Proportion (%) of patie nts with ESS score >10 .  
- Proportion (%) of patients with ESS Score <10 at baseline and ESS score >10.  
- 3-Months rate of total number of adverse event s. 
- Change in the differences in systolic and diastolic blood pressure measured during supine 
and standing po sitions.   
- Proportion (%) of patients with both symptomatic/non -symptomatic Orthostatic 
Hypotension . 
- 3-Months rate of total number of both symptomatic/non -symptomatic Orthostatic 
Hypotension . 
- Proportion (%) of patients with symptomatic Orthostatic Hypotens ion. 
- 3-Months rate of total number of symptomatic Orthostatic Hypotension . 
- Proportion (%)  of patients with daytime sleepiness/drowsiness related AE’s.  
- Proportion (%)  of patients with gastrointestinal (GI) adverse events  
- Proportion (%) of patients presenting neurological adverse events  
- Change in the  score of  Orthostatic Hypotension Symptoms Assessment (OHSA) question 
1. 
 
• To descriptively evaluate the comparability of P2B001 0.6/0.75 mg with reference  to the 
calibration arm (pramipexole ER)  in total UPDRS score (defined as sum of parts II and III, 
scores (0 -160). 
 
Safety & Tolerability  Objectives : 
The safety profile of the test product and comparators will be evaluated by changes in the safety 
parameters, including adverse events, concomitant medications, vital signs, laboratory parameters, 
physical and neurological examination s, ECGs, Questionnaire fo r Impulsive -Compulsive 
Disorders in Parkinson's Disease - Rating Scale  (QUIP -RS), Columbia Suicide Severity Rating 
Scale (CSSRS) , Orthostatic Hypotension Symptoms Assessment (OHSA) question 1  and Epworth 
Sleepiness Scale (ESS).  
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 16 of 131 
 
 Tolerability will be assessed  by percentage of subjects that complete the trial on treatment 
assigned.  
Adverse events, vital signs and other safety data will be followed up by an independent Data and 
Safety Monitoring Board (DSMB).  
 
Study Design :  
This study is a phase 3, twelve -week, multi-center, multinational, randomized, double -blind, 
double -dummy, parallel group study.  
Up to 525 eligible subjects with early untreated Parkinson’s disease (PD)  who are not early 
terminated from the study during screening or baseline visits  and are randomized to treatment  
with P2B001 once daily (pramipexole 0.6 mg / rasagiline 0.75 mg), or pramipexole 0.6 mg  once 
daily  (PPX 0.6) , or rasagiline 0.75 mg once daily  (RAS 0.75) , or pramipexole ER  titrated to 
optimal dose (1.5, 3.0 or 4.5mg)  using a randomization scheme of 2:2:2:1, respectively .  
Each subject  will be asked to take one capsule and 1-3 tablet s once daily. The capsules will 
contain either P2B 001 0.6/0.7 5mg or pramipexole 0.6 mg or rasagiline 0.75 mg or matching 
placebo. The tablets will contain either pramipexole ER 0.375 mg or pramipexole ER 1.5 mg or 
matching placebo.  
 
Dosing Regimen : 
• P2B001 pramipexole dihydrochloride 0.6  mg/Rasagiline 0.75 mg Once D aily + Placebo of 
Pramipexole ER.  
• Pramipexole dihydrochloride 0.6 mg Once Daily (PPX 0.6) + Placebo of Pramipexole ER.  
• Rasagiline 0.75 mg Once Daily  (RAS 0.75 ) + Placebo of Pramipexole ER.  
• Pramipexole ER individually titrated to optim al dose  + Placebo of P2B001.  
  
Study Structure:  
• Up-titration  phase  
• Maintenance phase  
• Down -titration phase  
• Safety follow -up phase.      
 
Up-Titration phase: A 3 -6 week double blind, double dummy titration phase with pram ipexole ER 
or matching placebo. During this phase subjects will also take 1 capsule of P2B001/RAS 
0.75/PPX0.6/Placebo  which does not need titration . For the first 3 weeks t he titration  of the 
pramipexole ER  will be increase d by weekly increments up to a daily dose of 1.5 mg as follows: 
0.375, 0 .75 and 1.5 mg. If needed, between weeks 3 and 6, the titration can continue to  a daily dose 
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 17 of 131 
 
 of 3.0 mg or 4.5 mg of pramipexole ER or matching placebo or reduced to a minimum of 1.5mg 
with the final level determined based on achieving satisfactory efficacy  and tolerability. On 
completion of the dose -titration phase  (end of week 6) , the minimum therapeutic dose of 
pramipexole ER 1.5 mg per day (or placebo) must be achieved by all the patients. The treatment 
with study medications of patients who cannot achie ve this dosage will be discontinued, but the 
subject will be requested to continue with all the study visits . 
 
Study visits for the titration phase:  
Subjects will be required to visit the clinic at the end of week 3 for a titration evaluation to assess 
the subject’s satisfaction with and tolera nce to the 1.5 mg dose of pramipexole ER (or placebo). 
At this visit, the PI or sub -Investigator may choose to keep the subject at  1.5 mg or increase the 
dose to 3.0 mg . Other study activities at this visit include assessment of CSSRS and QUIP -RS and 
review of adverse events and concomitant medications .  
At the end of week 4  a phone call to the subject will be conducted by the PI or sub -Investigator  to 
assess  the subject’s satisfaction with and tolera nce to pramipexole ER (or matching placebo)  and 
the possible need for increase of the dose. If the PI or sub -Investigator deem necessary , an 
unscheduled visit for a titration evaluation may be conducted  at this tim e. At the end of week 5  
the subject will be required to visit the clinic for a full study visit. I n addition to scheduled study 
activities, the dose of pramipexole ER (or matching placebo) will be evaluated again to assess the 
subject’s satisfaction and tolerability. As per the PI ’s or sub-Investigator’s  instructions, the dose 
may remain at 4.5 mg or decreased back to 3.0 mg or even to 1.5 mg if necessary. Following the 
end of week 6 no changes in dose are allowed. This will be deemed the  maintenance dose of 
pramipexole ER or matching placebo tablets  for the rest of the study.  During all of this time the 
subjects will also take 1 capsule of P2B001/RAS 0.75/PPX0.6/Placebo which do not need 
titration . 
 
Maintenance phase: Once the final dose level has been reached for the pramipexole ER, the 
subject will continue at that dose, together with the once daily P2B001/RAS 0.75/PPX0.6/Placebo 
capsule, until the end of Week 12.  
 
Down -titration phase: a 7-day gradual down titration of pramipexole ER o r matching placebo . The 
down titration should be done by reducing the dose every two days  by half (except for subjects 
taking 4.5 mg, these should reduce the dose to 3.0 mg and then continue to reduce by half every 
two days).  No treatment with a once daily P2B001/RAS 0.75/PPX0.6/Placebo capsule  during this 
time.  
 
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 18 of 131 
 
 Safety follow -up phase: a 7 day s period of no treatment  of pramipexole ER and 14 day period of 
no treatment for the P2B001/RAS 0.75/PPX0.6/Placebo capsule .  
 
 
 
Study design scheme:  
 
*Titration phase: Subjects can stop titration of pramipexole ER or placebo at 1.5 mg or can continue 
titration and increase the dose to 3.0 or 4.5 mg as optimal dose or decrease back to 3.0 or 1.5 mg. The 
dosage level achieved at the end of the titration ph ase (end of week 6)  is then held constant during the 
maintenance phase  ending at the end of week 12 . 
Study activities:  

Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 19 of 131 
 
 Subjects will undergo visit specific study activities  at screening, baseline , end of weeks  3, 4, 5, 8, 
12/Treatment Termination and a  safety follow up at end of week 14 ( see Appendix 1, schedule  of 
activities).     
UPDRS  II +III and ESS assessment s will be conducted at the baseline visit, as well as end of 
weeks 5, 8, and 12 /Treatment Termination . UPDRS III will also be conducted at screening.    
QUIP -RS will be conducted at the baseline visit, as well as end of weeks 3, 5, 8, 12 /Treatment 
Termination  and week 14 . CSSRS will be conducted at every study visit.   
PDQ39, CGI -S and HRQOL  SF-12 v 2 scales will be conducted at baseline and end of week 
12/Treatment Termination .  
CGI-I will be performed at end of weeks 5, 8 and 12/Treatment Termination visits.  OSHA 
question 1 will be completed  at baseline and end of weeks 5, 8 and 12/Treatment Terminati on, 
only for subjects experienc ing orthostatic hypotension.  
 
Subjects will take study medications  (capsule and tablets)  by mouth with a glass of water (8oz or 
240ml) . Study medications can be taken with or without food and efforts should be made to take 
the study medications at the same time every day.   
To preserve  the blind the capsules  of once daily P2B001/RAS 0.75/PPX0.6/Placebo  will be 
visually identical.  The tablets of the pramipexole ER and their placebos will be visually identical.  
 
Number of subjects:  
Up to 525  eligible subjects with early untreated Parkinson’s disease (PD ) who are not early 
terminated from the study during screening or baseline visits  and are randomized to treatment 
with P2B 001 0.6/0.75 or pramipexole 0.6 mg once daily, or rasagiline 0.75 mg once daily, or 
pramipexole ER titrated to optimal dose  (1.5, 3.0 or 4.5mg) using a randomization scheme of 
2:2:2:1, respectively . 
Diagnosis and Criteria for Eligibility : 
Inclusion Criteria  
1. Subject is informed and given ample time and opportunity to think about his/her 
participation in this study and has given his/her written informed consent on an EC/IRB 
approved consent form.  
2. Subject is willing and able to comply with all study requirements (protocol, clinic visits, 
procedures and medication administration).  
3. Subject is male or female ≥35 .0 years of age to ≤80.0  years of age at the time of 
enrollment . 
4. Subject has Parkinson's disease consistent with the UK Brain Bank Criteria  and must have 
bradykinesia with sequence effect.  If rest tremor does not exist must have prominent 
asymmetry of motor function.  
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 20 of 131 
 
 5. Subject with disease duration less than 3 years  since diagnosis . 
6. Subject has a H&Y stage score of < 3.  
7. Subject has a MMSE scor e ≥ 26.  
8. Women of child -bearing potential (WOCBP) * must use a reliable method of contraception 
(e.g., oral contraceptive or long -term injectable or implantable hormonal contraceptive, 
double -barrier methods [such as condom plus diaphragm, condom plus spermi cide foam, 
condom plus sponge], or intra -uterine devices)  for the entire study duration , and must have 
a negative serum pregnancy test at Screening and negative urine pregnancy at baseline 
visit.  
9. Subject was approved by a central Eligibility Monitoring Committee (EMC) based on 
suitability for the study, and his/her eligibility was confirmed by EMC signature on the 
Randomization Authorization Form (RAF).  
*WOCBP are defined as any female who has exp erienced menarche and who is NOT permanently 
sterile or postmenopaused. Postmenopausal is defined as 12 consecutive months with no menses 
without an alternative medical cause.  
 
Exclusion criteria  
Subjects are not permitted to enroll in the study if any 1 of the following criteria is met.  
1. Subject has previously participated in this study.  
2. Subject has participated in another study of an investigational medicinal product (IMP) or 
a medical device within the last 30 days or is currently participating in anothe r study of an 
IMP or medical device.  
3. Subject has an atypical parkinsonian syndrome or secondary parkinsonism (e.g., due to 
drugs, toxins, metabolic disorders, encephalitis, cerebrovascular disease or degenerative 
disease).  
4. Subject has a history of psychosi s or hallucinations within the previous 12 months.  
5. Subject has cognitive imp airment in the judgment of the I nvestigator that excludes him/her 
from understanding consent or participating in the study.  
6. Subject has previous exposure to levodopa or a dopamine agonist for longer than 4 
weeks; if previous exposure was less than 4 weeks then it must not be within 2 months 
prior to the baseline visit.  
7. Subject has previous exposure to a MAO -B inhibitor for longer than 4 weeks; if 
previous exposure was less than 4 we eks then it must not be within 3 months prior to 
the baseline visit.  
8. Subject who has taken anticholinergic drugs for PD or amantadine for longer than 4 
weeks; if previous exposure was less than 4 weeks then it must not be within 1 month 
prior to the baseli ne visit . 
9. Subject who is taking non -selective MAO inhibitors.  
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 21 of 131 
 
 10. Subject who is taking potent CYP1A2 inhibitors, e,g, Ciprofloxacin  
11. Subject who is taking antitussive agent dextromethorphan.  
12. Subject who is taking analgesic agents such as tramadol, meperidine, methadone and 
propoxyphene.  
13. Subject who is taking strong 3A4 inducers, e.g., St. John's Wort or cyclobenzaprine 
(tricyclic muscle relaxant).  
14. Subject who is taking dopamine antagonists, such as the neuroleptics (phenothiazines, 
butyrophenones, thioxanthenes) or metoclopramide.  
15. Marijuana or previous exposure to Marijuana during the last 30 days prior to the baseline 
visit or subject has a history of alcohol or drug abuse or dependence within the prior 12 
months, according to Investigator judgment , (alcohol intake is limited to 1 glass or shot 
per day during the whole study taken not less than 3 hours before or after dosing (see 
section 10.2).  
16. Any relevant medical, surgical, or psychiatric condition, laboratory value, or concomitant 
medication whic h, in the opinion of the Investigator, makes the subject unsuitable for 
study entry or potentially unable to complete all aspects of the study.  
17. Subject has moderate or severe  renal impairment (creatinine clearance < 50 mL/min) or on 
dialysis.  
18. Subject has moderate (Child -Pugh categorization B, score 7 -9) or severe (Child -Pugh 
categorization C, score 10 -15) hepatic impairment.  
19. Subject has a lifetime history of suicide attempt (including an active attempt, interrupted 
attempt or aborted attempt), or has suicidal ideation in the past 6 months as indicated by a 
positive response ('Yes') to either Question 4 or Question 5 of the Columbia -Suicide 
Severity Rating Scale (CSSRS) at Screening.  
20. Subject has known hypersensitivity or intolerance to pramipexol e or rasagiline or to any 
components or excipients of the test drug or placebo.  
21. Subject who has a history of neuroleptic malignant syndrome.  
22. Subject who is pregnant or breastfeeding.  
23. Subject, who, for any reason, is judged by the Investigator or the eligib ility monitoring 
committee (EMC ) to be inappropriate for this study, including a subject who is unable to 
communicate or cooperate with the I nvestigator or who has/had a clinically significant 
illness or abnormal physical examination that may compromise sa fety of the subject 
during the trial or affect ability of the subject to adhere to study procedures.  
 
A site will not be allowed to randomize subjects unless their diagnosis and suitability for the study 
has been confir med and documented by both the I nvest igator and the EMC and they are deemed 
to be a satisfactory candidate by the EMC.  
Test product:  
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 22 of 131 
 
 a. P2B001 pramipexole dihydrochloride 0.6 mg/rasagiline 0.75 mg Once Daily.  
Reference therapy:  
b. Pramipexole dihydrochloride 0.6 mg Once Daily.  
c. Rasagiline 0.75 mg Once Daily.  
Calibration arm:  
d. Pramipexole ER titrated to optimal dose (1.5, 3.0 or 4.5mg) Once Daily  
 
Duration of treatment:  
Subjects will receive study drug or matching placebo treatment for a total of 12 weeks followed 
by a 7 -day gradual discontinuation of treatment of pramipexole ER arm or matching placebo).    
 
Statistical Methodology:  
This study is a phase 3, twelve -week, multi -center, multinational, randomized, double -blind, 
double -dummy, parallel group study. Up  to 525 eligible subjects with early  untreated  Parkinson’s 
disease (PD) who are not early terminated from the study during screening or baseline visits  and 
are randomized to treatment with P2B 001 0.6/0.75 (150 subjects), or pramipexole 0.6 mg once daily 
(150 subjects), or rasagiline 0.75 mg once daily (150 subjects), or pramipexole E R titrated to 
therapeutic optimal dose (75 subjects) using a randomization scheme of 2:2:2:1, respectively.   
Randomization will take place following the completion of all screening procedures including 
subject approval by both site PI and the central EMC.   
This study is powered  to demonstrate the superiority  of (i) P2B001 0.6/0.75mg as compared to its 
individual components in the change from baseline to Week 12/Treatment Termination in Total 
UPDRS score  and, (ii) to demonstrate the superiority of P2B 001 0.6/0.75mg over pramipexole ER 
in the change from baseline to Week 12/Treatment Termination in the ESS .  
Treatment with pramipexole ER will serve as a calibration arm to better characterize P2B001 
against currently used therapy. Therefore, with the except ion of change from baseline to Week 
12/Treatment Termination in the ESS , only descriptive statistic s and no formal significance testing  
will be made between the pramipexole ER arm and the other three study arms . 
Week 12/Treatment Termination  is defined for all statistical analyses  involving significance  as the 
last visit in which a subject was treated with the study drug.  
 
Sample Size Rational:  
The study was powered to allow achieving two goals:  
• To demonstrate the superiority of P2B 001 0.6/0.75mg compared to its individual components 
in the primary endpoint, the  change from baseline to Week 12/ Treatment Termination  in total 
UPDRS score:  
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 23 of 131 
 
 - The power to meet the primary endpoint was estimated based on simulation runs assuming 
equal arms size of P2B 001 0.6/0.75mg and its individual components as well as repeated 
UPDRS measurements at baseline, week 5, week 8 and week 12.  
- The expected STD of the change from baseline was assumed to be 6.0 UPDRS points.  
- The expected treatment effect of P2B 001 0.6/0.75mg is 3 UPDRS points over rasagiline 
0.75mg and 2.25 UPDRS points over 0.6mg pramipexole.  
- Sequential correlations between changes from baseline will be 0.7 and 0.49 between these 
obtained at week 5 and at week 12.  
- Missing observations rate of 10%  occurring at random.  
- The statistical model used in the simulation study was the Mixed Model for Repeated 
Measures (MMRM) (SAS® MIXED procedure with REPEATED sub -command) testing 
two contrasts: P2B 001 0.6/0.75mg vs. rasagiline 0.75mg and P2B 001 0.6/0.75mg vs. 
pramipexole 0.6mg at Week 12/ Treatment Termination . 
- In order to consider the study as successful both tested contrasts have to be statistically 
significant at 5% two -tailed each.  
The simulation indicates that a total of  150 subjects  to be included in  each P2B001 0.6/0.75mg 
arm, rasagiline 0.75mg arm and pramipexole 0.6mg arm will provide 87.6% power to detect a 
statistically significant effect size favoring P2B001 0.6/0.75mg by 3 UPDRS points over 
rasagiline 0.75mg and 2.25 UPDRS points ove r pramipexole  0.6mg .   
• To demonstrate the superiority of P2B 001 0.6/0.75mg over pramipexole ER in the first 
secondary endpoint, namely, the change from baseline to Week 12/ Treatment Termination  in 
the ESS:  
- The power to meet this secondary endpoint was estimated using the two -sample t -test for 
mean difference at a two -sided alpha of 5% (SAS® POWER procedure).  
- The expected STD of the change from baseline was assumed to be 3.0 ESS points.  
- The expected treatment effect of P2B 001 0.6/0.75mg over pramipexole ER is 1.5 ESS 
points.  
- According to the gate keeping method for multiple endpoints while testing for the secondary 
endpoints, this secondary endpoint will be considered as met only in the case that both 
primary endpoint contrasts as well as the P2B 001 0.6/0 .75mg over pramipexole ER 
comparison in the change from baseline to Week 12/ Treatment Termination  in the ESS will 
be met at two -tailed alpha level of 5% each.  
This analysis indicates that a total of 150 subjects to be included in the P2B001 0.6/0.75mg arm 
and 75 subjects to be  included in  pramipexole ER arm, considering the above assumptions, will 
provide a power of 94.1% to detect a statistically significant ef fect size at the magnitude of 1.5 
ESS units or more at a two -sided alpha level of 5%.  
 
Sample Size Re -Assessment:  
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 24 of 131 
 
 To examine whether the variance estimate used in power calculations for the primary endpoint was 
adequate, an assessment of the variance magnitude will be performed after at least 1/3 of the 
subjects complete the study treatment period. The EM algorithm of Gould and Shih 
(Communications in Statistics. A Theory and Methods, 21, 2833 -2853, 1992), will be applied to 
estimate the varia nce of the change from baseline to Week 12/ Treatment Termination  in total 
UPDRS score, without breaking the blind . In the case that the variance estimate will be found to be 
larger than the one projected, the sponsor reserves the right to up -size the study  via protocol 
amendment.  
 
Randomization:  
Randomization will take place following the completion of all screening procedures including 
subject approval by both site PI and the central EMC . 
Subjects will be randomized to  treatment with P2B 001 0.6/0.75  (approximately 150 subjects), or 
pramipexole 0.6  mg once daily ( approximately 150 subjects), or rasagiline 0.75 mg once daily 
(approximately 150 subjects), or pramipexole ER titrated to therapeutic optimal dose 
(approximately 75 subjects) using a  randomization scheme of 2:2:2:1, respectively, stratified by 
region . 
 
Overall Significance Level and Multiplicity Adjustment:  
The overall significance level for this study will be 5% using two -tailed tests. No interim analyses 
or futility analyses are pla nned for this study.  
The overall, experiment -wise type -I error rate of 5% will be preserved according to the below plan:  
1. The principal analysis of the primary endpoint is designed to demonstrate the efficacy of 
P2B001 0.6/0.75mg as compared to its individual components in the changes from baseline to 
Week 12/ Treatment Termination . Accordingly, analysis will employ two contrasts: P2B 001 
0.6/0.75mg vs. pramipexole 0.6mg once daily and, P2B 001 0.6/0.75mg vs. rasagiline 0.75mg 
once daily. The type -I error of 5% for multiple contrasts testing for the primary endpoint will 
be preserved by determining that the primary endpoint is met only if both comparisons will 
favor P2B 001 0.6/0.75mg at a two -tailed alpha level of 5% each.     
2. Multiplicity adjustment for  multiple endpoints testing for the secondary endpoints will utilize 
the gate keeping hierarchical method according to the following order and plan:  
- For the 1st secondary endpoint, namely, the P2B 001 0.6/0.75mg vs. pramipexole ER contrast 
in the change fro m baseline to Week 12/ Treatment Termination  in the ESS, will be 
considered as met only if both primary endpoint contrast s as above defined and the P2B 001 
0.6/0.75mg vs. pramipexole ER contrast in the change from baseline to Week 12/ Treatment 
Termination  in the ESS will all be met (total of 3 contrasts) at a two -tailed alpha level of 5% 
each.     
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 25 of 131 
 
 - The 2nd secondary endpoint, namely, the change from baseline to Week 12/ Treatment 
Termination  visit in the Total PDQ39 will be considered as met if all of the 3 pre vious tested 
contrasts (primary endpoint and 1st secondary endpoint) as well the two contrasts: P2B 001 
0.6/0.75mg vs. pramipexole 0.6mg once daily and, P2B 001 0.6/0.75mg vs. rasagiline 
0.75mg once daily in the 2nd secondary endpoint will all be met (total of 5 contrasts) at a 
two-tailed alpha level of 5% each.  
- The 3rd secondary endpoint, namely, the change from baseline to Week 12/ Treatment 
Termination  visit in the ADL UPDRS (part II) score will be considered as met if all of the 
5 previous tested contrasts  (primary endpoint, 1st and 2nd secondary endpoints) as well the 
two contrasts: P2B 001 0.6/0.75mg vs. pramipexole 0.6mg once daily and, P2B 001 
0.6/0.75mg vs. rasagiline 0.75mg once daily in the 3rd secondary endpoint will all be met 
(total of 7 contrasts) at a two -tailed alpha level of 5% each.  
- The 4th secondary endpoint, namely, the change from baseline to Week 12/ Treatment 
Termination  visit in the motor UPDRS (part III) score will be considered as  met if all of the 
7 previous tested contrasts (primary endpoint, 1st, 2nd and 3rd secondary endpoints) as well 
the two contrasts: P2B 001 0.6/0.75mg vs. pramipexole 0.6mg once daily and, P2B 001 
0.6/0.75mg vs. rasagiline 0.75mg once daily in the 4th seconda ry endpoint will all be met 
(total of 9 contrasts) at a two -tailed alpha level of 5% each.  
- The 5th secondary endpoint, namely, the CGI -S responder’s analysis at Week 12/ Treatment 
Termination  visit (change from baseline ≥1 CGI -S points) will be considered a s met if all 
of the 9 previous tested contrasts (primary endpoint, 1st, 2nd, 3rd and 4th secondary endpoints) 
as well the two contrasts: P2B 001 0.6/0.75mg vs. pramipexole 0.6mg once daily and, 
P2B001 0.6/0.75mg vs. rasagiline 0.75mg once daily in the 4th secondary endpoint will all 
be met (total of 11 contrasts) at a two -tailed alpha level of 5% each.  
 
Principal Analysis of the Primary Endpoint:  
The primary efficacy endpoint for this study is the change from baseline to Week 12/ Treatment 
Termination  in total UPDRS score (defined as sum of parts II and III, scores (0 -160). The statistical 
model will be a Mixed Model for Repeated Measures (MMRM) (SAS® MIXED procedure with 
REPEATED sub -command). The model will include the following fixed effec ts: categorical week 
in trial by treatment interaction, country  or geographical region (CGR) , and baseline UPDRS score. 
The model will use the unstructured covariance structure and the REML estimation method and 
degrees of freedom will be adjusted using th e Kenward -Roger method. Data from all three changes 
form baseline to post -baseline visits (weeks 5, 8 and 12) collected from all subjects randomized into 
the study will be used as response in the model. The differences between the P2B 001 0.6/0.75mg 
arm as compared to its 2 individual components at Week 12/Treatment Termination  will be 
estimated and tested using 2 contrasts: P2B 001 0.6/0.75mg vs. pramipexole 0.6mg and, P2B 001 
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 26 of 131 
 
 0.6/0.75 mg vs. rasagiline 0.75mg . The study primary endpoint will be considered as met only if 
both contrasts will favor P2B 001 0.6/0.75mg at a two -tailed alpha level of 5% each.  
 
Statistical Analysis Plan (SAP)  
A more detailed SAP will be developed while the study is ongoing and prior to locking the 
database and un -blinding.  
 
If ever there is a discrepancy in the between the Protocol and the Statistical Analysis Plan, the 
methods defined in the SAP will have precedence.  
 
 
 
  
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 27 of 131 
 
 3 INTRODUCTION  
3.1 Background   
Parkinson’s disease (PD) is an age -related neurodegenerative disorder. The maj or motor 
symptoms include rigidity, tremor, and bradykinesia. Levodopa (L -DOPA) provides meaningful 
benefit for most patients, particularly in the early stages of the disease. However, chronic L -
DOPA treatment is associated with the development of motor co mplications ( motor fluctuations  
and dyskinesia) in the majority of individuals.  Further, levodopa induced off time and 
dyskinesia are dose -related and seen with higher doses of L -DOPA  (Olanow CW M. F., 2013)  . 
To delay the introduction of L -DOPA and to permit the use of lower doses, many physicians 
choose to initiate therapy with a monoamine oxidase Type B (MAO -B) inhibitor, frequently 
rasagiline, a dopamine agonist, commonly pramipexole, or both  (often in sequ ential order) .  The 
use of these treatments prior to the introduction of L -DOPA can provide satisfactory clinical 
control in the early stages of the disease, enable lower doses of L -DOPA to be used when it is 
required and delay developing L -DOPA associated  motor complications.  
Pramipexole is a non -ergot, specific and selective dopamine receptor agonist of the dopamine D2 
subfamily  (Perez -Lloret S, 2010) . Rasagiline is a selective and irreversible monoamine oxidase 
B (MAO -B) inhi bitor  (Youdim MB, 2001)  . Thus, while pramipexole compensates for the lack 
of endogenous neurotransmitters by activating the postsynaptic dopamine receptor, rasagiline 
causes an enhancement of synaptic dopamine levels by inhibi ting dopamine oxidative 
metabolism.  
Pramipexole has been shown to possess neurotropic activity in animal models  (Imamura K, 
2008)  (Li C, 2010) . In the last decade, studies of rasagiline have shown that it also works 
through additional anti apoptotic mechanisms (Wu Y, 2015) , and neurotropic effects (Azilect 
EPAR) that may contribute to its anti -parkinsonian benefit . Therefore , further compatibility of 
the mechanisms of these two agents may exist.  
While the use of alternative treatment prior to introduction of L -DOPA is now an acceptable 
approach  (Olanow W, 2009) , approved therapeutic doses of pramipexole and rasagiline have 
potential safety concerns and therapeutic limitations.  For example, therapeutic doses of 
dopamine agonists are typically associated with nausea, vomiting , constipation and  orthostatic 
hypotension.  Furt her, pramipexole is also associated with a risk of impulse control disorders, 
peripheral edema, psychosis and excessive daytime sleepiness, and a risk of sudden onset sleep 
episodes in unintended situations such as while driving.  These side effects are mo re pronounced 
with higher dosages.  Rasagiline is largely well tolerated but has limited efficacy and also has 
potential safety concerns, particularly with respect to the risk of a hypertensive crisis with foods 
that are high in tyramine and as serotonin s yndrome particularly when employed in high doses or 
in combination with selective serotonin reuptake inhibitors and other anti -depressants that are 
commonly prescribed in Parkinson’s disease.  Again, higher doses are associated with a greater 
risk of devel oping these adverse effects.  
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 28 of 131 
 
  
Pharma Two B’s therapeutic strategy is to develop a fixed -dose combination of low doses of 
agents with complementary mechanisms of action (ie, a dopamine agonist and a MAO -B 
inhibitor) in an attempt to obtain enhanced anti -Parkinsonian efficacy and a better safety profile 
in comparison to what can be achieved with higher doses of either agent alone, as the drugs are 
currently employed.  
Pharma Two B has investigated the effects of combining low doses of pramipexole and 
rasagilin e in both animal models and PD patients.  Nonclinical data demonstrate that low doses 
of the MAO -B inhibitor rasagiline and the dopamine agonist pramipexole act synergistically 
with respect to behavioural effects and striatal dopamine.   
In animal studies,  administering both agents in a slow infusion over 24 hours (mimicking 
extended -release) further improves their efficacy, presumably by allowing the agents to work 
together for a longer time, enhancing their mutual action.  The half -lives of the currently available 
pramipexole and rasagiline  vary (T 1/2 is 8-12 hours for pramipexole, and 1.5 -3.5 hours for 
rasagiline)  (Wright CE, 1997)  (Thebalut JJ, 2004) . Therefore, the P2B001 combination comprises 
an extended release (ER) profile for both pramipexole and rasagiline, which enables release 
throughout the day for both drugs, allowing for a longer  time of mutual action.  
 
P2B001 is intended to offer a novel approach to PD treatment in that it would be:  
• a fixed -dose combination of the two agents;  
• an extended -release formulation of both pramipexole and rasagiline; and  
• a new low -dose regimen of the two agents intended to maximize efficacy while limiting 
known adverse effects of approved higher doses of the i ndividual components.  
 
A Phase 2b clinical study (P2B001/001) in patients with early Parkinson’s disease testing the 
low-dose combinations of pramipexole (0.3 or 0.6 mg) and rasagiline (0.75 mg) in an extended -
release formulation has recently been completed and demonstrated that the combination provides 
highly significant and clinically meaningful benefits in comparison to placebo, with a good 
safety profile  (Olanow CW K. K., 2017) . The primary efficacy endpoint was the  change from 
baseline to Week 12 in total UPDRS (I+II+III) score. The UPDRS data showed significant 
improvement at each time point relative to baseline (p<0.0001 at 4, 8, and 12 weeks) for both the 
0.3/0.75 mg and 0.6/0.75 mg dose combinations. The placebo -subtracted differences were 
statistically significant at 12 weeks, these were -4.67 points for 0.6/0.75 mg (p=0.0004) and -
3.84 points for 0.3/0.75 mg ( p=0.0027).    
Out of the two above tested doses, the 0.6/0.75 mg dose was selected for the phase III study. 
Although between -group differences in efficacy were not statistically significant, there was 
consistent numerical benefit for this dose on total, motor and ADL UPDRS scores, PDQ39 and 
CGI-severity.  
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 29 of 131 
 
 3.2 Preclinical Pharmacology Studies   
Several non -clinical pharmacology studies assessing the effects of the proposed drug 
combination have been conducted. When the combination of rasagiline and pramipexole were 
administered together at doses that individually produce only small changes in striatal dopamine 
levels in MPTP -lesioned animals, greater than additive recovery of dopamine levels were 
observed. Further, when the sustained -release dosage is mimicked, the effect is greater than 
when the same combination is administered as immediate release. This has been  supported in a 
further study in which L -DOPA -induced contralateral turning and the stepping test in the 6 -
OHDA -lesioned rat model showed greater than additive changes when rasagiline and 
pramipexole were administered in combination.  
3.3 Toxicology Studies  
A review of the pharmacological profiles of pramipexole and rasagiline revealed that both products 
are highly specific in their activities.  Rasagiline is highly specific for MAO -B ( Lecht S, 2007) . 
Similarly, pramipexole demons trated specificity for D2 -D3 dopamine receptors  (Summary Basis 
of Approval NDA 20667., 1997) .  The nonclinical development programs for Mirapex and Azilect 
included full batteries of toxicity testing needed for approval of  chronically administered drug 
products.  These studies identified few end organs for toxicity other than those predicted by the 
pharmacology of the two substances.  Toxicological interactions are not predicted by the available 
human and animal data.   
In addition, evaluation of adverse effects in the LARGO and PRESTO studies showed no 
indication of an increase in dopaminergic adverse effects in patients when rasagiline was added to 
dopamine agonist treatment.  Also, increases in adverse dopaminergic or oth er adverse effects have 
not been noted in clinical studies in which other MAO inhibitors (e.g., selegiline) have been used 
with pramipexole (Du F, 2005) , (Hauser RA, 2010) , (Rascol PB, 2010) , (Hubble JP, 1995) , 
(Shannon KM, 1997) , (PSG, 1997) , (Mirapex ER Label, 2010)   
The P2B001/00 1 phase 2b study did not show any new or unexpected adverse events and showed 
a decrease in most dopaminergic adverse events.  
 
3.4 Clinical Studies  
Pharma Two B Ltd. has conducted three clinical trials with its low -dose, extended -release, fixed 
dose formulation of pramipexole and rasagiline for the treatment of early Parkinson’s disease.  
The initial pharmacokinetic study (Study 10/10) was four arms, crossover, pharmacokinetic 
study in healthy, fasted young adults comparing immediate release rasagiline  (Azilect®, 1 mg, 
commercial), ER pramipexole (Mirapex  ER®, 0.75 mg, commercial), both commercial drugs 
taken together, and Pharma Two B’s proprietary P2B001 containing doses of rasagiline (1 mg) 
and pramipexole (0.75  mg), both ER.  Results indicated that no pharmacokinetic interactions 
occurred between the components when given together. The Cmax and AUC of each component 
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 30 of 131 
 
 in the combination were either equal (in case of Pramipexole) or lower (in case of Rasagiline) 
compared to the Cmax and AUC of the drugs  given alone, indicating that no safety issues 
resulting from increased exposure are expected. In this study, the availability of the drugs in the  
P2B001 is about 90% for pramipexole and about 80% for rasagiline relative to the commercial 
mono -therapies.   Furthermore, both drugs were present in plasma throughout the day and the 
high peaks associated with the commercial products were avoided with P2B001. The second 
study has recently been completed. This was a phase 2b, twelve -week multi -center, randomized, 
double -blind, placebo -controlled, parallel group study, to determine the safety, tolerability and 
efficacy of two doses of P2B001 in subjects with early Parkinson’s disease. The   study tested 
two low -dose, fixed -dose combinations of P2B001, once -daily con taining pramipexole and 
rasagiline (0.6 mg/0.75 mg and 0.3 mg/0.75 mg) relative to an identical placebo capsule. The 
results demonstrated robust statistically significant and clinically meaningful improvement 
results compared to placebo in Parkinson’s dise ase symptoms with a favorable safety profile at 
two dosage strengths of the combination product. The primary efficacy endpoint was the change 
from baseline to Week 12 in total UPDRS (I+II+III) score . The UPDRS data showed significant 
improvement at each time point relative to baseline (p<0.0001 at 4, 8, and 12 weeks) for both the 
0.3/0.75 mg and 0.6/0.75 mg dose combinations. The placebo -subtracted differences were 
statistically significant at 12 weeks , these were -4.67 points for 0.6/0.75 mg (p=0.00 04) and -
3.84 points for 0.3/0.75 mg (0.0027).   Adverse events of frequency ≥ 5% are listed in the table 
below.  
 
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 31 of 131 
 
 Common Adverse Events (Frequency ≥5%) (P2B001/001) Number and % of Subjects  
 Placebo  
(N=50 ) P2B001 0.3/0.75  
(N=50 ) P2B001 0.6/0.75  
(N=49 ) 
Diarrhea  3 (6%)  0 (0%)  0 (0%)  
Nausea  1 (6%)  6 (12%)  10 (20.4%)  
Fatigue  1 (2%)  1 (2%)  4 (8.2%)  
Nasopharyngitis  5 (10%)  2 (4%)  2 (4.1%)  
Dizziness  4 (8%)  2 (4%)  5 (10.2%)  
Headache  4 (8%)  1 (2%)  1 (2%)  
Somnolence  0 (0%)  4 (8%)  8 (16.3%)  
Tremor  3 (6%)  3 (6%)  4 (8.2%)  
Insomnia  2 (4%)  0 (0%)  3 (6.1%)  
Orthostatic 
hypotension  4 (8%)  1 (2%)  2 (4.1%)  
 
As for severity, most of the adverse events (frequency ≥5%) were mild.  Interestingly most of the 
somnolence reported for the 0.6/0.75 mg dose were mild (67%) while for the 0.3/0.75 mg dose 
most were moderate. A second pharmacokinetic study (Study P2B001 /002a) was recently 
completed in  healthy  male and non-pregnant female volunteers, comparing the effect of food 
(high-fat meal versus fasting ) on the bioavailability of pramipexole and rasagiline from a single 
oral dose of P2B001 Pramipexole/Rasagiline 0.6 mg /0.75 mg once daily capsule . Results indicated 
that food does not alter the peak or extent of absorption of both pramipexole and rasagiline from 
P2B001 .  
 
3.5 Summary of Non -Clinical and Clinical Studies  
P2B001 is an oral fixed -dose, extended release product that combines pramipexole and rasagiline 
for the treatment of early Parkinson’s disease. The Pharma Two B product is novel in that it would 
be: 
• A fixed -dose combination of the two agents.  
• A low -dose regimen intended to maximize efficacy while limit ing adverse effects.  
• The first product incorporating a extend ed release formulation of rasagiline.  
 
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 32 of 131 
 
 Pharma Two B Ltd. has completed several studies characterizing P2B001 in a rodent model of 
PD, a phase 1 study with healthy volunteers and a phase 2b study with  early  PD patients, all 
demonstrated the therapeutic advantage of Pharma Two B’s proprietary extended release 
combination:  
• The nonclinical studies in rodents PD models suggest a therapeutic ad vantage of combining 
low doses of rasagiline and pramipexole and suggest further improvement when both are 
administered in a sustained fashion.  
• The Phase 1 study (Study 10/10) indicates the absence of a pharmacokinetic interaction  
between pramipexole and r asagiline when co -administered. Further, when administered  
at equivalent doses, the plasma profile of pramipexole from Pharma Two B ’s extended  
release combination product mirrors that of Mirapex ER®. The plasma profile from  
Pharma Two B ’s extended -release combination product differs markedly, as expected, in 
Cmax from that of immediate -release Azilect, but provides similar exposure.  
• The 12 -week Phase 2B, multi -center, randomized, double -blind, placebo -controlled,  parallel 
group study of P2B001 in subjects w ith early Parkinson ’s disease (study  
P2B001/001) demonstrated statistically significant and clinically meaningful  improvement 
compared to placebo in Parkinson ’s disease symptoms with a favorable  safety profile at two 
dosage strengths of the combination pro duct (0.6 mg pramipexole/0.75 mg rasagiline and 0.3 
mg pramipexole/0.75 mg rasagiline).  
 
P2B001 at dose of 0.6 mg pramipexole/0.75 mg rasagiline will be used for further development 
of Pharma Two B’s product.  
4 STUDY OBJECTIVE S 
 
Pharma Two B intend s to show that: 
• P2B001 has superior efficacy  as compared  to each of its components . 
• P2B001 is safe and tolerable.  
• P2B001 has descriptively comparable efficacy as well as  safety  benefits as compared to 
pramipexol e ER .  
4.1 Primary Objective   
 
• To determine the superiority  of P2B 001 0.6/0.75 mg as compared to its individual 
components in the change  of total UPDRS score (defined as sum of parts II and III, scores 
(0-160).  
 
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 33 of 131 
 
 4.2 Secondary Objectives   
• To determine the superiority of P2B 001 0.6/0.75  mg as compared to pramipexole ER  in the 
change  of Epworth Sleepiness Scale (ESS)  score .  
• To determine the efficacy of P2B 001 0.6/0.75 mg as compared to its individual components 
in the c hange of Total PDQ39  score . 
• To determine the efficacy of P2B 001 0.6/0.75 mg as compared to its individual components 
in the c hange of ADL UPDRS (part II) score.  
• To determine the efficacy of P2B 001 0.6/0.75 mg as compared to its individual components 
in the c hange of motor UPDRS (part III) score.  
• To determine the efficacy of P2B 001 0.6/0.75 mg as compared to its individual components 
in the CGI-S responder ’s analysis  (change from baseline ≥1 CGI -S points).  
4.3 Exploratory Objectiv es: 
• To evaluate the superiority  of P2B 001 0.6/0.75 mg compared to its indivi dual components in 
the following endpoints:  
- Change  in each of the 8 PDQ39 subscales scores.  
- Change in  the score of  Health -Related Quality of Life (HRQOL) SF -12v2 questionnaire.  
- Clinical  Global Impression of Improvement (CGI -I). 
 
• To evaluate the superiority of P2B 001 0.6/0.75 mg over pramipexole ER with respect to the 
following outcome measures:  
- Proportion (%) of patients with ESS score >10 .  
- Proportion (%) of patients with ESS Score <10 at baseline and ESS score >10.  
- 3-Months rate of total number  of adverse events.  
- Change in the differences in systolic and diastolic blood pressure measured during supine 
and standing positions.   
- Proportion (%) of patients with both symptomatic/non -symptomatic Orthostatic 
Hypotension . 
- 3-Months rate of total number of both symptomatic/non -symptomatic Orthostatic 
Hypotension . 
- Proportion (%) of patients with symptomatic Orthostatic Hypotension . 
- 3-Months rate of total number of symptomatic Orthostatic Hypotension . 
- Proportion (%)  of patients with daytime sleepiness/drowsiness related AE’s.  
- Proportion (%)  of patients with gastrointestinal (GI) adverse events  
- Proportion (%) of patients presenting neurological adverse events  
- Change in the  score of  Orthostatic Hypotension Symp toms Assessment (OHSA) question 1. 
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 34 of 131 
 
 • To descriptively evaluate the comparability of P2B 001 0.6/0.75 mg with reference  to the 
calibration arm (pramipexole ER)  in total UPDRS score (defined as sum of parts II and III, 
scores (0 -160). 
Note that n o formal efficacy comparisons will be made between the calibration arm of 
pramipexole ER to the other three treatment arms.   
 
4.4 Safety & Tolerability  Objectives  
 
The safety profile of the test product and comparators will be evaluated by changes in the safe ty 
parameters, including adverse events, concomitant medications, vital signs, laboratory 
parameters, physical and neurological examination s, ECGs, Questionnaire for Impulsive -
Compulsive Disorders in Parkinson's Disease - Rating Scale  (QUIP -RS), Columbia Su icide 
Severity Rating Scale (CSSRS) , Orthostatic Hypotension Symptoms Assessment (OHSA) 
question 1  and Epworth Sleepiness Scale (ESS).  
Tolerability will be assessed by percentage of subjects that complete the trial on treatment 
assigned.  
5 INVESTIGATIONAL PR ODUCT  
 
The drug combination P2B001 is comprised of two drugs; pramipexole and rasagiline, both 
currently approved drugs and routinely used in  standard therapy for  early  PD. Each active 
pharmaceutical ingredient (API)  is formulated separately as extended -release pellets (i.e., inert 
sugar bead core layered with drug and covered with an extended release coating). The two types 
of pellets are packed into a capsule to provide the desired dose.  
 
Pramipexole is a non -ergot, sp ecific and selective dopamine receptor agonist of the dopamine D2 
subfamily (Perez -Lloret S, 2010) , currently marketed as immediate release and as extended 
release . Rasagiline is a selective and irreversible monoamine oxidase B  (MAO -B) inhibitor 
(Youdim MB, 2001) . Thus, while pramipexole compensates for the lack of endogenous 
neurotransmitters by activating the postsynaptic dopamine receptor, rasagiline causes an 
enhancement of synaptic dopamine leve ls by inhibiting dopamine oxidative metabolism.  
 
Pramipexole is currently marketed as immediate release and as extended release (ER). In this 
study the ER product will be used as a calibration arm . The starting dose  of pramipexole ER  is 
0.375 mg given once  per day. Based on efficacy and tolerability, dosages may be increased 
gradually, not more frequently than every 5 to 7 days, first to 0.75 mg per day and then by 0.75 
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 35 of 131 
 
 mg increments up to a maximum recommended dose of 4.5 mg per day  (Summary Basis of 
Approval NDA 20667., 1997) . 
 
Rasagiline is only marketed as immediate release. The recommended monotherapy dose of  
rasagiline is 1 mg once daily  (  Azilect Label , 2010) . 
5.1 Dosage  
 
The dosage  for the three main study arms will be: 
• P2B001 (pramipexole dihydrochloride 0.6 mg/rasagiline 0.75 mg) once daily  
• Pramipexole dihydrochloride (0.6 mg) once daily  
• Rasagiline (0.75 mg) once daily  
 
The dosage for the calibration arm will be : 
• Pramipexole  ER individually titrated to an optimal dose  (1.5-4.5mg/day).  
 
The c ombination product (P2B001) and its individual components, pramipexole and rasagiline 
were  produced by: Catalent Pharma solutions Somerset, USA address: 14 Schoolhouse Rd.  
Somerset, NJ 088 73, USA.  
 
The pramipexole ER comparator and its placebo tablets were  produced by: 
Dr. Reddy's Laboratories Limited, FTO UNIT 3, Survey No 41 Bachupally village, Qutubullapur 
Mandal Ranga Reddy District Telangana 500090 India  
 
5.2 Dose Modification  
 
Subjects may be allowed to miss a dose  of study medication if :  
1) Subject  develops an adverse event that the Investigator believes requires the subject’s dose to 
be held  temporarily , or  
2) Subject  loses their kit of study medication and a replacement kit is requested, in this situation 
the PI should request an emergency shipment to alert the distributor to ship the replacement kit 
urgently ).  
During the pramipexole ER titration phase , the PI or sub -Investigator may modify  (up or down)  
subject’s  dose to either 1.5, 3 .0 or 4.5 mg of the pramipexole ER/identical placebo to reach the 
optimal tolerated therapeutic dose . Following the titration phase, after week 6, no modifications 
are allowed.  
If the sub ject experience s intolerable adverse events , dosing  may be held temporarily or 
withdrawn  (all treatments, including both capsules and tablets , please note that pramipexole  
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 36 of 131 
 
 ER/matching placebo tablets need to be down titrated gradually (see down titration instructions 
in section 6.1) . However , the subject will continue to be followed -up according to the protocol 
pre-planned schedule of activities   
No other dose modifications will be allowed in this study.   
5.3 Method of Administration &  Meals  
 
Subjects will take the study medications (capsule and tablets) by mouth with a glass of water 
(8oz or 240ml). Study medication can be taken with or without food and effort s should be made  
to take the study medication at about the same time every day .  
6 STUD Y DESIGN  
6.1 Overall Study Design and Plan Description  
 
This study is a phase 3 , twelve -week , randomized, double -blind, double -dummy, 4 -arm, parallel 
group, multi -center, multinational  study to determine the efficacy, safety  and tolerability of 
P2B001 in subjects with early Parkinson ’s disease as compared to its  individual components  and 
compared  to a calibration arm of pramipexole ER . 
 
Up to  525 eligible subjects with early untreated PD, who are not early terminated from the study 
during screening or baseline visits and are randomized to treatment with P2B001 0.6/0.75 or 
pramipexole 0.6 mg once daily, or rasagiline 0.75 mg once daily, or pramipexole ER titrated to 
optimal dose (1.5, 3.0 or 4.5mg) using a randomization scheme of 2:2:2:1, respectively. 
Rando mization will take place following the completion of all screening procedures including 
subject approval by both site PI and the central EMC . Subjects will be recruited from 
approximately 70 sites in North America  and Europe.  
 
Each subject  will be asked to take one capsule and 1-3 tablet s once daily . The capsules will 
contain either P2B 001 0.6/0.75  mg or pramipexole 0.6 mg or rasagiline 0.75 mg or matching 
placebo. The tablets will contain either Pramipexole ER or matching placebo.  
 
Dosing Regim en: 
 
• P2B001 pramipexole dihydrochloride 0.6mg/Rasagiline 0.75 mg Once Daily + Placebo 
of Pramipexole ER.  
• Pramipexole dihydrochloride 0.6 mg Once Daily  (PPX 0.6)  + Placebo of Pramipexole 
ER. 
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 37 of 131 
 
 • Rasagiline 0.75 mg Once Daily  (RAS 0.75)  + Placebo of Pramipexole ER.  
• Pramipexole ER individually titrated to optimal dose  + Placebo of P2B001.  
 
Study Structure:  
• Up-titration phase  
• Maintenance phase  
• Down -titration phase  
• Safety follow -up phase.     
 
Up-Titration phase: A 3 -6 week double blind, double dummy titration phase with pramipexole ER 
or matching placebo. During this phase subjects will also take 1 capsule of P2B001/RAS 
0.75/PPX0.6/Placebo which does not need titration. For the first 3 weeks t he titration  of the 
pramipexole ER  will be increase d by weekly increments up to a daily dose of 1.5 mg as follows: 
0.375, 0.75 and 1.5 mg. If needed, between weeks 3 and 6, the titration can continue to  a daily 
dose of  3.0 mg or 4.5 mg of pramipexole ER or mat ching placebo or reduced to a minimum of 
1.5mg with the final level determined based on achieving satisfactory efficacy and tolerability. On 
completion of the dose -titration phase  (end of week 6) , the minimum therapeutic dose of 
Pramipexole ER 1.5 mg per d ay (or placebo) must be achieved by all the patients. The treatment 
with study medications of patients who cannot achieve this dosage will be discontinued, but the 
subject will be requested to continue with all the study visits . 
 
Maintenance phase: Once th e final dose level has been reached for the pramipexole ER, the 
subject will continue at that dose, together with the once daily P2B001/RAS 
0.75/PPX0.6/Placebo capsule, until the end of Week 12.  
 
Down -titration phase: a 7-day gradual down titration of pramipexole ER or matching placebo . 
The down titration should be done by reducing the dose every two days  by half (except for 
subjects taking 4.5 mg, these should reduce the dose to 3.0 mg and then continue to reduce by 
half ever y two days) . There is no  treatment with once daily P2B001/RAS 0.75/PPX0.6/Placebo 
capsule s during this period .  
 
Safety follow -up phase: a 7 day s period of no treatment of pramipexole ER and 14-day period of 
no treatment for the P2B001/RAS 0.75/PPX0.6/Plac ebo capsule.   
 
  
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 38 of 131 
 
 Study design scheme:  
 
 
*Titration phase: Subjects can stop titration of pramipexole ER or placebo at 1.5 mg or can continue titration and increase th e 
dose to 3.0 or 4.5 mg to optimal dose or decrease back to 3.0 or 1.5 mg. The dosage level achieved at the end of the titration 
phase  (end of week 6) is then held constant during the maintenance phase  ending at the end of week 12 . 

Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 39 of 131 
 
  
6.2 Rationale for Study Design, study population and Doses  
 
The study is designed to show the contribution of both active  component s, pramipexole and 
rasagiline , to the efficacy of the combination product P2B001 by comparing the efficacy 
between P2B001 and its individual components as the co -primary objectives . In addition, the 
study  inclu des a calibration arm in order to characterize  the benefits of P2B001  in respect to 
safety and efficacy of  currently used therapeutic doses of  pramipexole ER.  
 
Early Parkinson 's disease patients are chosen for this study, since they are the patient popula tion 
that most likely can benefit from the combination product. The use of the combination product 
can delay the beginning of treatment with L -DOPA  and as consequence reduce and delay the risk 
of developing motor complications with L -DOPA treatment.  
 
The s tudy was adequatel y powered to allow demonstration of  the efficacy of P2B001 over its 2 
components by randomly allocating 150 subjects to each of P2B001 arms and its 2 components. 
Additional 75 subjects will also be randomized t o treatment with pramipexole  ER to  allow  
characterization of the benefits of P2B001 with reference  to pramipexole ER titrated to 
individual optimal dose s.  
The dose of P2B001 chosen for this study is based on the  results of the previous phase 2b  dose 
ranging study ( P2B001/001 ). Both doses  of P2B001  that were tested (0.6 mg pramipexole/0.75 
mg rasagiline and 0.3 mg pramipexole/0.75 mg rasagiline)  provided significant clinical  benefits 
with a good safety profile . The  0.6 mg pramipexole/ 0.75 mg  rasagiline dose  was chose n because 
there was consistent numerical benefit for this dose on total,  motor and ADL UPDRS scores, 
PDQ39 and CGI -severity  assessments . Both doses were well tolerated with an adverse event 
profile similar to placebo, with the exception of somnolence and m ild nausea, known adverse 
events of pramipexole. Slightly more  cases of somnolence and nausea were reported for the 0.6 
mg pramipexole/0.75 mg rasagiline dose , but both doses did not show statistically significant 
differences from placebo in the ESS scale  and the reports of nausea in both doses were mostly 
mild and transient.  
 
Subjects with mild to moderate renal impairment and subjects with mild hepatic impairment 
were included in the previous phase 2b study and were fol lowed up with monthly renal and live r 
function tests to assure compliance with exclusion criteria 17 and 18 and these  showed no 
significant changes . In the current study  subjects with mild renal and or mild hepatic impairment  
will also be included with the same additional follow up  to assure compliance wi th exclusion 
criteria 17 and 18 . In case of worsening in a subject 's liver or renal condition  and the subject is 
not compliant with the above exclusion criteria , their participation in the study will be stopped. 
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 40 of 131 
 
 Subject s with modera te renal  impairment (creatinine clearance between 30 and 50 mL/min) will 
be excluded  in the current study due to possible titration of pramipexole ER tablets to doses 
above the recommended dose in such patient populations,  which is 2.25mg /day.   
7 STUDY POPU LATION  
7.1 Number of Subjects  
Study population includes 525 eligible early stage untreated PD patients  who are not early 
terminated from the study during screening or baseline visits .  Subject will be recruited from  
approximately 70 sites in North America and Europe . 
 
7.2 Subjects Enrolment  
All subjects enrolled must be eligible as per Inclusion/Exclusion Criteria . Personal interview 
including medical history, physical and neurological examination, and evaluation for trial 
eligibility will be done as specified in Schedule  of Activities , Appendix I.  
 
7.3 Inclusion Criteria  
Subjects must meet all the inclusion criteria to be eligible:  
 
1. Subject is informed and given ample time and opportunity to think about his/her 
participation in this study and has given his/her written informed consent on an EC/IRB 
approved consent form . 
 
2. Subject is willing and able to comply with all study requirements (protocol, clinic visits, 
procedures and me dication administration).  
 
3. Subject is male or female ≥35.0 years of age to ≤80.0  years of age at the time of 
enrollment  
 
4. Subject has Parkinson's disease consistent with the UK Brain Bank Criteria  and must 
have bradykinesia with sequence effect.  If rest tremor does not exist must have 
prominent asymmetry of motor function.  
 
5. Subject with disease duration  less than 3 years  since diagnosis . 
 
6. Subject has a H&Y stage score of < 3.  
 
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 41 of 131 
 
 7. Subject has a MMSE score ≥ 26.  
 
8. Women of child -bearing potential (WOCBP) * must use a reliable method of 
contraception  (e.g., oral contraceptive or long -term injectable or implantable hormonal 
contraceptive, double -barrier methods [such as condom plus diaphragm , condom plus 
spermicide foam, condom plus sponge], or intra -uterine d evices)  for the entire  study 
duration , and must have a negative serum pregnancy test at Screening  and negative urine 
pregnancy at baseline visit.  
 
9. Subject was approved  by a central Eligibility Monitoring Committee (EMC)  based on 
suitability for the study , and his/her eligibility was confirmed by EMC signature on the 
Randomization Authorization Form (RAF).  
*WOCBP are defined as any female who has experienced menarche and who is NOT 
permanently sterile or postmenopausal . Postmenopausal is defined as 12 consecutive months 
with no menses without an alternative medical cause.  
 
7.4 Exclusion Criteria  
Subjects are not  permitted to enroll in the study if any 1 of the following criteria is met.  
 
1. Subject has previously participated in this study.  
 
2. Subject has participated in another study of an investigational medicinal product (IMP) or 
a medical device within the last 30  days or is currently participating in another study of 
an IMP or medical device.  
 
3. Subject has an atypical parkinsonian syndrome or secondary parkinsonism (e.g., due to 
drugs, toxins,  metabolic disorders, encephalitis, cerebrovascular disease or degenerati ve 
disease).  
 
4. Subject has a history of psychosis or hallucinations within the previous 12 months.  
 
5. Subject has cognitive imp airment in the judgment of the I nvestigator that excludes  
him/her from understanding consent or participating in the study . 
 
6. Subject has p revious exposure to levodopa or a dopamine agonist for longer than 4 
weeks; if previous exposure was less than 4 weeks then it must not be within 2 months 
prior to the baseline visit.  
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 42 of 131 
 
  
7. Subject has p revious exposure to a MAO -B inhibitor for lon ger than 4 weeks; if 
previous exposure was less than 4 weeks then it must not be within 3 months prior to 
the baseline visit.  
 
8. Subject who has taken anticholinergic drugs for PD or amantadine for longer than 4 
weeks; if previous exposure was less than 4 weeks then it must not be within 1 month 
prior to the baseline visit . 
 
9. Subject who is taking non-selective MAO inhibitors.  
 
10. Subject who is taking potent CYP1A2 inhibitors, e,g, Ciprofloxacin   
 
11. Subject who is taking  antitussive agent dextromethorphan.  
 
12. Subject who is taking analgesic agents such as tramadol, meperidine, methadone and 
propoxyphene.  
 
13. Subject who is taking strong 3A4 inducers, e.g., St. John's Wort or cyclobenzaprine 
(tricyclic muscle relaxant).  
 
14. Subject who is taking dopamine antagonists, such as the neuroleptics (phenothiazines, 
butyrophenones, thioxanthenes) or metoclopramide . 
 
15. Marijuana or previous exposure to Marijuana during the last 30 days prior to the baseline 
visit or subject has a history of alcohol or drug abuse or d ependence within the prior 12 
months, according to Investigator judgment, (alcohol intake is limited to 1 glass or shot 
per day during the whole study taken not less than 3 hours before or after dosing (see 
section 10.2).  
 
16. Any relevant medical, surgical, o r psychiatric condition, laboratory value, or concomitant 
medication which, in the opinion of the Investigator, makes the subject unsuitable for 
study entry or potentially unable to complete all aspects of the study.  
 
17. Subject has severe or moderate renal i mpairment  (creatinine clearance < 50 mL/min ) or 
on dialysis.  
 
18. Subject has moderate ( Child -Pugh  categorization B,  score 7 -9) or severe  (Child -Pugh 
categorization C, score 10 -15) hepatic impairment  ( Lucey MR, 1997) . 
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 43 of 131 
 
  
19. Subject has a lifetime history of suicide attempt (including an active attempt, interrupted 
attempt or aborted attempt), or has suicidal ideation in the past 6 months as indicated by a 
positive response ('Yes') to either Question 4 or Question 5 of the Col umbia -Suicide 
Severity Rating Scale (CSSRS) at Screening.  
 
20. Subject has known hypersensitivity  or intolerance  to pramipexole or rasagiline or to any 
components or excipients of the test drug or placebo.  
 
21. Subject who has a history of neuroleptic malignant syndrome.  
 
22. Subject who is pregnant or breastfeeding.  
 
23. Subject, who, for any reason, is judged by the Investiga tor or the EMC  to be 
inappropriate for this study, including a subject who is unable to com municate or 
cooperate with the I nvestigator or who has/had a clinically significant illness or abnormal 
physical examination that may compromise safety of the subjec t during the trial or affect 
ability of the subject to adhere to study procedures.  
 
A site will not be allowed to randomize subjects unless their diagnosis and suitability for the 
study has been confir med and documented by both the I nvestigator and the EMC  and they are 
deemed to be a satisfactory candidate by the EMC.  
 
7.5 Early Discontinuation  Subjects  
A subject can leave the study at any time for any reason without consequences, upon request.  The 
protocol distinguishes  between two types of early Termination s:   
• Early Treatment Termination (ETT)  
• Early Study Termination (EST)  
 
Early Treatment Termination  (ETT)  
A subject who discontinu ed study medication for any reason  before the end of week 12  will 
continue  pre-planned  study schedule of activities  as follow up . The subject will be requested to 
undergo a treatment termination visit as described in section 9.2.11  
Please note that P2B001/PPX 0.6/RAS 0.75/Placebo  capsules can be stopped immediately , while 
pramipexole  ER/matching placebo tablets need to  be gradually down titrated as described in 
section 6.1.  
The r easons for withdrawal could include the following:  
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 44 of 131 
 
 • Subject withdrawal of consent  to be treated with study medication (s) but still consenting to 
participate in study visits and activities  
• Request of the I nvestigator for any medical or other reason  
• Request of the primary care physician via the  Investigator  
• Pregnancy  
• Non-compliance  
• Subject who cannot achieve the minimum therapeutic dose of pramipexole ER  (or placebo) 
of 1.5 mg per day . 
• Major  protocol violation  
• Adverse Event/Experience  
• Lack of Efficacy  
• Subjects who, according to the I nvestigator, need additional therapy that is excluded in the 
protocol for the treatment of the disease.  
• Any other reason relating to the patient's safety or integrity of the study data . 
 
If a subject suspect  that she is pregnant, a urine test will be perfo rmed at the site. If the urine test 
is positive, study drug administration will be interrupted pending the results of a confirmatory 
blood/serum test. If the pregnancy is confirmed with a positive blood/serum test, then the subject 
will be permanent ly disc ontinued from study drug, but should participate in a Treatment 
Termination visit and continue with all the study visits as follow up visits up to and including 
safety  follow up visit at week 14. The PI will follow the subject until she has given birth.  
 
On completion of the dose -titration phase  (end of week 6) , the minimum therapeutic dose of 
pramipexole ER 1.5 mg per day (or placebo) must be achieved by all the patients. The treatment 
with study medications of patients who cannot achieve this dosage will be discontinued , but the 
subject will be requested to  continue with all the study visits . 
 
 
Early Study Termination  (EST)  
A subject who requests to stop study participation for any reason before the end of week 12 , 
including study treatment and study scheduled activities, will be requested to undergo a study 
termination visit as described in section 9.2.11 , unless  erroneously randomized or withdrew 
consent prior to  first dose.   
 
The r easons for EST could include the following:  
•  Pregnancy  
• Adverse Event/Experience  
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 45 of 131 
 
 • Subject withdrawal of consent  and refusal to continue participation  in study  due to lack of 
efficacy or due to other reasons  
• Lost to follow -up/failure to return  
• Death  
• Erroneously randomized  
• Withdrew consent prior to first dose  
 
If there is a medical reason for withdrawal  and the subject refuses to come to study visits after 
study medication was stopped , the subject will remain  under the supervision of the PI as long as 
the PI deems medically necessary.  
 
7.6 Subject Replacement  
A subject who leaves the study at any time for a ny reason will not be replaced.  
8 ASSESSMENTS  
8.1 Schedule of Activities  
See Appendix I for a table describing activities performed at each visit.  
8.2 Evaluation of Pramipexole ER (or Placebo) Dose  
 The subject will be required to visit the clinic at the end of week 3 and 5 (visit 3 and 4) and be 
available for a phone call at the end of week 4 for titration evaluation; to assess the tolerability  
and efficacy of the  pramipexole ER (or placebo)  and the possible need for changing the 
pramipexole ER dose.   
8.3 Safety and Tolerability  
8.3.1 Physical and Neurological Exams  
A complete physical exam  (consisting of a review of all body systems) and neurological exam 
(including evaluation o f mental status; motor function;  balance and coordination; sensory 
function; reflexes and cranial nerves) at visit 1  will be conducted  by the study neurologist  
(primary Investigator or sub -Investigator) . On visit 7 and unscheduled visit s a symptom -directed  
physical and neurological exam will be performed by the study neurologist .  
 
8.3.2 Safety Laboratory Tests – see Appendix II  
Hematology, chemistry and urinalysis tests will be performed as general measures of health.  
Eurofins  Scientific will be responsible for  shipment, storage, and testing of all laboratory 
samples.  Instructions will be included in the laboratory  manual.  
 
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 46 of 131 
 
 8.3.3 ECG  
12-lead ECG s will be performed  to evaluate the cardiovascular system  on the screening  and 
baseline  visits  and on visit 7.  
 
8.3.4 Vital Signs  
Vitals signs will  be measured at all visits except for Visit 3 . Blood pressure and pulse will be 
recorded after resting supine for 5 minutes and standing after at least 3 minute s.  Orthostatic 
hypotension is defined as a reduction of systolic blood pressure of at least 20 mm Hg or 10 mm 
Hg in diastolic blood pressure within 3 minutes of quiet standing  (Aronow WS, 2011) . Height 
will be measured  at screening only and weight will be measured at all visits.   
8.3.4.1  Orthostatic Hypotension Evaluation  
 
1. On baseline and visits 4, 5 and 6 , subjects that have OH according to the description 
above  (section 8. 3.4) will be asked to answer one question of the orth ostatic hypotension 
activity scale (OHAS) which inquires about dizziness, lightheadedness, feeling faint or 
feeling as though you might pass out . The answer is a scale from 0 to 10 where 0 is none 
and 10 is the worst possible.  
2. Change in the differences in  systolic and diastolic blood pressure measured during supine 
and standing positions.   
 
8.3.5 Concomitant Medications  
Concomitant medication logs will be completed at the Screening visit and will be updated at 
each subsequent visit.  The logs will include the medication taken by the subject over the past 3 
months.  A separate log will record anti -PD medications that were previously used . 
 
 
8.3.6 Adverse Events  
Adverse events  will be recorded after the signing of the informed consent of enrolled subjects 
throughout the study  and shall  be reviewed and updated at each subsequent visit and during any 
phone contact with the subject.  AEs for screen failure subjects will be captured only in the 
source documents and not in the eCRF . 
 
8.3.7 Sleep iness  
Sleep iness  will be evaluated  at baseline  and at end of weeks  5, 8 and 12 /Treatment Termination 
visit (visits 4 , 5 and 6) using the Epworth Sleepiness Scale  (ESS, see  Appendix III).  
 
8.3.8 Impulsive -Compulsive Disorders  
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 47 of 131 
 
 The q uestionnaire  for Impulsive -Compulsive Disorders in Parkinson's Disease , (QUIP -Rating  
Scale  Appendix V I), will be used  on the baseline visit and at end of weeks 3, 5, 8, 12/Treatment 
Termination visit and end of week 14 ( visits  3, 4, 5, 6 and 7).  The answers for all questions are 
based on current behaviors and behaviors occurred in the past 4 weeks.  
8.3.9 Suicidal ity 
Columbia Suicide Severity Rating Scale (CSSRS, see Appendix VIII) will be used.  Baseline / 
screening version of the CSSRS will be used at screening visit. This version assesses s uicidality 
in a patient’s lifetime and during the past six month s. The Since Last Visit  (SLV)  version of the 
CSSRS will be used at all consequent  visits. This version assesses suicidality since the patient’s 
last visit.   Efforts must be made  to ensure that the same trained team member completes this 
questionnaire for each subject .   
A subject with any suicidal ideation that answered YES to questions 4 or 5 in the CSSRS 
questionnaire will be referred to a mental health professional.  
CSSRS -SLV  will be used on the baseline visit and at end of weeks 3, 5, 8, 12/Treatment 
Termination visit and end of week 14 ( visits 3, 4, 5, 6 and 7).   
8.4 Efficacy  
Efforts must be made  to ensure that t he same I nvestigator complete s the UPDRS , CGI-S and 
CGI-I scales at all visits  that these scales  are done .   
8.4.1 UPDRS – see Appendix IX 
The UPDRS assesses motor and functional abilities of the subjects.  The total UPDRS is defined 
for this study as the sum of  Parts II and III (Activities of Daily Living a nd Motor sections) . 
These will be completed by history and examination. UPDRS II and III will be performed at 
baseline visit and at  end of weeks 5, 8 and 12/Treatment Termination ( visits 4,  5, and 6 ). UPDRS 
part III will be co mple ted also at screening visit to support diagnosis and the score  will be 
included in the RAF.   
The UPDRS  part III  evaluation will be conducted by a trained  neurologist  or other senior trained 
research staff with at least 10 years’ experience  in conducting the UPDRS. All attempts will be 
made to ensure that the same trained research staff member perform s the UPDRS  part III  at all 
visits  for each subject  and at approximately the same time of the day and time following 
administration of medication .  The UPDRS part  II will be completed by a trained neurologist  or 
other trained  research  staff member as delegated by the Site PI . For consistency efforts must be 
made to ensure that the same trained research staff member will do the UPDRS part  II at all 
required visits f or all subjects.  
8.4.2 Clinical Global Impression  - severity ( CGI -S) - Appendix IV 
This s cale will be completed by the I nvestigator  at baseline and at end of week 12 /Treatment 
termination  (visit 6 ). The scale rates the subject’s overall well-being , including the Parkinson’s 
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 48 of 131 
 
 disease symptoms over the week before the visit.  The CGI scale refers to the global impression 
of the subject and requires clinical experience with the syndrome under assessment . The CGI-S 
scale  is a 7 -point scale that requires the clinician to rate the severity of the subject 's illness at the 
time of assessment, relative to the clinician's past experience with patients who have the same 
diagnosis. Considering total clinical expe rience, a subject  is assessed on severity of illness at the 
time of rating  using a nominal scoring system with:  1, normal, not at all ill; 2, borderline ill; 3, 
mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill. Efforts must  be 
made to ensure that the same neurologist performs the CGI-S at all visits.  
8.4.3 Clinical Global Impression of Improvement  (CGI -I) – Appendix XIV 
This scale will be c ompleted by the I nvestigator  at end of weeks 5, 8 and 12/Treatment 
Termination ( visits 4 , 5 and 6 ). The scale rates the subject’s overall  well-being, including the 
Parkinson’s disease symptoms over the week before the visit.   
The CGI -I scale is a 7 -point scale that requires the clinician to rate the improvement  of the 
subject's illness relative to the baseline visit using a nominal scoring system with:  1, very much 
improved ; 2, much improved ; 3, minimally improved ; 4, no change ; 5, minimally worse ; 6, 
much worse ; or 7, very much worse . Efforts must be made to ensure that the same neurologist 
performs the CGI -I at all visits . 
8.4.4  Quality of Life PDQ39 – Appendix X  
This is a PD specific health -related quality of life scale  that will be perfo rmed at baseline visit 
and at end of  week 12/Treatment Termination (visit 6 ). There are 39 questions in the PDQ -39, 
with 8 discrete scales:  
• mobility (10 items)  
• activities of daily living (6 items)  
• emotional well -being (6 items)  
• stigma (4 items)  
• social support (3 items)  
• cognitions (4 items)  
• communication (3 items)  
• bodily discomfort (3 items)  
Subjects are asked to think about their health and general well -being and to consider how often 
in the last month they have experienced certain events (e.g. difficulty walking 100 yards). 
Subjects are asked to indicate the frequency of each event by selecting one of 5 options ( Likert 
Scale): ever/occasionally/sometimes/often/always or cannot do at all.  
8.4.5 Health -Related Quality of Life (HRQOL) SF -12v2 questionnai re – Appendix 
VII 
The HRQOL SF -12v2 questionnaire assesses the physical and mental health of the patient using 
12 questions related to eight aspects of health (physical and social functioning , role limitation 
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 49 of 131 
 
 due to physical limitation, vitality , role limi tation due to emotional  problems,  bodily  pain,  mental 
and general  health ). This questionnaire will be filled in on the baseline visit and at end of week 
12/Treatment Termination (visits 2, and 6 ).  
8.5 Compliance  
8.5.1 Study Compliance  
At each study visit the Investigator and/or site coordinator will assess the subject’s compliance 
with the prescribed regimen for the study medication  using pill counts .  This will include checks 
of protocol compliance and use of study drug in order to assess the reliability of s ubject -
generated data.  Subjects who fail to comply with the study requirements may be withdrawn 
from the study, following consultation with the sponsor.  
The I nvestigator and clinical staff will make all efforts to ensure all enrolled subjects  attend all 
study visits. If a subject missed a visit all efforts will be made to reschedule the visit within the 
time frame allowed in this protocol, which is 28 ±2 days from the previous visit .  In case the 
subject  cannot complete the visit in the appropriate time , the subject  will continue to the  next 
routine visit . If safety issue s arise, an unscheduled visit may be done.  
The I nvestigator and clinical  staff will make all efforts to ensure all subject s’ efficacy and safety 
scales  are fully completed at each visit. If it is discovered that data is missing from these scales 
after they  were initially completed, the I nvestigator or a member of the clinical  staff can contact 
the subject , up until the following routine visit, to obtain this missing data . If missing data is not 
collected by the time of the following routine subject visit, no additional follow -up will be 
permitted, and this data will be considered missing. Details regarding the collection of this 
missing data (including ti me, date, data points collected and who collected them) will  be 
documented in the source documents and the eCRF . 
8.6 Screening Evaluations  
 
The following scales or tests will be used for screening evaluations:  
• UK Parkinson's Disease Society Brain Bank Clinical  Diagnostic Criteria – (Appendix X I) 
will be used to confirm the Parkinson’s disease diagnosis.  
• Modified Hoehn & Yahr Stage  (Appendix XII ) The scale should be c ompleted with the 
Investigator rating PD symptoms to confirm that the subject meets inclusion criteria 
related to stage of disease.   
• Mini -Mental State Examination (MMSE) (Appendix XIII) MMSE, a 30 points 
questionnaire, will be completed to evaluate the subject for cognitive  abilities necessary 
for study participation.  
• Columbia Suicide Severity Rating Scale - baseline, CSSRS -BL, (Appendix  VIII)  
• UPDRS part III (Appendix IX)  
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 50 of 131 
 
 9 STUDY CONDUCT  
9.1 Study Period  
 
The study duration per subject is 14 weeks in addition to up to 28 days fo r screening. The whole 
study duration is expected to be approximately 24-18  months.  
9.2 Study Procedure s 
 
9.2.1 Detailed Study Plan  
 
A detailed Schedule  of Activities is provided in Appendix I. 
The study includes 7 visits. The first visit will allow screening of potential subjects that will 
participate in the study.  This period of time between the screening visit and enrollment of a 
subject to the study is named the screening phase. The treatment phase is when subje cts are 
receiving  treatment with the study drugs. During the treatment phase, subjects’ condition will be 
evaluated every 5-3 weeks (visits 2 -6). The first 6 weeks of the treatment period will include a 
titration of the Pramipexole ER dose or its placebo  to optimal dose  (titration phase) . One capsule 
a day of P2B001/PPX 0.6/RAS 0.75/Placebo will be taken at this time without any need for 
titration . This will be followed by a  maintenance phase ending at the end of week 12 . The safet y 
follow up phase will st art after week 12 which will include a week (week 13) of no treatment of 
the P2B001 or its components and a down -titration of pramipexole ER or its placebo. Week 14 
will include no treatment at all. The  end of the study drug treatment and a follow up safet y visit 
will be performed at the end of week 14 (visit 7).  
 
9.2.2 Visit 1 - Screening Visit  
 
Prior to performing any study activity, the subject will be thoroughly informed on all aspects of 
the study. The subject will be requested to sign an Ethics Committee/ investigational Review 
Board (EC/IRB) approved informed consent form, after which a unique subject number will be 
assigned to the subject.  
Adverse events  will be recorded after the signing of  the informed consent of enrolled subjects . 
Subjects will be assesse d for study eligibility by the I nvestigator  at the screening visit .  
Subject eligibility will be assessed based on clinical procedures:  
- Medical history – Complete medic al history including PD history  
- Complete physical and neurological examination  
- Vital signs ( HR, BP RR and temperature ), height, weight, and  ECG  
- Previous and concomitant drug history (record of drugs used 3 months prior to study)  
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 51 of 131 
 
 - Laboratory tests, including hematology, chemistry , urinalysis , coagulation and  a 
serum pregnancy test for w omen of childbearing potential (see Appendix II)  
- Mini Mental State Exam (MMSE)   
- Modified H&Y  staging  
- UPDRS part III  
- UK Parkinson's Disease Society Brain Bank Clinical Diagnostic Criteria  
- CSSRS -BL 
After completion of all the testing for the assessment of eligibil ity, it will be decided by the 
Investigator whether the subject is eligible for the study. For a subject to be eligible all the 
inclusion criteria must be met and none of the exclusion criteria must apply. Therefore, all the 
results f rom the screening procedures must be available before determining a subject’s 
eligibility. Subjects found eligible will be further reviewed by a central eligibility monitoring 
committee (see 16.4.2).  The maximal interval between the screening and baseline  visits is 28 
days that can be extended up to  35 days, however, additional Sponsor approval will be required . 
Extension beyond 35 days and up to 90 days may be approved but will require a new collection 
of screening laboratory samples at an unscheduled visit prior to baselin e. Subjects that are screen 
failures may rescreen for the study. If the rescreening visit is within 28 days (or 35 days with 
sponsor approval) of the original blood testing, the screenin g number remains the same and the 
blood draw does not need to be repeated, unless it is the reason for the screening failure.  
Subjects complying with inclusion/exclusion criteria will be randomly assigned to one of the 
four treatment groups by a central website -based  computer program using Randomization Trial 
Supply Management (RTSM). A randomi zation form must be completed  via the RTSM  as soon 
as possible after subject eligibility was confirmed in order to trigger shipment of investigational  
product for thi s subject.   
9.2.3 Visit 2 - Baseline  
The time between visit 1 ( screening ), and visit 2 ( baseline ), will be no less than  24 hours and no 
more than  28 days  (or up to 90 days with sponsor approval ). In this visit a  medication  kit will be 
dispensed to him /her together with  a leaflet of instructions for use . The subject will be given an 
emergency contact card with 24-hour contact numbers. The subject will be instructed to keep the 
contact card with him/her at all times.  
The following activities will be performed:  
- Dispensation of study medication kit  
- Vital  signs (HR, BP RR and temperature), weight and ECG  
- Urine p regnancy test for wom en of childbearing potential  
- Concomitant medications  
- Adverse events  review  
- Inclusion/Exclusion criteria review  
- Study drug dispensing and dosing instructions  
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 52 of 131 
 
 - UPDRS  II and III  questionnaire  
- CSSRS - SLV  questionnaire  
- CGI-S questionnaire  
- PDQ39 questionnaire  
- ESS questionnaire  
- QUIP -RS questionnaire  
- HRQOL SF -12v2  
- Orthostatic hypotension scale question 1 for subjects with OH  
 
The treatment should be started according to the dosing instructions t he day after  the baseline  
visit. 
9.2.4 Visit 3  
At the end of week 3  ±2 days subjects will be required to visit the clinic for tit ration evaluation 
regarding the ir satisfaction and tolerability with the 1.5 mg dose of Pramipexole ER (or placebo). 
The dose may remain 1.5 mg or  be increased to 3.0 mg . Additionally, the subject will continue to 
take 1 capsule a day of P2B001/PPX 0.6/RAS  0.75/placebo.  The following activities will be 
performed : 
- On-site evaluation of Pramipexole ER (or placebo) dose . 
- Concomitant medications  
- Adverse events review  
- CSSRS -SLV  questionnaire  
- QUIP -RS questionnaire  
9.2.5 Week 4 Phone Call  
At the end of week 4  a phone call to the subject wil l be conducted by the PI or sub -Investigator  
regarding the subject’s satisfaction and tolerability  of the treatment and the possible need for 
increase of the dose.  During this phone call a review of adverse events and concomit ant 
medications will also be done.  In addition, if the PI or sub -Investigator  deem necessary , an 
unscheduled visit for a titration evaluation may be conducted  at this time .  
9.2.6 Visit 4  
Visit 4  will take place 5 weeks after the baseline visit ±2 days. The following activities will be 
performed:  
- Evaluation of the pramipexole ER/placebo dose which may be changed if 
necessary only until the end of the next week, week 6.  
- Vital signs ( HR, BP RR and temperature) and weight  
- Concomitant medications  
- Adverse events review  
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 53 of 131 
 
 - Study drug accountability  
- Collect ion of  the titration kit, (Weeks  1-4) 
- UPDRS II, III  
- CSSRS -SLV  questionnaire  
- QUIP -RS questionnaire  
- ESS questionnaire  
- CGI-I questionnaire  
- Orthostatic hypotension scale  question 1  for subjects with OH  
- Laboratory tests for hepatic or renal function for subjects with 
mild hepatic failure or mild kidney failure respectively.  
 
9.2.7 Visit 5 
Visit 5 will take place 8 weeks after the baseline visit and start of medication treatment ± 2 days. 
The following activities will be performed:  
- Vital signs ( HR, BP RR and temperature) and weight  
- Concomitant medications  
- Adverse events review  
- Study drug accountability  
- Collect ion of the maintenance kit  (Box 1 of 2 , weeks 5 -8) 
- UPDRS II, III  
- CSSRS -SLV questionnaire  
- QUIP -RS questionnaire  
- ESS questionnaire  
- CGI-I questionnaire  
- Orthostatic hypotension scale  question 1  for subjects with OH  
- Laboratory tests for hepatic or renal function for subjects with 
mild hepatic failure or mild kidney failure respectively.  
9.2.8 Visit 6 – Treatment Termination  
Visit 6 will be performed at the end of the treatment phase, 12 weeks  ±2 days after the baseline 
visit. The following activities will be performed:  
- Vital signs (HR, BP RR and temperature), weight  
- Concomitant medications  
- Adverse events review  
- Study drugs accountability  
- Collect ion of  maintenance kit ( Box 2 of 2 Weeks  9-12) 
- UPDRS II and III questionnaire  
- CSSRS -SLV  questionnaire  
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 54 of 131 
 
 - CGI-S questionnaire  
- CGI-I questionnaire  
- PDQ39 questionnaire  
- ESS questionnaire  
- QUIP -RS questionnaire  
- HRQOL SF -12v2  
- Orthostatic hypotension scale  question 1  for subjects with OH  
9.2.9 Visit 7 – Safety Follow Up 
A  follow up safety visit will be performed 2 weeks ±2 days after the termination visit. Safety 
parameters will be evaluated, as follows:  
- Symptom -directed physical and neurological examination   
- Vital signs (HR, BP RR and temperature), weight and ECG  
- Concomitant medications  
- Adverse events review  
- Study drugs accountability  
- Collect ion of  down titration kit (week 13)   
- Laboratory tests, including hematology, chemistry , urinalysis and a serum     
pregnancy test for women of childbearing potential (see Appendix II)  
- CSSRS -SLV  questionnaire  
- QUIP -RS questionnaire  
 
9.2.10  Unscheduled Visits  
If needed, an unscheduled visit may take place . 
 
Unscheduled visit for titration follow -up 
During  the titration phase an unscheduled visit may be conducted to assess the need to raise or 
lower the dose of pramipexole ER /or placebo . In addition to the dose evaluation, a review of 
adverse events and concomitant medications  will be conducted.  No other study activities will be 
performed at this visit  unless safety considerations arise  (see next section) .  
 
Unscheduled visit for other reasons  
An unscheduled visit may take place  at any time during the study (e.g. PD symptoms or an AE 
that warrant personal evalua tion) . The following activities will be performed:  
- Vital signs (HR, BP RR and temperature) and weight  
- Concomitant medication  
- Adverse events review  
- Symptom -directed physical and neurological examination  
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 55 of 131 
 
 - Completion of any uncompleted efficacy or safety scales, as needed  
 
The date and reason for the visit and any data generated will be documented in the eCRF .  
9.2.11  Early Treatment /Study Termination Visit   
Subjects who terminate treatment /study  early ( following first dose and prior to visit 6) according 
to criteria in section 7.5  will be requested to undergo a treatment /study  termination visit. The 
treatment termination visit can be conducted as part of the next schedule d study visit if it is 
within 5 days of treatment termination. If the next s cheduled visit is more than 5 days away it is 
preferable , if possible,  to schedule an “unscheduled” visit as soon as possible . All efforts should 
be made to schedule the early treatment /study  termination visit as close to the treatment /study  
termination as  possible. All activities listed in the treatment termination (visit 6) and safety 
visits (visit 7) will be performed at this visit.  The entire study medication kit with all boxes and 
bottles left should be returned . The date and reason for the E TT and any  data generated from the 
ETT visit will be documented in the eCRF .  
 
Subject will be requested to continue all study schedule activities as in section 9.2.11.1. If a 
subject refuses to take part in the scheduled study visits and activities it will be documented as 
early study termination and the Investigator shall only foll ow up on any safety issues if needed.  
9.2.11.1  Follow -up visits of subjects that have terminated the study treatment early  
ETT subjects will be requested to continue with  all study visits and activities as planned, for 
follow up, without taking any study medicatio n. During these visits, all questionnaires and 
assessments will continue as planned for follow up. Accountability will be omitted  since study 
drug was returned at the ETT visit .  
 
Subjects may take rescue therapy during the follow -up visits; this will be d ocumented in the 
concomitant medication list.  
 
ETT subjects that decided later to stop their participation in the study will be requested to 
undergo a  study  termination visit. All activities listed in the treatment termination (visit 6) 
and safety visits (visit 7) will be performed at this visit.  
10 CONCOMITANT MEDICATIONS  
All concomitant medication that the subject is taking from the screening visit  should be recorded 
on the concomitant medications log.  In addition, any changes in concomitant medication or new 
medications added, including as a result of an inter -current illness must be recorded in the case 
report forms.  A separate log will record an ti-PD medications taken prior to enrollment . 
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 56 of 131 
 
 10.1 Prohibited Medication  
Subjects must not receive concomitant therapy with any of the following:  
• Other investigational therapy (washout period 30 days prior to study entry , baseline visit ) 
• Previous MAO -B inhibitors, selegiline or rasagiline, for longer than 4 weeks or within 
the previous 3 months  prior to  baseline visit . 
• Previous levodopa or dopamine agonists, for longer than 4 weeks or within the previous 2 
months prior to baseline visit.  
• Previous antich olinergic drugs for PD  (such as benztropine, orphenadrine 
hydrochloride, biperide n, ethopropazine, procyclidine, trihexyphenidyl) or amantadine 
for longer than 4 weeks; if previous exposure was less than 4 weeks then it must not be 
within 1 month prior to the baseline visit .  
• Subjects can take peripheral anticholinergic drugs (such as oxybutynin, orphenadrine 
citrate, tiotropium bromide etc..) if they are stable on low dose for at least 4 weeks 
prior to study entry, and without (or with minor) cognitive eff ects; however, once 
enrolled into the study use of new peripheral  anticholinergic drugs is prohibited. 
Patients should be followed very closely for possible cognitive side effects.  
• Non selective MAO inhibitors, such as phenelzine  or tranylcypromine  
• Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones,       
thioxanthenes) or metoclopramide . 
• Ciprofloxacin or other CYP1A2 inhibitors : may affect rasagiline plasma concentrations . 
• Antitussive agent Dextromethorph an.: co-administration with rasagiline may lead to 
psychosis.  
• Analgesic agents such as tramadol, methadone , meperidine  and propoxyphene  due to risk 
of serotonin syndrome . 
• St. John's Wort or cyclobenzaprine (tricyclic muscle relaxant).  
• Marijuana or previous exposure  to Marijuana during the last 30 days prior to the 
baseline visit . 
 
Care should be taken to avoid or minimize use of sympathomimetic medications, including 
nasal, oral and ophthalmic decongestants and cold remedies  due to poss ible hypertensive 
reactions.   
Care should be taken when giving study drugs with sedating medications  (e.g. Diphenhydramine , 
Doxylamine Succinate and other first generation antihistamines ) due to possible additive 
sedative effects with pramipexole .  
 
Special attention should  be given to symptoms and sign s of serotonin syndrome, when an 
antidepressant  is administered concomitantly with the study medication.  Subjects who are taking 
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 57 of 131 
 
 tricyclic or tetracyclic antidepressants, SSRIs, SNRIs or triazolopyridine antidepressants will be 
closely followed up by the PI for signs of serotonin syndrome, including:  
agitation or restlessness, confusion , rapid heart rate and  high blood pressure , dilated pupils , 
loss of muscle coordination or twitching muscles , muscle rigidity , heavy sweating , diarrhea , 
headache , shivering  or goose bumps . At each periodic meeting, the DSMB will review adverse 
events and vital signs reported fo r subjects taking antidepressants concomitantly. Severe or 
serious adverse events for such subjects will be reported to the DSMB within 48 hours of receipt 
of the report by the sponsor.  
 
 
10.2 Dietary Restrictions  
Alcohol may increase symptoms of drowsiness or sudden onset of sleep that can be caused by 
pramipexole. Subject will be requested to limit alcoholic consumption to one glass of wine or 
one shot a day , and not within three hours before or after taking the study medication.  
Dietary tyramine restriction is not ordinarily required with recommended doses of rasagiline. 
However, certain foods (e.g. aged cheeses, such as stilton cheese) may contain very high 
amounts (i.e. 150  mg) of tyramine and could potentially cause a hypertensive "cheese" reaction 
in subj ects taking rasagiline, even at recommended doses, due to mild increased sensitivity to 
tyramine.  
10.3 Rescue Therapy  
No rescue therapy will be allowed during the  treatment phase and the two weeks afterwards up 
until the safety follow up visit.  If needed by the subject for adequate treatment of subject’s  
Parkinson 's symptoms and according to the Investigator’s judgment the study medication will be 
discontinued and a rescue medication may be administered. This will be recorded on the 
concomitant medications log and in the reasons for treatment termination . Subject,  who stopped 
taking study treatment  prior to Visit 6, should return to the site for an Early Treatment 
Termination (E TT) visit  as soon as possible. ETT subjec ts will be requested to continue with 
study visits and activities as planned, for follow up, without taking any study medication.    
11 LABORATORIES  
11.1 Safety Laboratory Test s 
The safety laboratory tests (chemistry, hematology, coagulation and  urinalysis  see Appendix  II), 
conducted at screening , safety follow up visit , and additional liver function or kidney function 
tests, as needed,  will be carried out by the Eurofins  Central L aboratory  EU, 
Bergschot 71, 4817 PA Breda, Netherlands for sites in Europe and Eurofins Central Laboratory 
US 2430 New Holland Pike, Lancaster, PA 17601  for sites in USA and Canada.  
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 58 of 131 
 
 The tests will be done according to Eurofins Central Lab oratory  written Standard Operat ing 
Procedures.  Any value outside the normal range will be flagged for the attention of the Investigator 
or designee at the site. The Investigator or designee will indicate whether or not the value is of 
clinical significance.  
Any clinically important abno rmal laboratory values noted at the Screening visit will be recorded 
as medical history. In addition, in order for the Sponsor to collect additional information about 
clinically important laboratory abnormalities, at minimum, the following laboratory 
abnor malities should be captured from Baseline and onwards on the AE pages of the eCRF  as 
appropriate:  
• Any laboratory test result that meets the criteria for an AE or SAE;  
• Any laboratory abnormality that requires the subject to have study drug discontinued or 
interrupted;  
• Any laboratory abnormality that requires the subject to receive specific corrective therapy.  
All clinically important abnormal laboratory tests occurring during the study will be repeated in 
appropriate intervals until : (1) the value returns to  Baseline, (2) the value is judged to be 
clinically acceptable by the Investigator and the Sponsor, (3) a diagnosis that explains  the 
abnormal laboratory is made  or (4) subject is lost to follow -up. When possible, the Investigator 
should report the clinica l rather than the laboratory term (e.g., anemia versus low hemoglobin.)  
The central laboratory will perform all clinical laboratory tests. Detailed shipping/handling 
instructions  of laboratory supply  will be provided in a separate laboratory manual.  
11.2 Vital Signs, Height and Weight  
Respiration rate  (RR per minute)  and temperature will be measured, with the subject in the 
seated position for at least 5 minutes, at the visits specified in the Schedule  of Activities .  
Orthostatic measurements ( lying  and standing BP and 30 seconds of radial pulse) can be 
measured manually or using an automated BP machine and will be measured at every clinic visit , 
except visit 3 that is done for titration evaluation of Prami pexole ER or matching placebo . The 
subject’s BP and HR will be measured after the subject has been lying  for approximately 5 
minutes. The subject will be instructed to rise to a standing position, and a BP measurement will 
be taken after the subject has be en standing for 3 minutes.  HR will be determined for a period of 
30 seconds.  
 
All BP and HR measurements will be taken using the writing arm of each subject.  
 
Additional vital signs will be obtained at the discretion of the Investigator if clinically signi ficant 
signs or symptoms occur.  
 
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 59 of 131 
 
 The subject’s weight will be measured at every clinic visit  except visit 3 that is done for titration 
evaluation of Pramipexole ER or matching placebo . The subject’s height will only be measured 
at the Screening visit.  
11.3 Electrocardiograms ( ECG )  
A standard 12 -lead ECG will be performed at Screening, Baseline and Week 14/ET T. Additional 
ECGs will be performed if clinically indicated. ECGs will be conducted after approximately 5 
minutes supine or recumbent rest using a standard ECG machine equipped with computer -based 
interval measurements.  
The Investigator is responsible for  evaluating the ECG interpretation in relationship to clinical 
signs  and symptoms and reaching a medical decision regarding the subject’s medical status. The 
ECG findings should be assessed by the Investigator as normal, abnormal not clinically 
significant  (NCS), or abnormal clinically significant (CS), as appropriate. All abnormalities, 
whether assessed as clinically significant or not, will be recorded. The ECG tracing should be 
initialed and dated by the Investigator.  
12 STUDY DRUGS SUPPLY  
12.1 Drug Manufacturi ng 
Capsules of P2B001 , its individual components (pramipexole and rasagiline) and matching 
placebo were  manufactured by Catalent Pharma solutions Somerset , USA , address:  Schoolhouse 
Rd. 14 Somerset, NJ 08873, USA.   
Pramipexole ER tablets  and matching place bo were purchased from  Dr. Reddy's Laboratories 
Limited, FTO UNIT 3,  Survey No 41 Bachupally village Qutubullapur Mandal  
Ranga Reddy District Telangana 500090 India  
 
All bottle closures are tamper proof and child resistant.  
12.2 Treatment  Assignment and Randomization  
All subjects will be assigned a unique subject number at the screening visit (visit 1). The subjects 
found to be eligible for the study by both PI and the EMC will be randomized  as soon as possible 
in order to trigger shipmen t of investigational medication to the subject . At randomization, the 
subject will be given a unique randomization number which will be entered into the database but 
not used for subject follow -up. The same unique subject number allocated in the screening  visit 
will continue to be the subject ID number for the rest of the study . 
The randomization will be managed by a cloud -based R andomization and Trial Supply 
Management (RTSM)  system  of Medidata -Balance using a randomization list comprised of 
permuted block s, with stratification by region . Allocation will be to the next available record in 
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 60 of 131 
 
 the randomization list which corresponds to the appropriate stratum. Medication will be assigned 
based on the treatment group allocated at randomization.  
Study files will keep track of subject number and medication kit number . In case of medication 
kit los s or the patient ran out of drug f or any reason  the site can get a replacement medication kit 
by contact ing the RTSM  in order to get the appropriate medication kit number.  
12.3 Packaging and Labeling  
The study medication will be packed and labeled by Almac Group limited, 25 Fretz Road,  
Souderton, PA 18964, USA.  
The s tudy kit will include  an outer box containing 4 inner boxes ;  
• Weeks 1-4 box containing  three bottles:  one bottle of capsules of either P2B001/ RAS 
0.75/PPX 0.6 /placebo  once daily  (33 capsules ) (bottle C , labeled with a bl ue stripe) , one 
bottle with tablets of either Pramipexole ER  0.375  mg or matching placebo (30 tablets) , 
(bottle A,  labeled with a yellow strip e) and one bottle with either Pramipexole ER 1.5 mg  or 
matching placebo (30 tablets ), (bottle B, labeled with a pink strip e). 
• Two identical boxes for weeks 5-12. Each box containing 4 bottles:  one bottle of capsules of 
either P2B001/ RAS 0.75 /PPX 0.6 /Placebo (33 capsules) and 3 identical bottles with 
Pramipexole ER 1.5 mg  or matching placebo tablet s (30 tablets  each) . 
• Week 13 One box containing two bottles: one bottle of  tablets of either  Pramipexole  ER 
0.375  mg or matching placebo (30 tablets) and one bottle of tablets  of either Pramipexole ER 
1.5 mg  or matching placebo  
 
For subject’s  convenience  the bottle s are labeled with different colored stripes.  The bottle  of 
P2B001/ RAS 0.6 /PPX 0.75 /placebo  is labeled with a blue strip e named bottle C. The bottle of 
Pramipexole ER 0.375 mg /matching placebo is labeled with a yellow strip e named bottle A  and 
the bottle of Pramipexole ER 1.5 mg/ matching placebo is labeled with a pink strip e named bottle 
B. 
The whole study kit  with the 4  inner boxes  will be dispensed to the subject on visit 2. No further 
dispensing is needed on other visits . The subject will be requested to bring the used inner box 
with him/her for the next visit as follows :  
• Visit 4: retur n of box weeks 1 -4. 
• Visit 5: return of box used during weeks 5 -8 (1 out of 2  Week 5 -12). 
• Visit 6: return of box used during week s 8-12 (2 out of 2  Week 5 -12). 
• Visit 7: return of box week  13 
 
Since this product is intended for  once daily dosing , there is no need for the subject to carry the 
medication with him/her throughout the day, therefore, the subject will be instructed to keep the  
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 61 of 131 
 
 bottles with  the kit box throughout the study . The outer box and  each inner box will tamper 
evident sealed.  
 
The master English version of the labels on the bottles will include at least the following 
information as follow s:   
 
Label for P2B001  /RAS 0.75mg  / PPX 0.6mg  / placebo  bottle:  
• Study number : P2B001/003  
• Kit number  
• Subject number  
• Subject initials  
• Site number  
• Contents: 33 capsules, containing: Pramipexole / Rasagiline once daily 0.6/0.75 mg or 
Pramipexole 0.6 mg or Rasagiline 0.75 mg or placebo (Exp: mm/yyyy)  
• Storage conditions: 59 ⁰F - 77⁰F (15⁰C - 25⁰C). 
• Protect fro m exposure to high humidity.  
• Take 1 capsule by mouth with a glass of water (8oz or 240ml), do not chew, crush or cut. 
For further dosing instructions see “dosing instruction leaflet” provided by the clinical 
staff.  
• Packaging batch number  
• Caution: new Drug Limited by Federal (or United States) law to Investigational use / for 
clinical trial use only / Investigational drug. To be used by qualified investigators only.   
• Keep out of the reach of children.  
• Do not remove or ingest moisture resistant bags or caniste rs from the bottle.  
• Return all empty, partially used or unused bottles  from the current box to the clinic for 
accountability.  
• Sponsor name and location    
 
Label for Pramipexole ER tablets  1.5 mg  / matching placebo  bottle:  
• Study number: P2B001/003  
• Kit number  
• Subject number  
• Subject initials  
• Site number  
• Bottle # ____ out of _______  
• Contents: 1 x 30 tablets , containing Pramipexole 1.5 mg or placebo (exp: mm/yyyy)  
• Storage conditions: 59 ⁰F - 77⁰F (15⁰C - 25⁰C). 
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 62 of 131 
 
 • Take caplet /s by mouth with a gl ass of water (8oz or 240ml), do not chew, crush or cut. 
For further dosing instructions see “dosing instruction leaflet” provided by the clinical 
staff.  
• Packaging batch number  
• Caution: new Drug Limited by Federal (or United States) law to Investigational u se / for 
clinical trial use only /Investigational drug. To be used by qualified investigators only.   
• Keep out of the reach of children.  
• Do not remove or ingest moisture resistant bags or canisters from the bottle.  
• Return all empty, partially used or unused packages  from the current box  to the clinic for 
accountability.  
• Sponsor name and location  
• Protect from exposure to high humidity.  
• Please keep the bottles with the kit box together at all times.   
 
Label for Pramipexole ER tablets 0.375 mg  / matching  placeb o bottle:  
• Study number: P2B001/003  
• Kit number  
• Subject number  
• Subject initials  
• Site number  
• Contents: 1 x 30 tablets, containing Pramipexole 0.375 mg or placebo (exp: mm/yyyy)  
• Storage conditions: 59 ⁰F - 77⁰F (15⁰C - 25⁰C). 
• Take tablet/s by mouth with a glass of water (8oz or 240ml), do not chew, crush or cut. 
For further dosing instructions see “dosing instruction leaflet” provided by the clinical 
staff.   
• Packaging batch number  
• Caution: new Drug Limited by Federal (or United States) law to Investigationa l use / for 
clinical trial use only /Investigational drug. To be used by qualified investigators only.  
• Keep out of the reach of children.  
• Do not remove or ingest moisture resistant bags or canisters from the bottle.  
• Return all empty, partially used or unuse d packages  from the current box  to the clinic for 
accountability.  
• Sponsor name and location  
• Protect from exposure to high humidity  
• Please keep the bottles with the kit box together at all times.  
 
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 63 of 131 
 
 The following information  will be included o n the Inner boxes label  (up titration box, 
maintenance box  and down titration box) : 
 
• Study number: P2B001/003  
• Box type (either weeks 1 -4, Weeks 5 -12, Weeks 13)                   
• Kit number  
• Subject number  
• Subject initials  
• Investigator name    
• Site number  
• Contents  (one or more of the following , as relevant) :  
o 33 capsules, containing: Pramipexole / Rasagiline once daily 0.6/0.75 mg or 
Pramipexole 0.6 mg or Rasagiline 0.75 mg or placebo. (Exp: mm/yyyy)  
o 30 tablets , containing Pramipexole 1.5 mg or placebo (Exp: mm/yyyy)  
o 30 tablets, containing Pramipexole 0.375 mg or placebo (Exp: mm/yyyy)  
• Storage conditions: 59 ⁰F - 77⁰F (15⁰C - 25⁰C). Take  by mouth with a g lass of  water  (8oz 
or 240ml), do not chew, crush or cut. For further dosing instructions see “dosing 
instruc tion leaflet” provided by the clinical staff.  
• Packaging batch number  
• Caution: new Drug Limited by Federal (or United States) law to Investigational use / for 
clinical trial use only /Investigational drug. To be used by qualified investigators only.  
• Keep out  of the reach of children.  
• Return all empty, partially used or unused packages  from the current box  to the clinic for 
accountability.  
• Sponsor name and location    
• Protect from exposure to high humidity  
• Please keep the bottles with the kit box together at all times.  
 
The following information will be included in the Outer box label:  
 
• Study number: P2B001/003                   
• Kit number  
• Earliest expiry date  
• Subject number  
• Subject initials  
• Investigator name    
• Site number  
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 64 of 131 
 
 • Kit content  
• Storage cond itions: 59 ⁰F - 77⁰F (15⁰C - 25⁰C). 
• Packaging batch number  
• Caution: new Drug Limited by Federal (or United States) law to Investigational use / for 
clinical trial use only /Investigational drug. To be used by qualified investigators only.  
• Keep out of the reach of children.  
• Sponsor name and location   
• Protect from exposure to high humidity  
• Take by mouth with a glass of water (8oz or 240ml), do not chew, crush or cut.  
• For further dosing instructions see "dosing instruction leaflet" provided by the clinical 
staff. 
 
Specific information or language  required for sites in Canada and Europe  will be included 
according to local regulations of each country . The kit label to Canadian sites will include at 
least a French translation. The kit label to the European sites will include the relevant translation 
per the main language of the European country  
12.4 Distribution and Shipment  
Study drugs will be shipped to the study site, under the sponsor’s responsibility.  
The study drugs will be shipped and stored in ro om temperature between 15° and 25°C (59° F-
77°F). Protect from exposure to high humidity and light.  
All study drugs and materials will be packed in appropriate storage boxes.  
If, upon arrival at the investigational site, the study drugs appear to be damag ed, the sponsor 
should be contacted immediately.  
Each shipment of study drugs  for the study will contain a shipment form describing the content 
of shipment. This form will assist in maintaining current and accurate inventory records.  When a 
shipment is rec eived, the site I nvestigator/coordinator/pharmacist or depot will acknowledge 
receipt of the study drugs by signing the relevant shipping documents.  
12.5 Storage, Dispensing and Return  
The study drugs will be kept in a secure, limited -access, controlled storage  area.  
Only authorized personnel will have access to the study drugs. The study site personnel at each 
site will be responsible for correct storage and handling of the study drugs. Drug storage 
temperature will be monitored and recorded on a daily basis.  
The study drugs will be dispensed by the study site pharmacist  or by other  authorized personnel . 
All unused capsules /tablets  and all full, empty or partially empty bottles will be returned to the 
sponsor by the site monitor  after a full reconciliation of the site’s study drug inventory against 
the site’s drug accountability record s has been performed . 
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 65 of 131 
 
 The retest dates will be managed by  the Randomization Trial Supply Management (RTSM) 
system.  
12.6 Verification of Compliance with Treatment Regi men 
Subjects will be instructed to bring the last medication box used (open and unopened bottles) 
with them to visits 4, 5, 6 and 7  for compliance and accountability checks. During each study 
visits, (visits 4-7), the Investigator and/or site coordinator will assess the subject’s compliance 
with the prescribed regimen for the study medication. This will include checks of protocol 
compliance and use of study drug in order to assess the reliability of subject -generated dat a.  
Subjects who fail to comply with the study requirements may be withdrawn from the study, 
following consultation with the sponsor.  
Compliance with the dosing regimen will be determined by performing study drug accountability 
of returned study drugs use d and unused. The number of used, unused and lost capsules will be 
recorded in the study drug accountability records and the eCRF  by site personnel  at every post 
randomization visit .  
A subject will be considered non -compliant if he/she miss es more than 4 doses  of study 
medication within a 28 day period (less than 85% compliance) . Examples of reasons for missing 
a dose are 1) if a subject develops an adverse event that the Investigator believes requires the 
subject’s dose to be held, or 2) if a subject lose s their kit of study medication and a replacement 
kit is requested, which should arrive at the site within 1 -2 days (3 -4 days if a weekend is 
involved).  
12.7 Accountability  
For study drug accountability, the subject will be requested to bring for visits 4-7, all empty, 
partially used or unused bottles  from the box used during the previous month.  During these 
visits ( visits 4, 5, 6/ETT  and 7 ) the site staff will count the remaining capsules and tablets that 
the subject brought with him and document the results i n accountability  records. Only the opened 
box that was used during the last visit will be brought for the accountability. Accountability of 
the entire study medications kit (with all  boxes and bottles left) will be done at ETT visit for 
ETT subjects.  
The I nvestigator is responsible for the control of study drugs under investigation. Adequate 
records of the receipt  and disposition of the study drug must be maintained.  
Study drug s accou ntability records should contain the following information:  
▪ Shipment number, kit numbers, batch number, number of kits and date 
received for all shipments of  study drug received  by the site  
▪ Subject number, medication kit number, the date, batch number, an d 
quantity of study drug dispensed to AND  returned by the subject 
(when applicable)  
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 66 of 131 
 
 ▪ Kits numbers, batch number, number of kits (un -dispensed study 
drug) or number of capsules /tablets  (returned study drug) for all study 
drug returned to the Sponsor  
During each site visit, the monitor will review all study drug s accountability record s and study 
drug inventory on -site.  
 
12.8 Study End  
Once the study site has been closed out by the monitor all remaining unused and partially used 
drug supplies must be returned to the sponsor . Once this has been done,  the corresponding 
accountability records  must be kept at the study sites and a photocopy of these records will be 
sent to the sponsor . 
12.9 Blinding  
Blinding will be maintained during the whole course of the st udy. The I nvestigators, study 
coordinators, and their staff at the study site, the sponsor’s personnel and the personnel involved 
in subject assessment, monitoring, analysis and data management  will all be blinded to the 
subject assignment.  Specific , inde pendent, unblinded study personnel from the CRO will be 
available to provide the DSMB with periodic reports.  
12.9.1  Emergency Code Breaking  
Emergency code breaking will be managed by the IWR/ IVR system. The randomiz ation code 
may be broken by the I nvestigator w hen urgent action is required for the clinical management of 
the patient. Typically,  code breaks will occur only in emergency situations which may include 
the management of a serious adverse event. If possible, the sponsor, or designee, should be 
contacted  to discuss the case before the code is broken.   
If it becomes necessary to break the code during the study, the name of the person who breaks 
the code, the date, time and reason will be recorded in the RTSM . The reason for the break of the 
code should al so be documented in the eCRF. The I nvestigator should promptly document and 
explain to the Sponsor, or designee, any premature unblinding (e.g., accidental unblinding, 
unblinding due to a serious adverse event) of the investigational product.  
13 SAFETY/ADVER SE EVENTS  
13.1 Adverse Events definition  
An adverse event is a ny untoward medical occurrence in a clinical investigation subject who is 
administered a medicinal product whether or not considered related to the medicinal product. An 
AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory 
finding, for example), symptom or disease (new or exacerbated), temporally associated  with the 
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 67 of 131 
 
 use of a medicinal product, whether or not considered related to the product. Pre -existing signs 
and symptoms should not be considered AEs unless they worsen unexpectedly post -study drug 
administration. In addition, any study procedure -related AE  that occurs after study participants 
have signed the Informed Consent Form (ICF) and prior to administration of the first dose of 
study drug will be recorded as an AE.  Any adverse event that occurs post -study drug 
administration will be considered a treat ment -emergent AE. Any adverse event that occurs prior -
study drug administration will be considered a baseline -emergent AE.  Again, all events should 
be entered whether or not the event is considered to be related to the study drug.  
The date of onset, a desc ription of the AE, severity, seriousness, action taken, relationship to the 
study drug s (causality),  outcome of the event and date of resolution will be recorded.  The final 
study report will include all of these details for each AE as well as the calculate d duration.  
The I nvestigator will assess the severity of the AE as:  
▪ mild: AE which is easily tolerated  
▪ moderate:  AE sufficiently discomforting to interfere with daily 
activity.  
▪ severe:  AE which prevents normal daily activities.  
 
The I nvestigator will ass ess the causality of the AE as (see section 13. 2): 
▪ unrelated  
▪ possibly related  
▪ probably related  
13.2 AE Causality Definitions  
TERM  DEFINITION  CLARIFICATION  
Unrelated  This category applies to those AEs which, 
after careful consideration, are clearly due to 
extraneous causes (disease, environment, etc.)   
Possibly  This category applies to those AEs for which, 
after careful medical consideration at the time 
they are evaluated, a connection with the test 
drug administration appears unlikely but 
cannot be ruled out with certainty.  An AE may be considered possibly related if or 
when (at least two of the following):  
• It follows a reasonable temporal sequence 
from administration of the drug.  
• A causal relationship to the experimental 
treatment cannot be reasonably excluded 
and an alternative explanation (e.g., 
concomitant medication or concomitant 
disease) cannot be excluded or reasonably 
suggested as causing the AE.  
• It follows a known pattern of 
response to the test drug.  
Probably  This category applies to those AEs which, 
after careful medical consideration at the time An AE may be considered probably related if or 
when (at least three of the following):  
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 68 of 131 
 
 TERM  DEFINITION  CLARIFICATION  
they are evaluated, are felt with a high degree 
of certainty to be related to the test drug.  • It follows a reasonable temporal sequence 
from administration of the drug.  
• It could not be reasonably explained by the 
known characteristics of the subject’s clinical 
state, environmental or toxic factors or other 
modes of therapy administered to the subject.  
• It disappears or decreases on cessation or 
reduction in dose. There are important 
exceptions when an adverse event does not 
disappear upon discontinuation of the drug, 
yet drug -relatedness clearly exists.  
• It follows a known pat tern of response to the 
test drug.  
 
In case of an AE, the Investigator will initiate appropriate treatment according to his medical 
judgment and will decide whether to withdraw the subject  from the study.  Subjects should be 
followed clinically until all parameters (including laboratory tests) have either returned to 
normal, or are otherwise explained.  
 
An abnormal result of diagnostic procedures including abnormal laboratory findings will be 
considered an AE if it:  
• results in subject’s withdrawal by the I nvestigator  
• is associated with a serious adverse event  
• is associated with clinical signs or symptoms  
• is considered by the physician to be of clinical significance  
All adverse events will be recorded in the source documents for all study subjects from the 
signing of the ICF until the subject has completed the study (i.e., following completion of Visit 7 
(week 14)  or screen fails or prematurely discontinues from the study, whichever occurs first.  
For randomized subjects all adverse events will be recorded in the eCRF. For screen failure 
subjects, adverse events will be captured only in the source documents and not in the eCRF.  
13.3 Reporting Orthostatic Hypotension  as AE  
Only the following instances of orthostatic hypotension need to be recorded as an adverse event:  
• Any drop in systolic or diastolic blood pressure that the PI deems is clinically significant. 
The decision could be based on observations during the visit or if a subject complains of 
symptoms related to orthostatic hypotension, however, thi s is left ultimately to the 
judgment of the PI.   
• A drop of over 30 mm Hg in systolic or 20 mm Hg in diastolic blood pressure should 
automatically be considered as clinically significant, even if asymptomatic, and thus 
should be captured as an adverse even t. 
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 69 of 131 
 
 13.4 Serious Adverse Event (SAE)  
An SAE is defined as an AE that results in any of the following outcomes:  
▪ death  
▪ life-threatening  
▪ requires inpatient hospitalization  or prolongs hospitalization  
▪ persistent or significant disability/incapacity  
▪ a congenital abnormality or birth defect  
▪ an important medical event which requires medical intervention to 
prevent the above outcomes.  
Important medical events are those which may not be immediately life -threatening, but may 
jeopardiz e the subject and may require intervention to prevent one of the other serious outcomes 
listed above. Examples of such events are intensive treatment in an emergency room or at home 
for allergic bronchospasm; blood dyscrasias or convulsions that do not res ult in hospitalization; 
resulting in an adverse event will normally be considered serious by this criterion.  
13.5 SAE Reporting  
Any AE meeting the definition of serious, occurring after signing of informed consent or during 
30 days after the last dose administr ation and, from then on, only if the study treatment is 
assessed as “suspected” with regard to causality, must be recorded on the SAE Report Form 
provided by PRA Health Science . The SAE must be reported within 24 hours from the 
Investigator’s knowledge of its occurrence to:  
Sites in Europe:  
PRA Drug Safety Centre Email (EAPA): MHGSafety@prahs.com   
PRA Drug Safety Centre Fax (EAPA): + 44 (0) 1792 525 720  
PRA Safety Helpline EAPA: +49 621 8782 154  
Sites in USA and Canada:  
PRA Drug Safety Centre Email (NA): CHOSafety@prahs.com  
PRA Drug Safety Centre Fax (NA): 1 -888-772-6919  
PRA Safety Helpline NA: 1 -800-772-2215  
 
 
The I nvestigator must be prepared to supply the sponsor with the following information:  
a) Investigator name and center number  
b) Subject  ID number  
c) Medication kit number  
d) Subject initials  
e) Subject demographics  
f) Clinical Event  
g) description  
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 70 of 131 
 
 h) date of onset  
i) severity  
j) treatment (including hospitalization)  
k) relationship to study drug (causality)  
l) action taken regarding study drug  
m) if the SAE was Fatal or Life -threatening  
cause of death (whether or not the death was related to study drug)  
autopsy findings (if available)  
n) Medical History case report form (copy)  
o) Concomitant Medication case r eport form (copy)  
p) Any relevant laboratory reports  
Follow -up information  or new  information about any SAE should be forwarded by the site to 
PRA Health Science Safety  within 24 hours of the information becoming available. This 
information should be sent to the sponsor’s appointed safety monitor.  
The clinical site will be responsible for notifying their  IRB and the subject’s General Practitioner 
of all SAEs that occur at their site.  
The sponsor /CRO  will submit a summary of the clinical course of the SAEs to the authorities, 
according to regulations.  
Subjects who have had an SAE must be followed clinically until all parameters (including 
laboratory) have either returned to normal, stabilized or are otherwise explained.  
 
Overdose:  
Taking more than 1 capsule per day  and/or  more than 4.5  mg of pramipexole ER or matching  
placebo  is considered an overdose . Cases of overdose, whether accidental or intentional, that 
result in serious adverse reactions are to be reported as an SAE within one business day after the 
Investigator becoming aware of the overdose.  The overdose should be reported on the standard 
SAE report form and sent to PRA Safety using the information below.  
Sites in  Europe : 
PRA Drug Safety C entre Email (EAPA): MHGSafety@prahs.com  
PRA Drug Safety Centre Fax (EAPA): + 44 (0) 1792 525 720  
PRA Safety Helpline EAPA: +49 621 8782 154  
Sites in USA and Canada:  
PRA Drug Safety Centre Email (NA): CHOSafety@prahs.com  
PRA Drug Safety Centre Fax (NA): 1 -888-772-6919  
PRA Safety Helpline NA: 1 -800-772-2215  
 
All cases of overdoses,  even if not associated with adverse reactions , shall be re corded within 
EDC, including  symptoms, corrective treatment  and outcome of overdose.  
 
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 71 of 131 
 
 13.6 Pregnancy  
Should a pregnancy occur , it must be reported and recorded on a pregnancy report form. 
However, pregnancy is not regarded as an AE for the purposes of t his protocol, unless there is a 
suspicion that the study drug may have interfered with the effectiveness of a contraceptive 
medication.  
The outcome of all pregnancies (i.e., spontaneous miscarriage, elective termination, normal birth 
or congenital abnorma lity) must be followed up and documented even if the subject was 
discontinued from the study.  
All reports of congenital abnormalities/birth defects are to be considered SAEs. Spontaneous 
miscarriages should also be reported and handled as SAEs. Elective ab ortions without 
complications will not be regarded as AEs.  
13.7 Suspected Unexpected Serious Adverse Reaction (SUSAR)  
Adverse reactions are all untoward and unintended responses to the investigational product 
related to any dose administrated. Unexpected advers e reaction is those of which the nature, or 
severity, is not consistent with the applicable product information.  
All SUSAR s should be reported to the authorities.  
Investigators will also be notified of all unexpected, serious, drug -related events (i.e., 7 - or 15 -
day expedited safety reports) that occur during the clinical trial; those events will be reported to 
the site in a blinded fashion. Each site is responsible for notifying its IRB of these expedited 
safety reports, in accordance with applica ble site practices.  
14 DATA MANAGEMENT AND QUALITY ASSURANCE  
14.1 Handling of Data  
An Electronic Data Capture (EDC) system to collect subject electronic Case Report Form 
(eCRF) information will be used. All the information collected during the study will be recorded 
in the eCRF identified by subject  initials and subject ID number , for each subject enrolled, 
includ ing those removed for any reason after administ ered the first dose. It is the responsibility 
of the Investigator and Co -Investigator to ensure that the eCRFs are properly and completely 
filled in.  
Central data management will be performed by PRA . Internet -based remote data capture will be 
used for entering, managing, and validating data from centers. The following regulation will be 
followed:  
• FDA 21CRF part 11 rule  
• ICH, Good Clinical Practice, Consolidated guideline  
• FDA Guidance for Industry “Computer ized system used in clinical trials.  
• EU Directives  
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 72 of 131 
 
 14.2 Coding of Adverse Events, Drugs and Diseases  
All AEs will be coded using the Medical Dictionary for Regulatory Activities Terminology 
(MedDRA) latest version.  Concomitant medications will be coded accor ding to the WHO drug 
dictionary.  
14.3 Data Quality Assurance  
All aspects of the study will be carefully monitored with respect to Good Clinical Practices 
(GCP) and SOPs for compliance with applicable government regulations. The study monitor will 
be an authoriz ed individual designated by the Sponsor. The study monitor will have access to all 
records necessary to ensure integrity of the data and will periodically review the progress of the 
study with the PI.  Study monitoring will be conducted according to a moni toring plan.  
15 STATISTICAL METHODOLOGY  
This study is a phase 3, twelve -week, multi -center, multinational, randomized, double -blind, 
double -dummy, parallel group study.  Up to 525 eligible subjects with early untreated Parkinson’s 
disease (PD) who are not early terminated from the study during screening or baseline visits and 
are randomized to treatment  with P2B001 0.6/0.75 (150 subjects), or pramipexole 0.6 mg once 
daily ( 150 subjects), or rasagiline 0.75 mg once daily (150 subjects), or pramipexole ER titrated 
to therapeutic optimal dose (75 subjects) using a randomization scheme of 2:2:2:1, respectively.   
Randomization will take place following the completion of all scre ening procedures including 
subject approval by both site PI and the central EMC.   
This study is powered  to demonstrate the superiority  of (i) P2B001 0.6/0.75mg as compared to its 
individual components in the change from baseline to Week 12/Treatment Termination in Total 
UPDRS score and , (ii) to demonstrate the superiority of P2B 001 0.6/0.75mg over pramipexole ER 
in the change from baseline to Week 12/ Treatment Termination in the ESS .  
Treatment with pramipexole ER will serve as a calibration arm to better characterize P2B001 
against currently used therapy. Therefore, with the exception of change from baseline to Week 
12/Treatment Termination in the ESS , only descriptive statistic s and no formal significance testing  
will be made between the pramipexole ER arm and the other three study arms.  
Week 12/Treatment Termination  is defined for all statistical analyses  involving significance 
testing  as the last visit in which a subject was treated with the study drug.  
15.1 Sample Size Rationale  
The study was powered to allow achieving two goals:  
• To demonstrate the superiority of P2B 001 0.6/0.75mg compared to its individual components 
in the primary endpoi nt, the change from baseline to Week 12/ Treatment Termination in total 
UPDRS score:  
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 73 of 131 
 
 - The power to meet the primary endpoint was estimated based on simulation runs assuming 
equal arms size of P2B 001 0.6/0.75mg and its individual components as well as repeated 
UPDRS measurements at baseline, week 4, week 8 and week 12.  
- The expected STD of the change from baseline was assumed to be 6.0 UPDRS points.  
- The expected treatment effect of P2B 001 0.6/0.75mg is 3 UPDRS points over rasagiline 
0.75mg and 2.25 UPDRS points over 0.6mg pramipexole.  
- Sequential correlations between changes from baseline will be 0.7 and 0.49 between these 
obtained at week 4 and at week 12.  
- Missing observations rate of 10% occurring at random.  
- The statistical model used in the simulation study was the Mixed Model for Repeated 
Measures (MMRM) (SAS® MIXED procedure with REPEATED sub -command) testing 
two contrasts: P2B 001 0.6/0.75mg vs. rasagiline 0.75mg and P2B 001 0.6/0.75mg vs. 
pramipexol e 0.6mg  at Week 12/ Treatment Termination.  
- In order to consider the study as successful both tested contrasts have to be statistically 
significant at 5% two -tailed each.  
The simulation indicates that a total of 150  subjects per group treated with P2B001 0.6/0.75mg, 
rasagiline 0.75mg arm or pramipexole  0.6mg will provide 87.6% power to detect a statistically 
significant effect size favoring P2B001 0.6/0.75mg by 3 UPDRS points over rasagiline 0.75mg  
and 2.25 UPDRS points over pramipexole 0.6mg .   
• To demonstrate the superiority of P2B 001 0.6/0.75mg over pramipexole ER in the first 
secondary endpoint, namely, the change from baseline to Week 12/ Treatment Termination in 
the ESS:  
- The power to meet this secondary endpoint was estimated using the two -sample  t-test for 
mean difference at a two -sided alpha of 5% (SAS® POWER procedure).  
- The expected STD of the change from baseline was assumed to be 3.0 ESS points.  
- The expected treatment effect of P2B 001 0.6/0.75mg over pramipexole ER is 1.5 ESS 
points.  
- Accordin g to the gate keeping method for multiple endpoints while testing for the 
secondary endpoints, this secondary endpoint will be considered as met only in the case 
that both primary endpoint contrasts as well as the P2B 001 0.6/0.75mg over Pramipexole 
ER comp arison in the change from baseline to Week 12/ Treatment Termination in the ESS 
will be met at two -tailed alpha level of 5% each.  
This analysis indicates that a total of 150 subjects per group treated with  P2B001 0.6/0.75mg 
and 75 subjects treated with  pramipexole ER arm, considering the above assumptions, will 
provide a power of 94.1% to detect a statistically significant effect size at the magnitude of 1.5 
ESS units or more at a two -sided alpha level of 5%.  
15.2 Sample Size Re -Assessment  
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 74 of 131 
 
 To examine whether the  variance estimate used in power calculations for the primary endpoint 
was adequate, an assessment of the variance magnitude will be performed after at least 1/3 of the 
subjects complete the study treatment period. The EM algorithm of Gould and Shih 
(Commu nications in Statistics. A Theory and Methods, 21, 2833 -2853, 1992), will be applied to 
estimate the variance of the change from baseline to Week 12/ Treatment Termination in total 
UPDRS score, without breaking the blind . In the case that the variance estim ate will be found to 
be larger than the one projected, the sponsor reserves the right to up -size the study via protocol 
amendment.  
15.3 Randomization  
Randomization will take place following the completion of all screening procedures including 
subject approval by both site PI and the central EMC . 
Up to 525 eligible subjects with early untreated Parkinson’s disease (PD) who are not early 
terminated from the study during screening or baseline visits and are randomized to treatment  
with P2B001 0.6/0.75 (approximately 150 subjects), or pramipexole 0.6 mg on ce daily 
(approximately 150 subjects), or rasagiline 0.75 mg once daily (approximately 150 subjects), or 
pramipexole ER titrated to therapeutic optimal dose (approximately 75 subjects) using a 
randomization scheme of 2:2:2:1, respectively.  
15.4 Data Analyses S ets 
The following data analysis sets are defined for this study:  
• Intention -to-Treat Analysis Set (ITT) : The ITT Analysis Set will include all eligible and 
randomized subjects who are not early terminated from the study during screening or 
baseline visits  according to the treatment group to which they are originally randomized  
to. The Intention -to-Treat (ITT) analysis set will serve as the principal analysis set for 
efficacy assessments  
• Modified Intention -to-Treat Analysis Set (mITT) : The mITT Analyses Set is a subset of 
the ITT  Analysis Set including subjects  who have  at least one post -baseline UPDRS  
assessment and have taken at  least one study drug dose according to the treatment group to 
which they are originally randomized  to.  
• Complete rs Analysis Set ( CO): The complete rs analysis set (CO) will consist of all subjects 
who complete the 12 weeks of the study  according to treatment actually administered . 
• Per Protocol Analysis Set (PP): The per -protocol analysis set (PP) will consist of all subjects 
included  in the CO analysis set without any major protocol violations  according to treatment 
actually administered . 
• Safety Analysis Set (ST): The safety analysis set (ST) will consist of all subjects who have 
been randomized and received at least one study drug ac cording to treatment actually 
administered.  The safety analysis set  (ST) will serve as the principal analysis set for safety 
assessments.  
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 75 of 131 
 
  
15.5 Overall Significance Level  and Multiplicity Adjustment:  
The overall significance level for this study will be 5% using two -tailed tests. No interim analyses 
or futility analyses are planned for this study.  
The overall, experiment -wise type -I error rate of 5% will be preserved according to the below plan:  
1. The principal analysis of the primary endpoint is designed to d emonstrate the efficacy of 
P2B001 0.6/0.75mg as compared to its individual components in the changes from baseline to 
Week 12/ Treatment Termination. Accordingly, analysis will employ two contrasts: P2B 001 
0.6/0.75mg vs. pramipexole 0.6mg once daily and, P2 B001 0.6/0.75mg vs. rasagiline 0.75mg 
once daily. The type -I error of 5% for multiple contrasts testing for the primary endpoint will 
be preserved by determining that the primary endpoint is met only if both comparisons will 
favor P2B 001 0.6/0.75mg at a tw o-tailed alpha level of 5% each.     
2. Multiplicity adjustment for multiple endpoints testing for the secondary endpoints will utilize 
the gate keeping hierarchical method according to the following order and plan:  
- For the 1st secondary endpoint, namely, the P2B 001 0.6/0.75mg vs. Pramipexole ER 
contrast in the change from baseline to Week 12 /Treatment Termination in the ESS, will 
be considered as met only if both primary endpoint contrast s as above defined and the 
P2B0011  0.6/0 .75mg vs. pramipexole ER contrast in the change from baseline to Week 
12/Treatment Termination in the ESS will all be met (total of 3 contrasts) at a two -tailed 
alpha level of 5% each.     
- The 2nd secondary endpoint, namely, the change from baseline to Wee k 12/ Treatment 
Termination visit in the Total PDQ39 will be considered as met if all of the 3 previous 
tested contrasts (primary endpoint and 1st secondary endpoint) as well the two contrasts: 
P2B001 0.6/0.75mg vs. pramipexole 0.6mg once daily and, P2B 001 0.6/0.75mg vs. 
rasagiline 0.75mg once daily in the 2nd secondary endpoint will all be met (total of 5 
contrasts) at a two -tailed alpha level of 5% each.  
- The 3rd secondary endpoint, namely, the change from baseline to Week 12/ Treatment 
Termination visit in the ADL UPDRS (part II) score will be considered as met if all of the 
5 previous tested contrasts (primary endpoint, 1st and 2nd secondary endpoints) as well the 
two contrasts: P2B 001 0.6/0.75mg vs. Pramipexole 0.6mg once daily and, P2B 001 
0.6/0.75mg vs. r asagiline 0.75mg once daily in the 3rd secondary endpoint will all be met 
(total of 7 contrasts) at a two -tailed alpha level of 5% each.  
- The 4th secondary endpoint, namely, the change from baseline to Week 12/ Treatment 
Termination visit in the motor UPDRS (part III) score will be considered as met if all of 
the 7 previous tested contrasts (primary endpoint, 1st, 2nd and 3rd secondary endpoints) as 
well the two contrasts: P2B 001 0.6/0.75mg vs. Pramipexole 0.6mg once daily and, P2B 001 
0.6/0.75mg vs. rasagilin e 0.75mg once daily in the 4th secondary endpoint will all be met 
(total of 9 contrasts) at a two -tailed alpha level of 5% each.  
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 76 of 131 
 
 - The 5th secondary endpoint, namely, the CGI -S responder’s analysis at Week 12/ Treatment 
Termination visit (change from baseline  ≥1 CGI -S points) will be considered as met if all 
of the 9 previous tested contrasts (primary endpoint, 1st, 2nd, 3rd and 4th secondary 
endpoints) as well the two contrasts: P2B 001 0.6/0.75mg vs. Pramipexole 0.6mg once daily 
and, P2B 001 0.6/0.75mg vs. rasagiline 0.75mg once daily in the 4th secondary endpoint 
will all be met (total of 11 contrasts) at a two -tailed alpha level of 5% each.  
15.6 Study Population Summary  
The ITT analysis set  will be used to describe study population. Descriptive statistics of these data 
will be provided by treatment group and overall.  
15.6.1  Subject Disposition  
Data from subjects who are randomized, subjects who are randomized regardless of treatment 
(ITT), mITT, CO, PP and ST analysis sets, subjects who have reached the End of Study visit 
according to study plan , subjects who early discontinued  treatment or study follow -up will be 
summarized. Data from subjects who early discontinued  study IP treatment or study fol low-up will 
also be displayed by discontinuation reaso n using descriptive statistics. The denominator for 
calculating the percentages will be the set of ITT. This summary table will also describe all subjects 
screened into  the study.  
15.6.2  Study Inclusion and Ex clusion Criteria  
Although it is expected that all subjects randomized into the study will meet all study inclusion 
and exclusion criteria there might be some subjects that will be granted waivers allowing them to 
be enrolled into the study. The number and proportion (%) of the ITT analysis set subjects who 
failed to meet study inclusions/exclusion criteria will be reported  broken down by criteria . 
15.6.3  Demographics and Baseline Characteristics  
Demographics and baseline data will be displayed for the ITT analysis  set. Subject demographic 
and baseline characteristics, including baseline prognostic factors will be examined to assess the 
comparability of the treatment groups. For continuous variables, descriptive statistics (number [n], 
mean, standard deviation (SD),  standard error, median, minimum, and maximum) will be 
provided. For categorical variables, subject counts and percentages will be provided. Categories 
for missing data will be presented.  
Summary statistics of these parameters will also be provided when b roken down by geographical 
region, and by US/Non -US sub -populations.  
15.6.4  Medical History  
The incidence (no. of patients) of past medical conditions will be provided when broken down by 
System Organ Class ( SOC ) and Preferred Term  (PT) according to MedDRA dictio nary. Subjects 
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 77 of 131 
 
 with at least 1 past medical condition in each SOC /PT category  will be summarized using 
descriptive statistics. Subjects will be coun ted only once in each category.  
15.6.5  Prior and Concomitant Medications  
All prior and concomitant medications will be coded using the WHODRUG  dictionary. The 
incidence of prior medications and separately those consumed concomitantly ; from the day of 1st 
study IP administration and onwards,  will be summarized using descriptive statistics by 
Therapeutic Main Group (ATC Level 2) and dictionary Preferred T erm.  
Subjects will only be counted once in each Therapeutic Main Group, and only once in each 
Preferred Term category.  
15.6.5.1  Pre-Study Medications  
Analyses will include only coded medications that were initiated one day or more prior to the 1st 
administration of study IP. Medications in which start date will not be reported in the database will 
also be considered as pre -study medications.   
Incidence table including subject counts (no. of subjects) and percentages broken down by 
Therapeutic Main Group and Preferred Term as well as by treatment group  will be generated.  
Summary statistics of pre -study medications will also be provided when broken down by US/Non -
US sub -populations.  
15.6.5.2  Concomitant  Medications  
Analyses will include  only coded medications that were consumed  after 1st study IP administration. 
Medications in which start date will not be reported in database will also be considered as 
concomitant m edications. Medic ations lacking stop date will be considered as ongoing for the 
purpose of analysis.  
Incidence table including subject counts (no. of subjects) and percentages broken down by 
Therapeutic Main Group and Preferred Term  as well as by treatment  group  will be generated.  
Summary statistics of concomitant medications will also be provided when broken down by 
US/Non -US sub -populations.  
15.6.5.3  Disallowed Medications Use  
The following medications are disallowed :  
• Other investigational therapy (washout period 30 days prior to study entry, baseline visit)  
• Previous MAO -B inhibitors, selegiline or rasagiline, for longer than 4 weeks or within the 
previous 3 months prior to baseline visit.  
• Previous levodopa or dopamine agonists, for longer than 4 we eks or within the previous 2 
months prior to baseline visit.  
• Previous anticholinergic drugs for PD (such as benztropine, orphenadrine hydrochloride, 
biperiden, ethopropazine, procyclidine, trihexyphenidyl) or amantadine for longer than 4 
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 78 of 131 
 
 weeks; if previou s exposure was less than 4 weeks then it must not be within 1 month 
prior to the baseline visit .  
• Subjects can take peripheral anticholinergic drugs (such as oxybutynin, orphenadrine 
citrate, tiotropium bromide etc..) if they are stable on low dose for at least 4 weeks prior to 
study entry, and without (or with minor) cognitive effects; however, once enrolled into the 
study use of new peripheral  anticholinergic drugs is prohibited. Patients should be 
followed very closely for possible cognitive side effects . 
• MAO inhibitors, such as phenelzine  or tranylcypromine  
• Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones,    
thioxanthenes) or metoclopramide . 
• Ciprofloxacin or other CYP1A2 inhibitors: may affect rasagiline plasma concentratio ns. 
• Antitussive agent Dextromethorphan.: co -administration with rasagiline may lead to 
psychosis.  
• Analgesic agents such as tramadol, methadone, meperidine and propoxyphene due to risk of 
serotonin syndrome.  
• St. John's Wort or cyclobenzaprine (tricyclic mus cle relaxant).  
• Marijuana or previous exposure  to Marijuana during the last 30 days prior to the baseline 
visit.  
 
Incidence table including subject counts (no. of subjects) and percentages broken down by 
treatment group  will be generated and data listing will be provided.  
15.6.6  Protocol Violations/Deviations  
Protocol deviations and violations will be  recorded on an ongoing basis and will be included in a 
DV domain in the SDTM database.  
The number of s ubjects with at least 1 p rotocol violation /deviation  in each category will be 
summarized using descriptive statistics. Detailed individual subject listing will also be provided.  
15.6.7  Efficacy Endpoints and Analyses  
All efficacy endpoints will be tested for the ITT analysis set controll ing for multiplicity as detailed 
in Section 15.5. 
An effort to obtain the  efficacy outcome measures data regardless if study treatment was 
discontinued will be ma de. 
Week 12/Treatment Termination  is defined for all statistical analyses involving significance 
testing as the last visit in which a subject was treated with the study drug.  
15.6.8  Primary Efficacy Endpoint and Principal Statistical Analysis  
The primary efficacy endpoint for this study is the change from baseline to Week 12/ Treatment 
Termination in total UPDRS score (defined as sum of parts II and III, scores (0 -160). The statistical 
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 79 of 131 
 
 model will be a Mixed Model for Repeated Measures (MMRM) (SAS® MIXED pro cedure with 
REPEATED sub -command). The model will include the following fixed effects: categorical week 
in trial by treatment interaction, country  or geographical region (CGR) , and baseline UPDRS 
score. The model will use the unstructured covariance struct ure and the REML estimation method 
and degrees of freedom will be adjusted using the Kenward -Roger method. Data from all three 
changes form baseline to post -baseline visits (weeks 4, 8 and 12) collected from all subjects 
randomized into the study will be u sed as response in the model. The differences between the 
P2B001 0.6/0.75mg arm as compared to its 2 individual components at Week 12/Treatment 
Termination will be estimated and tested using 2 contrasts: P2B 001 0.6/0.75mg vs. pramipexole 
0.6mg and P2B 001 0.6/0.75mg vs. rasagiline 0.75mg. The study primary endpoint will be 
considered as met only if both contrasts will favor P2B 001 0.6/0.75mg at a two -tailed alpha level 
of 5% each.  
15.6.9  Sensitivity Analys es for the Primary Endpoint  
The robustness of the results of  the principal analysis of the primary endpoint will be explored 
employing the following:  
15.6.9.1  Sensitivity Analysis Using Difference Analyses Sets  
The primary analysis  described above will be used for the  ITT, mITT, CO and PP Analysis Sets  
with or without efficacy measurements taken after study treatment termination . 
15.6.9.2  Sensitivity Analysis Using Change from Baseline to Last Observed Value (LOV)  
The Total UPDRS score change from baseline to last observed value (LOV) , with or without 
UPDRS measurements taken after study treatment termination,  will be calculated  and analyzed  for 
the ITT Analysis Set.  
The statistical model  to be used for the analysis of t he change from baseline to LOV  in the Total 
UPDRS score  will be an analysis of covariance  (SAS® MIXED procedure ) and the model will 
include treatment group, CGR and baseline Total UPDRS score . The c hange from baseline to LOV  
will be used as response variable in the model and differences between P2B 001 0.6/0.75mg to its 
2 individual components at LOV  will be tested using 2 contrasts: P2B 001 0.6/0.75mg vs. 
pramipexole 0.6mg and P2B 001 0.6/0.75mg vs. rasagiline 0.75mg.  
15.6.9.3  Sensitivity Analysis Using the Total UPDRS Responders Analysis  
The ITT analysis set will further be used t o compare the LOV  responders’ rate , with or without 
UPDRS measurements taken after study treatment termination,  between the P2B001 0.6/0.75mg  
and its 2 individual components  in the primary endpoint.  
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 80 of 131 
 
 A subject with  an improvement of 4 point or more at LOV as compared to baseline will be classified 
as a “Responder” while o ther randomized subjects not falling into this definition  will be classified 
as a “Non -Responders”.  
The analysis of this binary end-point will be based on estimating 2 contrast s (2 contrasts: P2B 001 
0.6/0.75mg vs. pramipexole 0.6mg and P2B 001 0.6/0.75mg vs. rasagiline 0.75mg ) derived from a 
baseline -adjusted, Logistic Regression model [SAS® PROC GENMOD with DIST=BIN and 
LINK=LOGIT] to this binary outcome measure . In addi tion to the treatment group the model will 
include the following covariates: CGR and baseline Total UPDRS score . The treatment effect 
(odds -ratios) of P2B001 0.6/0.75mg  vs its 2 individual components  at LOV  on the proportion of 
responders at week 12/Treatm ent Termination  and the corresponding adjusted proportions will be 
displayed.  In addition, the number and proportion of responders at Week 12/ Treatment 
Termination  will be displayed by treatment group.  
15.6.9.4  Sensitivity Analysis Accounting for Missing Values  
The ITT analysis set will be used for the below sensitivity analysis.  
To evaluate the possible impact of missing values on the principal analysis of the primary endpoint 
results assuming all missing data are Missing Not At Random (MNAR), a sensitivi ty analysis 
using the Tipping Point Method  and multiple imputations will be performed according to the 
following steps:  
1. Multiple Imputations Assuming Missing At Random Missingness Mechanism: The Multiple 
Imputations procedure, using the Markov -Chain -Monte -Carlo (MCMC) method (SAS® MI 
procedure) will be used on the total UPDRS  at baseline  and at LOV,  with or without UPDRS 
measurements taken after study treatment termination, to impute Missing At Random (MAR) 
missing values. Treatment  and country  will be incl uded in the imputation model.  
The number of imputations that will be used will be 100. Minimum and maximum imputation 
values will be 0 and 160 in line with the total UPDRS score range . The seed that will be used 
for the MI procedure random numbers generato r will be 12345678.  
2. The change from baseline based on step  1 will then be calculated.  
3. For the P2B001 0.6/0.75mg  -treated subjects only with imputed missing values, the value of 
S, the tipping parameter, where S>0 (reduction over time is an improvement), will be added to 
the calculated change from baseline artificially worsening the change for  these  imputed values . 
4. Each of the 100 imputed data sets for a given S will be analyzed using an ANCOVA model 
(SAS® MIXED procedure) to derive the treatment effect  of the P2B001 0.6/0.75mg  vs its 2 
individual components  and standard errors . The model will include treatment, country and 
baseline Total UPDRS score.  
5. Treatment effects, 95% CI s and p -value s will be calculated  for a given S using the 
SAS® MIANA LYZE procedure  on the treatment effects and SE estimates for each of the 100 
imputed datasets .  
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 81 of 131 
 
 6. Imputations and analyses will be repeated while increasing S by 1% each time until one of the 
two p-value s (for the two between groups contrasts)  in the primary  model will be greater than 
0.05. The first S causing significance  on both contrasts  to be lost is the tipping point .  
15.6.10  Key Secondary  Efficacy  Endpoints  and Analyses  
All efficacy endpoints will be tested for the ITT analysis . Secondary endpoints will be tested once 
both primary endpoint contrasts ( P2B001 0.6/0.75mg as compared to its individual components ) 
will favor P2B 001 0.6/0.75mg at a two -tailed alpha level of 5% each .  
Multiplicity adjustment for multiple endpoints testing for the secondary endpoint s will utilize the 
gate keeping hierarchical method according to the following order and plan:  
15.6.10.1  Change from Baseline to Week 12/ Treatment Termination in the ESS  
For the 1st secondary endpoint, namely, the P2B 001 0.6/0.75mg vs. Pramipexole ER contrast in 
the change from baseline to Week 12/ Treatment Termination in the ESS, will be considered as 
met only if both primary endpoint contrast s as above defined and the P2B 001 0.6/0.75mg vs. 
pramipexole ER contrast in the change from baseline to Week 12/ Treatment Termination in the 
ESS will all be met (total of 3 contrasts) at a two -tailed alpha level of 5% each.  
The statistical model  to be used for the analysis of the change from baseline to Week 12/ Treatment 
Termination in the ESS  will be a Mixed Model for Repeated Measures (MMRM) (SAS® MIXED 
procedure with REPEATED sub -command). The model will include the following fixed effects: 
categorical week in trial by treatment interaction, CGR , and baseline ESS score. The model will 
use the unstructured covariance structure and the REML estimation method and degrees of 
freedom will be adjusted using the Kenward -Roger method. Data from all three changes form 
baseline to post -baseline visits (weeks 5, 8 and 12) co llected from all subjects randomized into the 
study will be used as response in the model. The difference between the P2B 001 0.6/0.75mg as 
compared to Pramipexole ER at Week 12/Treatment Termination will be estimated and tested 
using a contrast.  
15.6.10.2  Change fro m Baseline to Week 12/ Treatment  Termination in the Total PDQ39  
The 2nd secondary endpoint, namely, the change from baseline to Week 12/ Treatment Termination 
visit in the Total PDQ39 will be considered as met if all of the 3 previous tested contrasts (prima ry 
endpoint and 1st secondary endpoint) as well the two contrasts: P2B 001 0.6/0.75mg vs. 
pramipexole 0.6mg once daily and, P2B 001 0.6/0.75mg vs. rasagiline 0.75mg once daily in the 
2nd secondary endpoint will all be met (total of 5 contrasts) at a two -tailed alpha level of 5% each.  
The statistical model  to be used for the analysis of the change from baseline to Week 12/ Treatment 
Termination visit in the Total PDQ39  will be an analysis of covariance  (SAS® MIXED procedure ) 
and the model will include treatment  group, CGR and baseline PDQ39  score . The c hange from 
baseline to Week 12/ Treatment Termination will be used as response variable in the model and 
differences between P2B 001 0.6/0.75mg to its  2 individual components at Week 12/ Treatment 
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 82 of 131 
 
 Termination will be tested using 2 contrasts: P2B 001 0.6/0.75mg vs. pramipexole 0.6mg and 
P2B001 0.6/0.75mg vs. rasagiline 0.75mg.  
15.6.10.3  Change from Baseline to Week 12/ Treatment Termination in the ADL UPDRS 
(part II)  
The 3rd secondary endpoint, namely, the chan ge from baseline to Week 12/ Treatment Termination 
in the ADL UPDRS (part II) score will be considered as met if all of the 5 previous tested contrasts 
(primary endpoint, 1st and 2nd secondary endpoints) as well the two contrasts: P2B 001 0.6/0.75mg 
vs. pramipexole 0.6mg once daily and, P2B 001 0.6/0.75mg vs. rasagiline 0.75mg once daily in the 
3rd secondary endpoint will all be met (total of 7 contrasts) at a two -tailed alpha level of 5% each.  
The statistical model  to be used for the analysis of the change fr om baseline to Week 12/ Treatment 
Termination in the ADL UPDRS (part II)  will be a Mixed Model for Repeated Measures (MMRM) 
(SAS® MIXED procedure with REPEATED sub -command). The model will include the following 
fixed effects: categorical week in trial by treatment interaction, CGR , and baseline ADL UPDRS 
(part II) . The model will use the unstructured covariance structure and the REM L estimation 
method and degrees of freedom will be adjusted using the Kenward -Roger method. Data from all 
three changes form baseline to post -baseline visits (weeks 5, 8 and 12) collected from all subjects 
randomized into the study will be used as response  in the model.  
The difference between P2B 001 0.6/0.75mg to its  2 individual components  at Week 12/ Treatment 
Termination  will be tested using 2 contrasts: P2B 001 0.6/0.75mg vs. pramipexole 0.6mg and 
P2B001 0.6/0.75mg vs. rasagiline 0.75mg.  
15.6.10.4  Change from Baseline to Week 12/ Treatment Termination in the Motor 
UPDRS (part III) Score 
The 4th secondary endpoint, namely, the change from baseline to Week 12/ Treatment Termination 
in the motor UPDRS (part III) score will be considered as met if all of the 7 previous t ested 
contrasts (primary endpoint, 1st, 2nd and 3rd secondary endpoints) as well the two contrasts: P2B 001 
0.6/0.75mg vs. pramipexole 0.6mg once daily and, P2B 001 0.6/0.75mg vs. rasagiline 0.75mg once 
daily in the 4th secondary endpoint will all be met (to tal of 9 contrasts) at a two -tailed alpha level 
of 5% each.  
The statistical model  to be used for the analysis of the change from baseline to Week 12/ Treatment 
Termination in the Motor UPDRS (part III)  will be a Mixed Model for Repeated Measures 
(MMRM) (SAS® MIXED procedure with REPEATED sub -command). The model will include 
the following fixed effects: categorical week in trial by treatment interaction, CGR , and baseline 
Motor UPDRS (part III) . The model will use the unstructured covariance structure and the REML 
estimation method and degrees of freedom will be adjusted using the Kenward -Roger method. 
Data from all three changes form baseline to post -baseline visits (weeks 5, 8 and 12) collecte d 
from all subjects randomized into the study will be used as response in the model.  
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 83 of 131 
 
 The difference between P2B 001 0.6/0.75mg to its  2 individual components  at Week 12/ Treatment 
Termination  will be tested using 2 contrasts: P2B 001 0.6/0.75mg vs. pramipexo le 0.6mg and 
P2B001 0.6/0.75mg vs. rasagiline 0.75mg.  
15.6.10.5  CGI-S Responder’s Analysis at Week 12/ Treatment Termination (change from 
baseline ≥1 CGI -S points)  
The 5th secondary endpoint, namely, the CGI -S responder’s analysis at Week 12/ Treatment 
Termination (ch ange from baseline ≥1 CGI -S points) will be considered as met if all of the 9 
previous tested contrasts (primary endpoint, 1st, 2nd, 3rd and 4th secondary endpoints) as well the 
two contrasts: P2B 001 0.6/0.75mg vs. pramipexole 0.6mg once daily and, P2B 001 0.6/0.75mg vs. 
rasagiline 0.75mg once daily in the 4th secondary endpoint will all be met (total of 11 contrasts) at 
a two -tailed alpha level of 5% each.  
A subject with  an improvement of 1 point or more at Week12/ Treatment  Termination as compared 
to baseli ne will be classified as a “Responder” while o ther randomized subjects not falling into 
this definition  will be classified as a “Non -Responders”.  
 
The analysis of this binary end -point will be based on estimating 2 contrasts (2 contrasts: 
P2B001 0.6/0.75mg vs. pramipexole 0.6mg and P2B001 0.6/0.75mg vs. rasagiline 0.75mg) 
derived from a baseline -adjusted, Logistic Regression model [SAS® PROC GENMOD with 
DIST=BIN and LINK=LOGIT] to this binary outcome measure. In addition to the treatment 
group th e model will include the following covariates: CGR  and baseline CGI -S. The treatment 
effect (odds -ratios) of P2B001 0.6/0.75mg vs its 2 individual components at Week 12/Treatment 
Termination on the proportion of responders at Week 12/Treatment Termination and the 
corresponding adjusted proportions will be displayed. In addition, the number and proportion of 
responders at Week 12/Treatment Termination will be displayed by treatment group.  Exploratory 
Efficacy Endpoints  
Analyses of the exploratory endpoints w ill provide additional insight into the therapeutic effect 
of P2B001 0.6/0.75. These endpoints will be tested for the ITT analysis set using the nominal 
alpha level of 5% without controlling for multiplicity. Detailed statistical methodology to be 
used for  the analyses of these exploratory endpoints will be provided in a more detailed SAP to 
be developed while the study is ongoing and prior to locking the database and unblinding . 
15.6.11  The exploratory endpoints to be analyzed are:  
• To evaluate the efficacy of P2B001  0.6/0.75 mg compared to its individual components in 
the following endpoints:  
- Change from baseline to Week 12/ Treatment Termination visit in each of the 8 PDQ39 
subscales scores.  
- Change from baseline to Week 12/ Treatment Termination visit in Health -Related Quality 
of Life (HRQOL) SF -12v2 questionnaire.  
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 84 of 131 
 
 - Clinical Global Impression of Improvement (CGI -I) at Week 12/ Treatment T ermination 
visit.  
• To evaluate the superiority of  P2B001  0.6/0.75 mg over Pramipexole ER  with respec t to the 
following outcome measures : 
- Proportion (%)  of patients with ESS score >10 at W eek 12/ Treatment Termination . 
- Proportion (%)  of patients with  ESS Score <10 at baseline  and ESS score >10 at W eek 
12/Treatment Termination . 
- 3-Months rate of total number of a dverse event s. 
- Change from baseline to Week 12/Treatment Termination in the differences in systolic and 
diastolic blood pressure measured during supine and standing positions.   
- Proportion (%) of patients with both symptomatic/non -symptomatic Orthostatic 
Hypotension . 
- 3-Months rate of total number of both symptomatic/non -symptomatic Orthostatic 
Hypotension . 
- Proportion (%) of patients with symptomatic Orthostatic Hypotension . 
- 3-Months rate of total number of symptomatic Orthostatic Hypotension . 
- Proportion (%)  of patients with daytime sleepiness/drowsiness related AE’s.  
- Proportion (%)  of patients with gastrointestinal (GI) adverse events  
- Proportion (%) of patients presenting neurological adverse events  
- Change from baseline to Week 12/Treatment  Termination visit in the Orthostatic 
Hypotension Symptoms Assessment (OHSA) question 1.  
 
• To descriptively evaluate the comparability of P2B001  0.6/0.75 mg with reference to the 
calibration arm (Pramipexole ER) in total UPDRS score (defined as sum of parts II and III, 
scores (0 -160).  
15.7 Safety Assessments  
All safety  assessments will use the Safety Analysis Set (ST) which include s all randomized 
subjects who were administered at least one study dose,  according to the treatment actually 
received. The ST analysis set will serve as the principal analysis set for safety  assessment . Safety 
analyses will exclude measurements taken 30 days after study treatm ent discontinuation as well as 
adverse events initiated 30 days after study treatment discontinuation.  
15.7.1  Adverse Events  
Adverse events will be recorded from the time a subject has signed the Informed Consent Form 
until the end of subject’s study participatio n, including up to Week 14 Follow -Up visit,  regardless 
of study IP administration.  
The MedDRA dictionary  will be  used to sta ndardize the terms used by the I nvestigator to describe 
the Adverse Events (AEs).   
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 85 of 131 
 
 The following will be incorporated into the analysis of adverse events:  
• As analysis of AEs can incorporate only coded AEs, it is mandatory that at the time of database 
lock all AEs will be coded.  
• Adverse events analyses will include only the Treatment Emergent Adverse Events (TEAEs), 
namely, those e vents which started at the time of first study IP administration or afterwards. 
AEs lacking start day or AEs recorded on day of first study IP lacking start time will be 
considered as TEAE.  
The following analyses are pre -planned for adverse events:  
• The inc idence (no. of patients) and frequency (no. of events) of most frequent TEAEs (>5% 
of subjects in at least one study arm) by Preferred Term  (PT). 
• The incidence (no. of patients) and frequency (no. of events) of TEAEs broken down by 
System Organ Class ( SOC ) and PT. 
• The incidence (no. of patients) and frequency (no. of events) of TEAEs by SOC  and PT in 
Subjects Early Discontinued  from Study/Treatment.  
• The incidence (no. of patients) and frequency (no. of events) of serious TEAEs by SOC  and 
PT 
• The incidence (no. of patients) and frequency (no. of events) of TEAEs when broken down by 
severity.  
• The incidence (no. of patients) and frequency (no. of events)  of TEAEs broken down by 
relationship to study IP.  
• The incidence (no. of patients) and frequency (no. of events) of TEAEs when broken down by 
action taken  with study IP .  
• The incidence (no. of patients) and frequency (no. of events) of TEAEs when broken d own by 
event outcome.  
• Adverse Events dictionary used to code Investigator’s verbatim terms will be provided.  
• Individual subject listings of all SAEs, treatment emergent SAEs, TEAEs and non -TEAEs.  
15.7.2  Laboratory Tests  
Analyses of safety central laboratory data will be performed in the following manner:  
• The more detailed SAP to be developed while the study is ongoing and prior to locking the 
database and unblinding  will provide quantitative criteria used to define the potentially 
clinically significant (PCS) abnormal laboratory values. Measurements to be used  in the 
analysis are those taken only after the initiation of the 1 st study IP administration . The 
incidence tables of PCS lab values as well as the individual subject listing will be provided. 
Please note that the denominator to be used for calculating percentages is the number of 
subjects with at least one  measurement post initiation of the 1 st study IP administration . 
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 86 of 131 
 
 • Quant itative laboratory measurements will be  categorized with reference to the normal ranges 
as Low, Normal or High. The incidence (no. of subjects) of abnormal values at any time post 
initiation of the 1st study IP administration , calculated for subjects with normal values at 
baseline will be provided. Analysis will include, per tested parameter, those subjects with 
normal baseline and at least one post -treatment  measurement. Summary table will display the 
number and relative percentage of subjects with at leas t one abnormal value (above upper or 
below the lower normal range) at any time post initiation of the 1st study IP administration . 
• Quantitative laboratory measurements will be categorized with reference to the normal ranges 
as Low, Normal or High. Shift an alysis of the categorical change fr om baseline to each 
scheduled visit and to the last observed value will be provided. In case of sporadic repeated 
measurement within a visit , the last measurement per visit will be used to represent subject’s 
value in the  analysis.  
Box-Plots of measurements done  and figures of mean values ±  SEs as well as descriptive statistics 
for all laboratory quantitative parameters and changes from baseline will be provided by scheduled 
visits and treatment groups.  In case of sporadic repeated measurement within a visit , the last 
measurement per visit will be used to represent subject’s value in the analysis.  
15.7.3  Vital Signs  
Analyses of vital signs  will be performed in the following manner:  
• The more detailed SAP to be developed while the study is ongoing and prior to locking the 
database and unblinding  will provide quantitative criteria  used to define the potentially 
clinically significant (PCS) abnormal values. Measurements to be used in the analysis are those 
taken immediately following the first administration of the study IP and onwards . The 
incidence tables of PCS values as well as the individual subject listing will be provided. The 
denominator to be used for calculating percentages is the number of subjects with a t least one 
observation post 1st study IP administration . 
• Box-Plots of measurements done, figures of mean values ±SEs as well as descriptive statistics 
for all parameters and changes from baseline  (derived)  will be provided by scheduled visits 
and treatmen t groups. Please note that the last measurement per visit will be used to represent 
subject’s value in the analysis in case of sporadic repeated measurement within a visit.  
15.8  ECG  
The incidence of abnormal ECG findings will be presented by treatment group. S hift analysis from 
baseline will be provided as well.  
15.9 Columbia Suicide Severity Rating Scale (CSSRS ) 
The Columbia  Suicide Severity Rating Scale Screening/Baseline Version (CSSRS -BL) will be 
taken at screening. The Columbia  Suicide Severity Rating Scale Since Last Visit (CSSRS -SLV) 
was to be taken at baseline and in all subsequent study visits.  
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 87 of 131 
 
 Any positive answer to its behavior subcomponents at screening or baseline will identify  a subject 
as with “Suicidal Behavior at Bas eline”. Similarly, any positive answer to it’s the ideation 
subcomponents at any of these two visits will identify  a subject as with “Suicidal Ideation at 
Baseline”. A subject identified with either “Suicidal Behavior at Baseline” or with “Suicidal 
Ideatio n at Baseline” was also classified as with “Suicidal Behavior or Ideation at Baseline”.  
Similarly, any positive answer to its behavior subcomponents in any of the post -dosing visits will 
identify  a subject as with “Suicidal Behavior Post Dosing”. Similarly , any positive answer to it’s 
the ideation subcomponents in any of the post -randomization visits will identify  a subject as with 
“Suicidal Ideation Post Dosing”. A subject identified with either “Suicidal Behavior Post Dosing” 
or with “Suicidal Ideation Po st Dosing” was also classified as with “Suicidal Behavior or Ideation 
Post Dosing”.  
The distribution of the number of subjects by these classifications post -dosing as well as shift 
analysis from baseline will be displayed.  In addition, for the CSSRS -SLV, l isting of Post First 
Study Dose CSSRS (Ideation) Grade 4 and 5 / Suicidal Behavior  will be provided.  
15.10  Tolerability Assessments  
Tolerability analysis will be based on the number (%) of subjects who discontinued the study 
treatment  early  and  the number (%) o f subjects who discontinued study treatment  early  due to 
adverse events. Time to withdrawal will be presented by Kaplan -Meier curves.  
15.11  Exploratory Safety Endpoint  
Exploratory c omparison between P2B001  0.6/0.75 mg and Pramipexole ER at Week 
12/Treatment Termination  will be performed in the following safety endpoints:  
• Change from baseline to Week 12/Treatment Termination in the ESS score > 10.  
• Adverse event frequency  
• Change from baseline to Week 12/Treatment Termination in the differences in sys tolic and 
diastolic blood pressure measured during supine and standing positions.   
• Comparison of percentage of patients presenting with sleepiness/drowsiness related AE’s.  
• Comparison of percentage of patients presenting with gastrointestinal (GI) adverse events.  
• Comparison of percentage of patients presenting with neurological adverse events.  
• Change from baseline to Week 12/Treatment Termination visit in the Orthostatic 
Hypotension Symptoms Assessment (OHSA) question 1.  
15.12  Safety  assessment scales  
Results of scale assessments of daytime sleepiness, suicidality, and impulse control behaviors 
will be presented by study group  
15.13  Statistical Analysis Plan (SAP)  
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 88 of 131 
 
 A more detailed SAP will be developed while the study is ongoing and prior to locking the 
database and unblinding.  
 
If ever there is a discrepancy between the Protocol and the Statistical Analysis Plan, the methods 
defined in the SAP will have precedence.  
16 STUDY PERSONNEL  
16.1 Study Site  
At each study center the staff will consis t of a minimum of one Principal Investigator and a 
clinical coordinator.  If the Principal Investigator at a study center is not a neurologist, then the 
study center will need at least one sub-Investigator who is a neurologist. The neurologist will:  
Verify subject eligibility (including diagnosis of early PD  and UPDRS part III ) at Visits 1 and 2  
Perform complete physical and neurological examinations at Visit 1 and symptom -directed 
physical and neurological examination at visit 7 and unscheduled visits.  
The neurologist will also decide on the dose of Pramipexole ER (or matching placebo) during the 
titration phase based on subject reporting of efficacy and tolerability. This will be done by  a 
study visit  at the end of week 3,  and a phone call or an unschedule d visit a t the end of week 4 .  
The Pramipexole ER (or matching placebo) dose will be evaluated again a t the end of week 5  as 
part of the activities done in study visit 4.  
Assess Clinical Global Impression - Severity at Visits 2 and 6. 
Assess Clinical Global Impression - Improvement  at Visits 4, 5 and 6. 
Perform UPDRS  part III  at Visits 1, 2, 4, 5 and 6  or the Site PI may delegate this responsibility 
to other senior  trained  research staff with at least 10 years’ experience  in conducting t he UPDRS  
All other study  procedures can be conduct ed by the Principal  Investigator , Clinical  Coordinator 
or other member of the clinical staff with the relevant experience and who the PI has delegated to 
perform those procedures .   
16.1.1  The Principal Investigator  
The Principal Investigator (PI) will have overall responsibility to lead the site study team and all 
aspects of the study. The PI will oversee the accrual of appropriate subjects, the conduct of the 
study according to the trial protocol, commu nication with the IRB/EC, and the collection of 
required data.  
16.1.2  The Clinical Coordinator  or designee  
The clinical coordinator or designee, as delineated on the Personnel Delegation Log, will be 
responsible for subject scheduling; completing and reviewing a ll subjects’ case report forms and 
other documents and recording of adverse events  as well as drug accountability.  He/she will 
instruct the subject on proper study drug administration and completion of study scales  
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 89 of 131 
 
 (including follow -up phone calls to the subject  to obtain  missing data from subject efficacy or 
safety scales completed at the previous visit ).  He/she will instruct the subject on proper study 
drug dosing.  During the titration phase  at the end of Weeks 1, 2 and 6  he/she will make a phone 
call to the subject to assure  proper study dosing in the past week and remind of the dosing 
regimen for the next week .  
He/she will collect and forward blood samples and requests to the appropriate laboratories, will 
obtain and forward laboratory results and wi ll assist the Investigator.  
16.2 The Sponsor  
Pharma Two B 
3 Pek eris st. Weizmann science park  
Rehovot 7670203  Israel  
Tel: 972 8 9462672  
Fax: 972 8 9366832  
Email : David@pharma2b.com   
 
The sponsor will provide the following:  
- Final protocol  
- Study medication  
- Drug Distribution  
- Insurance for product liability  
16.3 CRO  
Name : PRA Health Science  
Address : 4130 ParkLake Avenue - Suite 400 Raleigh,  
North Carolina 27612  
Tel: +1 (919) 786 -8200    
Fax: +1 913.890.5969  
 
The CRO commissioned by Pharma Two B will assist in the conduct and analysis of the trial. 
The CRO will be responsible for the following:  
- Project management  
- Clinical operation  
- Drug safety plan and reporting  
- Study specific training  
- Data management  
- Monitoring  
- Quality Assurance  
- Final clinical report  
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 90 of 131 
 
 - Central laboratories  
 
 
16.3.1  CRO Clinical Trials Manager  
The CRO Clinical Trials Manager is  responsible for all aspects of the study including the proper 
design and conduct, and day -to-day activities of the study and to ensure that the sponsor supplies 
adequate resources to provide high quality study management, monitoring and data management.  
The Corporate Clinical Trials Manager will represent the sponsor on the study various 
Committees:  
Name : Lysander Stemmerik  or designee  
Address : PRA Health Science , WTC Papendorp, Papendorpseweg 100, 3528 BJ Utrecht ,  The 
Netherlands .  
Tel: +31 50.850.5749  
Email ;  StemmerikLysander@prahs.com  
 
The CRO will be responsible for review of all Serious Adverse Events (SAEs) to ensure that 
each SAE is adequately described to allow determination of deportability  to the Regulatory 
Authorities . 
 
16.3.2  Statistics and Data Management Centers (S&DM)  
The CRO ’s lead dat a manger  is responsible for data management of electronic CRF's . Statistic al 
analyses  will be performed  by StatExcellence Ltd., Israel .  
16.3.3  Medical Monitor  
The Medical Monitor is responsible to periodically review the safety data in a blinded fashion to 
inclu de AEs, vital signs, ECG and laboratory values. A consistency check of safety and efficacy 
variables will be performed.  
16.3.4  Local Clinical Trial Manager (LCTM)  
The LCTM based at CRO subsidiaries, is responsible for the local day -to-day activities of the 
study and to ensure that the sponsor supplies adequate resources to provide high quality study 
management, monitoring and data management.  The LCTM is responsible for submitting all 
safety reports to local  regulatory authorities and to I nvestigators, as require d. The LCTM 
supervises the monitoring activities.  
16.3.5  Clinical Research Associate  
Clinical Research Associate (CRA, monitor) is responsible for monitoring visits. These visits 
will be arranged in advance, at a mutually acceptable time, with site personnel. Suf ficient time 
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 91 of 131 
 
 must be allowed by the site personnel for the Monitor to review the relevant source doc uments. 
The coordinator and/or I nvestigator(s) should be available to answer questions or resolve data 
clarifications. Adequate time and space for these vis its should be made available by the 
Investigator. The monitor will review, on a regular basis, the progress of the study with the 
Investigator and other site personnel and check completeness and blind maintenance. The 
monitor will verify the data entered i nto the eCRF for accuracy and completeness. At the end of 
the study, a close -out monitoring visit will be performed.  
16.4 Study Committees   
16.4.1  Data & Safety Monitoring Board (DSMB)  
The DSMB is intended to assist and consult on any safety aspects to ensure the safety of study 
subjects. Pharma Two B with the study CRO ( PRA Health Science ) will be responsible to select 
DSMB members among different experts in the field. The committee wil l review , periodically, 
in unblinded fashion , all safety data accumulated in the study. The committee  will document all 
their recommendations  which will be  provided to the sponsor  and the CRO .    
16.4.2  Subject Central Eligibility Monitoring Committee (EMC)  
After  the Investigator has determined  a subject has met all of the inclusion criteria and none of 
the exclusion criteria  but before randomizing  the subject  via RTSM , the Investigator will need to 
complete  a randomization authorization form  (RAF) for that subject  and e-mail it to the E MC, 
which consists of expert Parkinson’s disease neurologists . Upon receipt of the RAF, the EMC 
will review the provided information to confirm the subject's eligibility for the study . Only after 
receiving  confirmation from the EMC that the subject meets eligibility criteria via  a signed RAF , 
may the Investigator randomize the subject using  the RTSM  system .    
The EMC may also reject the inclusion of a subject due to that subject not meeting eligibility 
criteria.  Any rejection will be explained  to the I nvestigator via email .  
17 REGULATORY AND ETHICAL ISSUES  
17.1 Compliance with Regulations Applicable to Clinical Trials  
The study will be conducted according to the protocol, the laws, regulations and administrative 
provisions relating to the implementation of GCP in the conduct of clinical trials on medicinal 
products for human use, as applicable by national legislation and directives, including Directive 
2001/20/EC of the European Parliament and the Council of the European Uni on and US 21 CFR 
Part 11, 50, 54, 56 and 312.  
17.2 Informed Consent  
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 92 of 131 
 
 The principles of informed consent, according to Declaration of Helsinki 1964 and all its 
updates, the International Conference on Harmonization (ICH) step 5 guidelines on Good 
Clinical Practic e (GCP), 21 CFR part 50 of the FDA Regulations and/or EU Directives, will be 
followed. A subject should not enter a clinical study or perform any study -related procedures 
until subject  has been properly informed, has been given time to contemplate particip ation, and 
has freely given his/her consent by signing and dating the EC/IRB approved informed consent 
form.  
The proposed consent form and any other documents relevant to the consent process must be 
submitted to the EC/IRB together with the protocol and mu st be approved prior to study start.  
A signed copy of the consent form will be given to the subject and the original will be 
maintained at the site following the signing and dating by the person administering the consent 
and witness (where appropriate).  
17.3 Ethics Committee (EC) / Institutional Review Board (IRB)  
The study must have unconditional approval in writing, by an appropriate Ethics 
Committee/Institutional Review Board (EC/IRB). A copy of the Letter of Approval from the 
EC/IRB, which contains specifi c identification of the documents approved, must be received by 
the sponsor prior to site initiation.  
Any substantial amendments to the protocol or subsequent changes to the informed consent form 
as a result of changes to the protocol and/or Investigator's  Brochure that is approved by the 
sponsor, must also be sent to the EC/IRB and written opinion has to be provided to the sponsor. 
Records of the EC/IRB review and opinion of all documents pertaining to this stu dy must be 
kept on file by the I nvestigator an d are subject to regulatory authority and/or sponsor inspection 
during or after completion of the study.  
Serious Adverse Events (SAEs) must also be  reported to the EC/IRB by the I nvestigator or the 
sponsor.  
Periodic status reports must be submitted to the  EC/IRB as required, as well as notification of 
completion of the study and a final report where applicable. A copy of all reports submitted to 
the EC/IRB must be sent to the sponsor.  
17.4 Protocol Amendments  
Changes to the protocol should only be made by an ap proved protocol amendment. Protocol 
amendments must be approved by the sponsor and each respective site’s EC/IRB prior to 
implementation.  
For clinical trial sites located in EU member states, the procedures outlined in Directive 
2001/20/EC, Article 10(a),  are applicable. Elsewhere, the country regulations apply.  
17.5 Subject Confidentiality  
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 93 of 131 
 
 All subject data will be identified only by a subject identification number, subject initials and 
date of birth. The subject’s personal data (e.g. name and address) will be blinded 
correspondingly in all data analyses. However, after receiving the subject’s approval (by signing 
the Informed Con sent), it is required that the I nvestigator permit the study monitor, independent 
auditor or regulatory agency personnel (with or with out the I nvestigator) to review that portion 
of the subject’s medical record that is directly related to the study. This shall include all study 
relevant documentation including subject medical history to verify eligibility; laboratory test 
result reports;  admission/ discharge summaries for hospital admissions occurring while the 
subject is in the study; and autopsy reports for deaths occurring during the study (where 
available).  
The subject's authorization allows the sponsor to receive and review the subje ct’s protected 
health information which may be re -disclosed to any authorized representative of the sponsor or 
central laboratory facility for review of subject medical records in the context of the study.  
17.6 Liability and Insurance  
A Certificate of Clinical Trials Insurance will be provided to the study centers by the sponsor  
upon request . 
18 DOCUMENTATION  
18.1 Study File and Site Documents  
Prior to the initiation of the study, the following documents must be received by the sponsor 
from the study site:  
• Confidential Disclosure Agreement  
• Signed protocol , amendment s and notifications (if applicable) pages by the Principal 
Investigator.  
• The Principal Investigator curriculum vitae and where required current medical license.  
• Signed Clinical Study Agreement . 
• EC/IRB membersh ip list or an official statement that the EC/IRB is in compliance the 
local regulations.  
• EC/IRB written opinion for the protocol, amendments, informed consent, subject 
information sheet (if applicable), advertisements (if applicable).  
18.2 Site Documents/Equipment Supplied by the Sponsor  
Prior to the initiation visit of the study, the sponsor will supply the site Investigator with the 
following items, in addition to the protocol:  
• Current version of the Investigator’s Brochure or equivalent as agreed with the regulatory 
authority.  
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 94 of 131 
 
 • Regulatory Binder including all  study related forms  
• Informed Consent Template  
• Insurance Certificate  
18.3 Maintenance and Retention of Records  
The Investigator will get from the sponsor an essential documents b inder  EDB  or set up a Site 
Master File ( SMF ) at the beginning of the study. It will be the responsibility of the Investigator 
and study staff to maintain a comprehensive and centralized filing system of all documents 
relevant to the study.  
These documents  include:   
• Subject  Files (Source documents) – substantiating the data entered in the eCRF  with 
regards to laboratory data, subject  histories, treatment regimens, etc.  
• Subject  Exclusion records – reflecting the reasons any subject  was screened for the study  
and found to be ineligible.  
• Drug Dispensing Log – reflecting the total amount of medication received and returned to 
the sponsor, and the amounts administrated to the subject . This information should agree 
with the information entered in the eCRF . 
• Informe d Consent Forms (ICF) – will be available for each subject  and will be verified 
for proper documentation.  
• Study Notes – this section of the eCRF  is used to explain any aspect of the study that is 
not easily entered on the routine eCRF , and could include items such as:  
• Deviations from the protocol; natu re, reasons and approval by the I nvestigator.  
• Comments or explanations of unusual findings.  
• Any data or clarification of data not explicitly requested on the eCRF . 
The EDB  or SMF will be stored in a secure but accessible manner. The essential documents will 
be legible and accurate. The participating centers will keep copies of relevant documents, 
including essential center -specific documents. Essential documents should be retained until at 
least 2 yea rs after the approval of a marketing application in an ICH region and until there are no 
pending or contemplated marketing applications in an ICH region or at least 2 years have elapsed 
since the formal discontinuation of clinical development of the Invest igational product. These 
documents should be retained for a longer period, however if required by the regulatory 
requirements or by inform ing the Investigator/institution as to when these documents no longer 
need to be retained.  
The EDB orSMF will be archi ved by the Sponsor for a minimum of 15 years following the 
signing of the clinical report.  
▪ Site I nvestigators will be instructed to retain all study records required 
by the sponsor and regulatory authorities in a secure and safe facility 
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 95 of 131 
 
 with limited acces s for at least 15 years or longer if required by local 
regulations.  
The site I nvestigator will be instructed to consult with the sponsor before disposal of any study 
records and to notify the sponsor of any change in the location, disposition or custody of  the 
study files.  
18.4 Data Handling  
An Electronic Data Capture (EDC) system to collect subject electronic Case Report Form 
(eCRF) information will be used. All the information collected during the study will be recorded 
in the eCRF identified by subject initia ls and  subject ID number , for each subject enrolled, 
including those removed for any reason after administ ering  the first dose. It is the responsibility 
of the Investigator and sub-Investigator to ensure that the eCRFs are properly and completely 
filled in . 
Central data management will be performed by PRA.  Internet -based remote data capture will be 
used for entering, managing, and validating data from centers. The following regulation will be 
followed:  
• FDA 21CRF part 11 rule  
• ICH, Good Clinical Practice , Consolidated guideline  
• FDA Guidance for Industry “Computerized system used in clinical trials.  
• EU Directives  
 
Data will be e ntered at the site by the site I nvestigator, study coordinator or the site coordinator, 
onto the eCRF.  
The eCRFs are used to record study data and are an integral part of the study and subsequent 
reports. Therefore, the eCRFs must be completed for each subject screened and enrolled 
according to the subject’s source data on a per -visit basis.  For screen failures , only date  of 
screening, date of screen failure, subject  demographic s and inclusion/exclusion cr iteria not met 
will be recorded within EDC . Any adverse event s for screen failures that occur after signing the 
ICF will be captured  only in the  source documents  and not in the eCRF .  
Subjects should not be identified by name. Appropriately coded identification and subject i nitials 
must be used. The site I nvestigator must keep a separate  log of subject names and addresses (i.e. 
Subject Identification Record).  
All data collected in the eCR F must be approved by the site I nvestigator or designee and can be 
verified against the subject’s source documents by the monitor, according to the monit oring plan.  
18.4.1  Source Documents  
Prescription forms, label logs, laboratory test results, ECG strips and all other source documents 
should be maintained and kept at the study site in the subject's study binder. If the hospital file is 
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 96 of 131 
 
 an electronic system (computerized database), all data should be printe d out, signed and dated by 
the Investigator.  
19 STUDY MONITORING  
19.1 Monitors and Monitoring Visits  
The Study monitor/CRA will be responsible for ensuring adherence to local regulations, EU 
Directives (wher e applicable), ICH guidelines and the sponsor’s SOPs. Study monitors for this 
trial will be provided by the sponsor or sponsor’s designee. The monitors will operate according 
to the EU Directives and in compliance with ICH guidelines, as well as local regu lations.  
Monitors will be trained to monitor the study. They will be trained on ICH GCP guidelines, 
study protocol.  
Regular monitoring of study data at the site will be performed in accordance with applicable 
regulations and according to a study specific m onitoring plan. The site will be monitored to 
ascertain that enrollment rate, data recording and protocol adherence are satisfactory. The 
frequency of monitoring the site may fluctuate depending upon enrollment rate and the quantity 
of data collected.  
The monitor will review the maintenance of regulatory documentation and Study Drug 
accountability. The monitor will review the progr ess of the study with the site I nvestigator and 
other site personnel on a regular basis. At the end of the study, a close -out mo nitoring visit will 
be performed. Monitoring visits will be arranged in advance with site personnel at a mutually 
acceptable time. Sufficient time must be allowed by the site personnel for the monitor to review 
eCRFs and relevant source documents or resolv e data clarifications. Adequate time and space for 
these visits will  be made available by the site I nvestigator.  
19.2 Primary Source Documents  
The site I nvestigator must maintain primary source documents supporting eCRF  data entries. 
These documents, which are considered “source data”, should include documentation of:  
▪ Demographic information  
▪ Evidence supporting the diagnosis/condition for which the subject is 
being studied  
▪ General information supporting the subject’s eligibility to participate 
in the study  
▪ Medic al history , physical and neurological findings  
▪ Hospitalization or Emergency Room records (if applicable)  
▪ Each study visit by date, including any relev ant findings/notes by the 
site I nvestigator(s); occurrence (or lack) of AEs; and changes in 
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 97 of 131 
 
 medication usa ge, including the date the IMP was commenced and 
completed  
▪ Drug dispensing  
▪ Vital signs  
▪ Subject evaluation scales  
▪ Any additional visits during the study  
▪ Any relevant telephone conversations with the subject regarding the 
study , subject’s satisfaction and tolerability  of the treatment during 
titration phase  or possible AEs  
▪ Original, signed informed consent forms for study participation  
The site I nvestigator must also retain all subject -specific printouts, reports of tests and 
procedures performed as a requirement of the study. During monitoring visits, the monitor will 
need to verify data in the eCRFs against these source data.   
20 USE  OF INFORMATIO N AND PUBLICATION  
20.1 Confidential Information  
All information supplied by the sponsor in association with this study and not previously 
published, is considered confidential information. This information includes, but is not limited 
to, the Investigator's Bro chure, clinical protocol, eCRF s and other scientific data. Any data 
collected during the study are also considered confidential. This confidential information shall 
remain the sole property of the sponsor, shall not be disclosed to others without the writt en 
consent of the sponsor and shall not be used except in the performance of this study.  
The information developed during the conduct of this clinical study is also considered 
confidential, and will be used by the sponsor in connection with the development  of P2B001. 
The information may be disclosed as deemed necessary by the sponsor. To allow the use of the 
information derived from  this clinical study, the site I nvestigator is obliged to provide the 
sponsor with complete test results and all data developed  in this study. Should the Investigator 
wish to publish the results of this study, the Investigator agrees to provide the sponsor with a 
manuscript for review 60 days prior to submission for publication. The sponsor retains the right 
to delete from the man uscript confidential information and to object to suggested publication 
and/or its timing (at the sole discretion of the sponsor).  
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 98 of 131 
 
 21 INVESTIGATOR AGREEMENT  
I have carefully read the foregoing protocol including all appendices and agree that it 
contains all the necessary information for conducting the study safely.  
I will conduct this study in strict accordance with this protocol and according to the current GCP 
regulations and will attempt to complete the study within the time designated.  
I will provide copi es of the protocol and all other information relating to pre -clinical and prior 
clinical experience submitted by the sponsor to all personnel responsible to me who participate 
in the study. I will discuss this information with them to assure that they are adequately informed 
regarding the drug and conduct of the study.  
I agree to keep records on all subject information (case report forms, shipment and drug return 
forms and all other information collected during the study) in accordance with the current GCP 
and local regulations.  
 
   
Principal Investigator’s name    
 
   
Signature    
 
   
Date    
   
Institution  
  
 
  
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 99 of 131 
 
 22 APPENDICES  
22.1 Appendix I: Schedule  of Activities : 
 
Visit Number  1 2 3 ****  4 5 6 7 
Visit Type  Screening  
 Baseline   
 End of 
Week     
3  
 End of 
Week     
4  
 End 
of 
Wee
k 5 
 End of 
Week 8 
 End 
of 
Wee
k 12  
 End of 
Week 
14  
 
Time  -28 days to 
day 0 ** Day 1  21 ±2 
days  28±2 
days  35 ±2 
days  56 ±2 
days  84 ±2 
days  98 ±2 
days  
ACTIVITIES          
Written Informed Consent  X        
Inclusion/Exclusion Criteria  X X       
UK Parkinson's Disease 
Society Brain Bank Clinical 
Diagnostic Criteria  
 X        
Modified H&Y Stage  X        
Mini Mental State Exam 
(MMSE)  X        
Medical History & 
Demographics  X        
Complete Physical and 
Neurological Examination  X        
Symptom -directed physical 
and neurological Examination         X 
Laboratory tests (serum 
biochemistry, hematology, 
urinalysis, serum pregnancy  
test)* X***        X 
Urine pregnancy test   X       
ECG  X X      X 
Randomization to Study 
Medication/Enrollment ID 
Assignment  X as soon 
as subject 
approved 
by PI and 
EMC         
Distribute Dosing Instruction 
Cards and emergency contact 
cards   X       
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 100 of 131 
 
 Visit Number  1 2 3 ****  4 5 6 7 
Visit Type  Screening  
 Baseline   
 End of 
Week     
3  
 End of 
Week     
4  
 End 
of 
Wee
k 5 
 End of 
Week 8 
 End 
of 
Wee
k 12  
 End of 
Week 
14  
 
Time  -28 days to 
day 0 ** Day 1  21 ±2 
days  28±2 
days  35 ±2 
days  56 ±2 
days  84 ±2 
days  98 ±2 
days  
Dispense Study Drug   X       
Phone call for evaluation of 
Pramipexole ER (or placebo) 
dose    X****      
Vital 
Signs/ Height/ Weight *****  X X   X X X X 
On-site e valuation of 
Pramipexole ER (or placebo) 
dose   X  X    
Concomitant Medication 
Review  X X X X X X X X 
Adverse Event Review  X X X X X X X X 
UPDRS Part III  X X   X X X  
UPDRS Part II   X   X X X  
Columbia Suicide Severity 
Rating Scale (CSSRS)  X X X  X X X X 
QUIP -RS  X X  X X X X 
PDQ -39  X     X  
Epworth Sleepiness Scale 
(ESS)   X   X X X  
Clinical Global Impression - 
severity  (CGI -S)  X     X  
Clinical Global Impression - 
improvement  (CGI -I)     X X X  
 HRQOL SF -12v2  X     X  
 OHSA question 1 ******   X   X X X  
Drug Accountability/ 
Compliance      X X X X 
Collect study drug kit from 
previous month      X X X X 
Trial Completion         X 
 
* Lab tests for renal/hepatic function s for subjects with mild renal and or mild hepatic impairment will be 
performed at visits 4 and 5. 
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 101 of 131 
 
 ** The maximal interval between the screening and baseline visits can be extended to 35 days,  however, 
additional Sponsor approval will be required. 35 – 90 days may  be approved but a new collection  of screening 
laboratory samples will be required  to verify eligibility  prior to baseline . 
*** Coagulation will also be performed at screening to determine eligibility  and at visits 4 and 5 for subjects 
with mild hepatic impairment . 
****  An unscheduled on-site visit may be conducted per  PI’s or sub-Investigator ’s decision  to evaluate the new 
dose and consider the need for further dose increase . 
*****height will be measured only at screening  
****** OHSA question 1 will be completed only by subjects experienc ing orthostatic hypotension   
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 102 of 131 
 
 22.2 Appendix  II: Laboratory Tests  
- Hematology  (will be performed on screening visit , and visit 7 safety follow up visit ):  
White Cell and Differential Count, Red Cell Count, Hemoglobin, Hematocrit, Mean Cell 
Volume, Mean Cell Hemoglobin, Mean Cell Hemoglobin Concentration and Platelet 
Count.  
- Clinical Chemistry  (will be performed on screening and visit 7 safety follow up visit ): 
Sodium  
Potass ium 
Chloride  
Glucose  
BUN  
Creatinine  
Calcium  
Phosphate  
Bilirubin  
Alkaline Phosphatase  
Gamma glutamyl transpeptidase (Gamma GT)  
Aspartate transaminase (SGOT; AST)  
Alanine transaminase (SGPT; ALT)  
Total protein  
Albumin  
Cholesterol  
- Urinalysis (will be perform ed on screening , and safety follow up visit):  pH, Protein, 
Glucose, Ketones, Urine microscopic: White Blood Cell Count, Red Blood Cell Count, 
Casts . 
- Coagulation  (will be performed at screening to determine eligibility  and at visits 4 and 5 
for subjects wit h mild hepatic  impairment  to determine compliance with exclusion 
criteria ): PT/INR – prothrombin time and ratio  as well as aPTT.  
 
Additional r enal / hepatic function s tests will be performed at visit s 4 and 5  for subjects with 
mild renal and or mild hepatic impairment, respectively.  
  
Serum  pregnancy test at  screening  and  safety visit  . Urine pregnancy test at baseline visit.   
(Minimum  sensitivity 25 IU/L or equivalent units of β -HCG) . 
  
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 103 of 131 
 
 22.3 Appendix II I: The Ep worth Sleepiness Scale (ESS)  
 
How likely are you to doze off or fall asleep in the situations described below, in contrast to 
feeling just tired?  
This refers to your usual way of life in recent times.  
Even if you haven't done some of these things recently try to work out how they would have 
affected you.  
Use the following scale to choose the most appropriate number for each situation: - 
 
0 = would never doze  
1 = Slight chance of dozing  
2 = Moderate chance of dozing  
3 = High chance of dozing  
 
Situation Chance of dozing  
Sitting and reading . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
Watching TV . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
Sitting, inactive in a public place (e.g. a theatre or a meeting) . . . . . . .  
As a passenger in a car for an hour without a break . . . . . . . . . . . . . . .  
Lying down to rest in the afternoon when circumstances permit . . . . .  
Sitting and talking to  someone . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
Sitting quietly after a lunch without alcohol . . . . . . . . . . . . . . . . . . . . . .  
In a car, while stopped for a few minutes in the traffic . . . . . . . . . . .  . . 
 
 
 
 
 
 
 
  
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 104 of 131 
 
  
22.4 Appendix IV: Clinical Global Impression - Severity  
The Clinical Global Impression – Severity scale (CGI -S) is a 7 -point scale that requires the 
clinician to rate the severity of the patient’s illness (Parkinson’s Disease) at the time of 
assessment relative to the clinician’s past experience with patients w ho have the same diagnosis 
as one of the following:  
 
0 = not assessed  
1 = normal;  
2 = borderline ill  
3 = mildly ill  
4 = moderately ill  
5 = markedly ill  
6 = severely ill  
7 = among the most extremely ill patients  
  
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 105 of 131 
 
 22.5 Appendix V : OHAS  question 1  (Kaufmann H, 2012)  
 
Question 1 :  “Dizziness, lightheadedness, feeling faint or feeling as though you might pass out" ” 
 
Please circle the number on the scale (where 0 = None and 10 = Worst Possible) that best rates 
how severe y our symptoms from low blood pressure have been on average over the past week . 
If you have  not experienced the symptom, circle zer o (0). PLEASE RATE THE SYMPTOMS 
THAT ARE DUE  ONLY TO YOUR LOW BLOOD PRESSURE PROBLEM.  
 
 
  
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 106 of 131 
 
 22.6 Appendix V I: Questionnaire for Impuls ive-Compulsive Disorders in 
Park inson’s disease rating Scale (QUIP -RS) 
Questionnaire for Impulsive -Compulsive Disorders in Parkinson’s Disease  (QUIP -RS version).  
The questionnaire  should be completed according to the past 4 weeks.  
 
 1. How much do you think about the following behaviors (such as having trouble keeping thoughts out of 
your mind or feeling guilty)?  
Gambling? ___Never(0) ___Rarely(1) ___Sometimes(2) ___Often(3) ___Very often(4)  
Sex? ___Never(0) ___Rarely(1) ___Sometime s(2) ___Often(3) ___Very often(4)  
Buying? ___Never(0) ___Rarely(1) ___Sometimes(2) ___Often(3) ___Very often(4)  
Eating? ___Never(0) ___Rarely(1) ___Sometimes(2) ___Often(3) ___Very often(4)  
Performing tasks or hobbies? ___Never(0) ___Rarely(1) ___Someti mes(2) ___Often(3) ___Very often(4)  
Repeating simple activities? ___Never(0) ___Rarely(1) ___Sometimes(2) ___Often(3) ___Very often(4)  
Taking your PD medications? ___Never(0) ___Rarely(1) ___Sometimes(2) ___Often(3) ___Very 
often(4)  
2. Do you have urges  or desires for the following behaviors that you feel are excessive or cause you 
distress (including becoming restless or irritable when unable to participate in them)?  
Gambling? ___Never(0) ___Rarely(1) ___Sometimes(2) ___Often(3) ___Very often(4)  
Sex? ___Never(0) ___Rarely(1) ___Sometimes(2) ___Often(3) ___Very often(4)  
Buying? ___Never(0) ___Rarely(1) ___Sometimes(2) ___Often(3) ___Very often(4)  
Eating? ___Never(0) ___Rarely(1) ___Sometimes(2) ___Often(3) ___Very often(4)  
Performing tasks or hobbies ? ___Never(0) ___Rarely(1) ___Sometimes(2) ___Often(3) ___Very often(4)  
Repeating simple activities? ___Never(0) ___Rarely(1) ___Sometimes(2) ___Often(3) ___Very often(4)  
Taking your PD medications? ___Never(0) ___Rarely(1) ___Sometimes(2) ___Often(3) __ _Very 
often(4)  
3. Do you have difficulty controlling the following behaviors (such as increasing them over time, or 
having trouble cutting down or stopping them)?  
Gambling? ___Never(0) ___Rarely(1) ___Sometimes(2) ___Often(3) ___Very often(4)  
Sex? ___Ne ver(0) ___Rarely(1) ___Sometimes(2) ___Often(3) ___Very often(4)  
Buying? ___Never(0) ___Rarely(1) ___Sometimes(2) ___Often(3) ___Very often(4)  
Eating? ___Never(0) ___Rarely(1) ___Sometimes(2) ___Often(3) ___Very often(4)  
Performing tasks or hobbies? ___ Never(0) ___Rarely(1) ___Sometimes(2) ___Often(3) ___Very often(4)  
Repeating simple activities? ___Never(0) ___Rarely(1) ___Sometimes(2) ___Often(3) ___Very often(4)  
Taking your PD medications? ___Never(0) ___Rarely(1) ___Sometimes(2) ___Often(3) ___Very  
often(4)  
4. Do you engage in activities specifically to continue the following behaviors (such as hiding what you 
are doing, lying, hoarding things, borrowing from others, accumulating debt, stealing, or being involved 
in illegal acts)?  
Gambling? ___Nev er(0) ___Rarely(1) ___Sometimes(2) ___Often(3) ___Very often(4)  
Sex? ___Never(0) ___Rarely(1) ___Sometimes(2) ___Often(3) ___Very often(4)  
Buying? ___Never(0) ___Rarely(1) ___Sometimes(2) ___Often(3) ___Very often(4)  
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 107 of 131 
 
 Eating? ___Never(0) ___Rarely(1) ___Sometimes(2) ___Often(3) ___Very often(4)  
Performing tasks or hobbies? ___Never(0) ___Rarely(1) ___Sometimes(2) ___Often(3) ___Very often(4)  
Repeating simple activities? ___Never(0) ___Rarely(1) ___Sometimes(2) ___Ofte n(3) ___Very often(4)  
Taking your PD medications? ___Never(0) ___Rarely(1) ___Sometimes(2) ___Often(3) ___Very 
often(4)  
 
  
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 108 of 131 
 
 22.7 Appendix VII: Health -Related Quality of Life (HRQOL) SF -12v2 
 
 
 
 

Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 109 of 131 
 
  

Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 110 of 131 
 
   

Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 111 of 131 
 
 22.8 Appendix VIII : Columbia Suicide Severity Rating Scale (CSSRS ) 
 
 

Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 112 of 131 
 
  
 

Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 113 of 131 
 
  
 
 

Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 114 of 131 
 
  
 
  

Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 115 of 131 
 
  
22.9 Appendix IX: UPDRS   (Fahn S, 1987)  
The Unified Parkinson's Disease Rating Scale  (UPDRS)  is divided into five parts. In this study 
only parts II and III will be performed and their scores will be summarize (maximum sum of 
160) .  Part II , Activities  of Daily Living (ADL)  (for both "on" and "off")  (questions 5 -17) is also 
historical information.  Part III (questions 18 -31) is done as a motor examination at the time of a 
visit as defined in this protocol.   
The various items to be rated are score d using a 5 -point system (i.e., 0 is normal and 4 indicates 
a severe abnormality).  
       
 
Part II: Activities of Daily Living (Sc ore 0 -4) 
 5)   Speech  
     0 - Normal  
     1 - Mildly affected.  No difficulty being understood.  
     2 - Moderately affected.  Sometimes asked to repeat statements.  
     3 - Severely affected.  Frequently asked to repeat statements.  
     4 - Unintelligibl e most of the time  
 
6)   Salivation  
     0 - Normal  
     1 - Slight but definite excess of saliva in mouth; may have nighttime  drooling  
     2 - Moderately excessive of saliva; may have minimal drooling  
     3 - Marked excess of saliva with some drooling  
     4 - Marked drooling, requires constant tissue or handkerchief  
 
7)   Swallowing  
     0 - Normal  
     1 - Rare choking  
     2 - Occasional choking  
     3 - Requires soft food  
     4 - Requires nasogastric tube or gastrotomy feeding  
 
8)   Handwriting  
     0 - Normal  
     1 - Slightly slow or small  
     2 - Moderately slow or small; all words are legible  
     3 - Severely affected; not all words are legible  
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 116 of 131 
 
      4 - The majority of words are not legible  
 
9)   Cutting Food, Handling Utensils  
     0 - Normal  
     1 - Somewhat slow, but no help needed  
     2 - Can cut most foods, although clumsy and slow; some help needed  
     3 - Food must be cut by someone, but can still feed slowl y 
     4 - Needs to be fed  
 
10)  Dressing  
0 - Normal  
1 - Somewhat slow, but no help needed  
2 - Occasional assistance with buttoning, getting arms in sleeves  
3 - Considerable help required, but can do some things alone  
4 – Helpless  
 
11)  Hygiene  
0 - Normal  
1 - Somewhat slow, but no help needed  
2 - Needs help to shower or bathe, or very slow in hygienic care  
3 - Requires assistance for washing, brushing teeth, combing hair, going  to bathroom  
4 - Foley catheter or other mechanical aids  
 
12)  Turning In Bed And Adjusting Bed Clothes  
 0 - Normal  
 1 - Somewhat slow and clumsy, but no help needed  
 2 - Can turn alone or adjust sheets, but with great difficulty  
 3 - Can initiate, but not turn or adjust sheets alone  
 4 – Helpless  
 
13) F alling  (Unrelated To Freezing ) 
0 - None  
1 - Rare falling  
2 - Occasionally falls, less than once per day  
3 - Falls an average of once daily  
4 - Falls more than once daily  
 
14) Freezing When Walking  
0 - None  
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 117 of 131 
 
 1 - Rare freezing when walking; may have start -hesitation        
2 - Occasional  freezing when walking  
3 - Frequent freezing.  Occasionally falls from freezing  
4 - Frequent falls from freezing  
 
15)  Walking  
  0 - Normal  
  1 -Mild difficulty.  May not swing arms or may tend to drag leg  
  2 - Moderate difficulty, but requires little or  no assistance  
  3 - Severe disturbance of walking, requiring assistance  
  4 - Cannot walk at all, even with assistance  
 
16)  Tremor  
   0 - Absent  
   1 - Slight and infrequently present  
   2 - Moderate; bothersome to patient  
   3 - Severe; interferes with many activities  
   4 - Marked; interferes with most activities.  
 
17)  Sensory Complaints Related To Parkinsonism  
  0 - None  
  1 - Occasionally has numbness, tingling or mild aching  
  2 - Frequently has numbness, tingling or aching; not distressing  
  3 - Frequent painful sensations  
  4 - Excruciating pain  
 
PART III: Motor Examination (score 0 -4) 
18)  Speech  
   0 - Normal  
   1 - Slight loss of expression, diction and/or volume  
   2 - Monoto ne, slurred but understandable; moderately impaired  
   3 - Marked impairment, difficult to understand -  
   4 – Unintelligible  
 
19)  Facial Expression  
     0 - Normal  
     1 - Minimal hypomania, could be normal “Poker Face”  
     2 - Slight but definitely a bnormal diminution of facial expression  
     3 - Moderate hypomania; lips parted some of the time  
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 118 of 131 
 
      4 - Masked or fixed faces with severe or complete loss of facial expression ; lips parted 1/4     
inch or more  
 
20)  Tremor at Rest  
Face, lips and chin 
     0 - Absent  
     1 - Slight and infrequently present  
     2 - Mild in amplitude and persistent; or moderate in amplitude, but only intermittently  
present  
     3 - Moderate in amplitude and present most of the time  
     4 - Marked in amplitude and  present most of the time  
 
Right hand  
     0 - Absent  
     1 - Slight and infrequently present  
     2 - Mild in amplitude and persistent; or moderate in amplitude, but only intermittently  
present  
     3 - Moderate in amplitude and present most of the time  
     4 - Marked in amplitude and present most of the time  
 
Left hand  
     0 - Absent  
     1 - Slight and infrequently present  
     2 - Mild in amplitude and persistent; or moderate in amplitude, but only intermittently  
present  
     3 - Moderate in amplit ude and present most of the time  
     4 - Marked in amplitude and present most of the time  
 
Right foot  
     0 - Absent  
     1 - Slight and infrequently present  
     2 - Mild in amplitude and persistent; or moderate in amplitude, but only intermittently  
present  
     3 - Moderate in amplitude and present most of the time  
     4 - Marked in amplitude and present most of the time  
 
Left foot  
     0 - Absent  
     1 - Slight and infrequently present  
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 119 of 131 
 
      2 - Mild in amplitude and persistent; or moderate in amplitude, but only intermittently  
present  
     3 - Moderate in amplitude and present most of the time  
     4 - Marked in amplitude and pres ent most of the time  
 
21)  Action or Postural Tremor Of Hands  
Right  
     0 - Absent  
     1 - Slight; present with action  
     2 - Moderate in amplitude, present with action  
     3 - Moderate in amplitude with posture holding as well as action  
     4 - Mark ed in amplitude; interfere with feeding  
Left 
     0 - Absent  
     1 - Slight; present with action  
     2 - Moderate in amplitude, present with action  
     3 - Moderate in amplitude with posture holding as well as action  
     4 - Marked in amplitude; interf ere with feeding  
 
22) RIGIDITY (Judged on Passive Movement of Major Joints with Subject Relaxed In  
   sitting position. Cogwheeling to be ignored)  
    Neck   
      0 - Absent  
      1 - Slight or detectable only when activated by mirror or other movements  
      2 - Mild or moderate  
      3 - Marked, but full range of motion easily achieved  
      4 - Severe, range of motion achieved with difficulty    
     Right Upper Extremities  
      0 - Absent  
      1 - Slight or detectable only when activated by mirror or other movements  
      2 - Mild or moderate  
      3 - Marked, but full range of motion easily achieved  
      4 - Severe, range of motion achieved with difficulty    
 
      Left Upper Extremities  
      0 - Absent  
      1 - Slight or detectable only  when activated by mirror or other movements  
      2 - Mild or moderate  
      3 - Marked, but full range of motion easily achieved  
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 120 of 131 
 
       4 - Severe, range of motion achieved with difficulty    
 
    Right Lower Extremities  
      0 - Absent  
      1 - Slight or detectable only when activated by mirror or other movements  
      2 - Mild or moderate  
      3 - Marked, but full range of motion easily achieved  
      4 - Severe, range of motion achieved with difficulty    
 
    Left Lower Extremities  
      0 - Absent  
      1 - Slight or detectable only when activated by mirror or other movements  
      2 - Mild or moderate  
      3 - Marked, but full range of motion easily achieved  
      4 - Severe, range of motion achieved with difficulty    
 
23) Finger Taps (Subject ta ps thumb with index finger in rapid succession  
with widest amplitude possible, each hand separately)  
Right hand  
0 - Normal  15/5 sec)  
1 - Mild slowing and/or reduction in amplitude (11 -14.5 sec)  
2 - Moderately impaired.  Definite and early fatiguing. May have occasional arrests in movement 
(7-10/5 sec)  
3 - Severely impaired. Frequent hesitation in initiating movements or arrests in ongoing 
movement (3 -6/5 sec)  
4 - Can barely perform the task (0 -2/5 sec)  
 
Left hand  
0 - Normal  15/5 sec)  
1 - Mild slowing and/or reduction in amplitude (11 -14.5 sec)  
2 - Moderately impaired.  Definite and early fatiguing. May have occasional arrests in movement 
(7-10/5 sec)  
3 - Severely impaired. Frequent hesitation in initiating movements or arrests in ongoing 
movement (3 -6/5 sec)  
4 - Can barely perform the task (0 -2/5 sec)  
 
24)  Hand Movement (Subject opens and closes hands in rapid succession with widest amplitude   
possible, each hand separately)  
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 121 of 131 
 
 Right  
     0 - Normal  
     1 - Mild slowing and/or reduction in amplitude  
     2 - Moderately impaired. Definite and early fatiguing.  May have occasional arrests in 
movements  
     3 - Severely impaired. Frequent hesitation in initiating movements or arrests in ongoing 
movement  
     4 - Can barely perform the task  
 
Left 
     0 - Normal  
     1 - Mild slowing and/or reduction in amplitude  
     2 - Moderately impaired. Definite and early fatiguing.  May have occasional arrests in 
movements  
     3 - Severely impaired. Frequent hesitation in initiating movements or arrests i n ongoing 
movement  
     4 - Can barely perform the task  
 
25)  Rapid Alternating Movements Of Hands (Pronation, supination  movements of hands, 
vertically or horizontally with as large an amplitude as possible, both hands simultaneously)  
 Right  
     0 - Normal  
     1 - Mild slowing and/or reduction in amplitude  
     2 - Moderately impaired.  Definite and early fatiguing. May have occasional arrests in 
movement  
     3 - Severely impaired. Frequent hesitation in initiating movements or arrests in ongoing 
movement  
     4 - Can barely perform the task  
Left 
     0 - Normal  
     1 - Mild slowing and/or reduction in amplitude  
     2 - Moderately impaired.  Definite and early fatiguing. May have occasional arrests in 
movement  
     3 - Severely impaired. Frequent h esitation in initiating movements or arrests in ongoing 
movement  
     4 - Can barely perform the task  
 
26)  Leg Agility (Subject taps heel on ground in rapid succession, picking up entire  
  leg. Amplitude should be about 3 inches)  
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 122 of 131 
 
 Right       
     0 - Norm al 
     1 - Mild slowing and/or reduction in amplitude  
     2  - Moderately   impaired. Definite and early fatiguing. May have occasional arrest in 
movement  
     3 - Severely impaired. Frequent hesitation in initiating movements or arrests in ongoing 
movem ent 
     4 - Can barely perform the task  
Left 
     0 - Normal  
     1 - Mild slowing and/or reduction in amplitude  
     2  - Moderately   impaired. Definite and early fatiguing. May have occasional arrest in 
movement  
     3 - Severely impaired. Frequent hes itation in initiating movements or arrests in ongoing 
movement  
     4 - Can barely perform the task  
 
27)  Arising From Chair (Subject attempts to arise from a straight -back wood or metal chair with 
arms folded across chest)  
     0 - Normal  
     1 - Slow, or may need more than one attempt  
     2 - Pushes self up from arms of seat  
     3 - Tends to fall back and may have to try more than one time, but can get up without help  
     4 - Unable to arise without help  
 
28)  Posture  
     0 - Normal e rect 
     1 - Not quite erect, slightly stooped posture; could be normal for older person  
     2 - Moderately stooped posture, definitely abnormal, can be slightly leaning  
      to one side  
     3 - Severely stooped posture with kyphosis; can be moderatel y leaning to one side  
     4 - Marked flexion with extreme abnormality of posture  
 
29)  Gait  
     0 - Normal  
     1 - Walks slowly, may shuffle with short steps, but no festination or propulsion  
     2 - Walks with difficulty, but requires little or no ass istance; may have some festination, short 
steps, or propulsion  
     3 - Severe disturbance, of gait requiring assistance  
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 123 of 131 
 
      4 - Cannot walk at all, even with assistance  
 
30)  Postural Stability (Response to sudden posterior displacement  
     0 - Normal  
     1 - Retropulsion, but recovers unaided  
     2 - Absence of postural response; would fall if not caught by examiner  
     3 - Very unstable, tends to lose balance spontaneously  
     4 - Unable to stand without assistance  
 
31)  Body Bradykinesia And Hypo kinesIA (Combining slowness, hesitancy, decreased arm 
swing, small amplitudes and poverty of movement in general)  
     0 - None  
     1 - Minimal slowness, giving movement a deliberate character; co uld be normal for some 
person. Possibly reduced amplitude.  
     2 - Mild degree of slowness and poverty of movement which is definitely abnormal.  
Alternatively, some reduced amplitude.  
     3 - Moderate slowness, poverty or small amplitude of movement  
     4 - Marked slowness, poverty or small amplitude of movement  
 
 
  
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 124 of 131 
 
 22.10  Appendix X: Quality of Life - PDQ39  
Please tick one box for each question.  
Due to having Parkinson’s disease, how often (never, occasionally, sometimes, often, always) 
during the last month have you:  
1. Had difficulty doing the leisure activities which you would like to do?  
2. Had difficulty looking after your home, e.g. DIY, ho use work, cooking?  
3. Had difficulty carrying bags of shopping?  
4. Had problems walking half a mile?  
5. Had problems walking 100yards?  
6. Had problems getting around the house as easily as you would like?  
7. Had difficulty getting around in public?  
8. Need ed someone else to accompany you when you went out?  
9. Felt frightened or worried about falling over in public?  
10. Been confined to the house more than you would like?  
11. Had difficulty washing yourself?  
12. Had difficulty dressing yourself?  
13. Had prob lems doing up your shoe laces?  
14. Had problems writing clearly?  
15. Had difficulty cutting up your food?  
16. Had difficulty holding a drink without spilling it?  
17. Felt depressed?  
18. Felt isolated and lonely?  
19. Felt weepy or tearful?  
20. Felt angry or bitter?  
21. Felt anxious?  
22. Felt worried about your future?  
23. Felt you had to conceal your Parkinson's from people?  
24. Avoided situations which involve eating or drinking in public?  
25. Felt embarrassed in public due to having Parkinson's dis ease?  
26. Felt worried by other people's reaction to you?  
27. Had problems with your close personal relationships?  
28. Lacked support in the ways you need from your spouse or partner? (If you do not have a 
spouse or partner please mention)  
29. Lacked suppo rt in the ways you need from your family or close friends?  
30. Unexpectedly fallen asleep during the day?  
31. Had problems with your concentration, e.g. when reading or watching TV?  
32. Felt your memory was bad?  
33. Had distressing dreams or hallucinations ? 
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 125 of 131 
 
 34. Had difficulty with your speech?  
35. Felt unable to communicate with people properly?  
36. Felt ignored by people?  
37. Had painful muscle cramps or spasms?  
38. Had aches and pains in your joints or body?  
39. Felt unpleasantly hot or cold?  
 
  
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 126 of 131 
 
 22.11  Appendix XI : UK Parkinson's Disease Society Brain Bank Clinical 
Diagnostic Criteria  (Hughes AJ, 1992)  
Step 1:  Diagnosis of Parkinsonian Syndrome  
•  Bradykinesia  
•  At least one of the following  
Muscular rigidity  
4-6 Hz rest tremor  
postural instability not caused by primary visual, vestibular, cerebellar, or proprioceptive dysfunction  
Step 2:  Exclude other cause of Parkinson's  
•  history of repeated strokes with stepwise progression of parkinsonian features  
•  history of repeated head injury  
•  history of definite encephalitis  
•  oculogyric crises  
•  neuroleptic treatment at onset of symptoms  
•  more than one affected relat ive  
•  sustained remission  
•  strictly unilateral features after 3 years  
•  supranuclear gaze palsy  
•  cerebellar signs  
•  early severe autonomic involvement  
•  early severe dementia with disturbances of memory, language, and praxis  
•  Babinski sign   
•  presence of cerebral tumor or communication hydrocephalus on imaging study  
•  negative response to large doses of levodopa in absence of malabsorption  
•  MPTP exposure  
Step 3:   Supportive prospective positive criteria for Parkinson’s disease  
Three  or more required for diagnosis of definite Parkinson’s diseas e in combination with step one  
•  Unilateral onset  
•  Rest tremor present  
•  Progressive disorder  
•  Persistent asymmetry affecting side of onset most  
•  Excellent response (70 -100%) to levodopa  
•  Severe levodopa -induced chorea  
•  Levodopa response for 5 years or more  
•  Clinical course of ten years or more  
*From: Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic  
Parkinson’s disease. A clinico -pathological study of 100 cases. JNNP 1992;55:181 -184. 
22.12  Appendix XII: Modified Hoehn & Yahr scale  
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 127 of 131 
 
 The H&Y  scale is a commonly used system for describing how the symptoms o f Parkinson's 
disease  progress. It was originally published in 1967 in the journal Neurology by Melvin Yahr 
and Margaret Hoehn. Th e original scale included stages 1 through 5. Since then, stage 0 has been 
added, and stages 1.5 and 2.5 have been proposed. This modified scale allocates stages from 0 to 
5 to indicate the relative level of disability.  
Stage 0: No signs of disease.  
Stage 1: Unilateral symptoms only.  
Stage 1.5: Unilateral and axial involvement.  
Stage 2: Bilateral symptoms. No impairment of balance.  
Stage 2.5: Mild bilateral disease with recovery on pull test.  
Stage 3: Balance impairment. Mild to moderate disease. Physically  independent.  
Stage 4: Severe disability, but still able to walk or stand unassisted.  
Stage 5: Needing a wheelchair or bedridden unless assisted.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 128 of 131 
 
 22.13  Appendix XI II: Mini -Mental State Examination (MMSE)  
Instructions: Score one point for each correct response within each question or activity.  
Questions  
Orientation to Time  
1. “What is the year?  Season?  Date?  Day?  Month?” 5 points  
Orientation to Place  
2.  “Where are we now?  State?  County?  Town/city?  Hospital?  Floor?” 5 points  
Registration  
3. Name 3 common objects (APPLE, TABLE and PENNY): Take 1 second to say each. Then 
ask the patient to repeat them after you have said them. Give 1 point for each correct answer. 
Then repeat them until he/she learns  all three . 3 points  
Attention and Calculation  
4. “Spell WORLD backwards.” (D -L-R-O-W) 5 points.  
Recall  
5.“Earlier I told you the names of three things.  Can you tell me what those were?” 3 points  
Naming  
6. Show the patient two simple objects, such as a wr ist watch and a pencil, and ask the patient to 
name them. 2 point.  
Repetition  
7. “Repeat the phrase: ‘No ifs, ands, or buts.’” 1 point  
Comprehension  
8. “Take the paper in your right hand, fold it in half, and put it on the floor.” (The examiner gives 
the p atient a piece of blank paper)  3 points  
Reading  
9. “Please read this and do what it says.” (Written instruction is “Close your eyes.”) 1 point.  
Writing  
10. “Make up and write a sentence about anything.” (This sentence must contain a noun and a 
verb.) 1 point.  
Copying  
11. “Please copy this picture.”  (The examiner gives the patient a blank piece of paper and asks 
him/her to draw the symbol below.  All 10 angles must be present and two must intersect.) 1 
point.  
30 points  total.  
Sources:   
• Folstein MF, F olstein SE, McHugh PR. "Mini -mental state": a practical method for grading the 
cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189 -198.  
  
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 129 of 131 
 
 22.14  Appendix X IV: Clinical Global Impression - Improvement  
 
The C linical Global Impression =impro vement (CGI -I) is a 7-point scale that requires the 
clinician to compares the patient's overall clinical condition after medication has been initiated to 
the one week period just prior to the initiation of medication use (baseline visit ) as one of the 
following : 
  
1=very much improved sin ce the initiation of treatment  
2=much improved   
3=minimally improved  
4=no change from baselin e (the initiation of treatment)   
5=minimally worse   
6= much worse   
7=very much worse si nce the initiation of treatment  
  
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 130 of 131 
 
 23 REFERENCE S 
 
Aronow WS, . (2011). Hypertension in the Elderly. JACC  , 57, 2037 –2114.  
Du F, L. R. (2005). Dopamine D3 receptor -preferring agonists induce neurotrophic effects on 
mesencephalic dopamine neurons. . Eur J Neurosci  , 22 (10), 2422 -2430.  
Fahn S, E. R. (1987). Uniﬁed Parkinson’s Disease Rating Scale. (M. C. Fahn S, Ed.) Recent 
Developments in Parkinson’s Disease,: Macmillan Healthcare Inf ormation;  , 2, 153 -163, 293 -
304. 
Hauser RA, S. A. (2010). Randomized, Double -Blind, Multicenter Evaluation of Pramipexole 
Extended Release Once Daily in Early Parkinson’s Disease . Movement Disorders  , 25 (15), 
2542 –2549.  
Hubble JP, K. W. (1995). Pramip exole in patients with early parkinson’s disease. Clin 
Neuropharmacol.  , 18, 338 -347. 
Hughes AJ, D. S. (1992). Accuracy of clinical diagnosis of idiopathic Parkinson’s disease. A 
clinico -pathological study of 100 cases. JNNP  , 55, 181 -184. 
Imamura K, T.  T. (2008). Pramipexole has astrocyte -mediated neuroprotective effects against 
lactacystin toxicity. Neurosci Lett.  , 440  (2), 97 -102. 
Kaufmann H, M. R. -K. (2012). The Orthostatic Hypotension Questionnaire (OHQ): validation of 
a novel symptom assessment sc ale. Clin Auton Res.  , 22 (2), 79 -90. 
Label, A. (2010).  Azilect Label .  Available at: 
http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021641s002s003s004s005s007s008s
010lbl.pdf  . 
Lecht S, H. S. (2007). Rasagiline – anovel MAO B inhibitor in  parkinson’s disease therapy. . 
Therapeutics and clinical risk management  , 3 (3), 467 -474. 
 Lucey MR, B. K. (1997). Minimal criteria for placement of adults on the liver transplant waiting 
list: a report of a national conference organized by the American Society of Transplant 
Physicians and the American Association for the Study of Liver Diseases. Liver Transpl Surg. , 3  
(6), 6 28-637. 
Li C, G. Y. (2010). Neuroprotection of pramipexole in UPS impairment induced animal model 
of Parkinson's disease. Neurochem Res.  , 35 (10), 1546 -1556.  
Mirapex ER Label. (2010). Mirapex ER Label,. Available at: 
http://www.accessdata.fda.gov/drugsa tfda_docs/label/2010/022421lbl.pdf.   
Olanow CW, Kieburtz K, Leinonen M, Elmer L, Giladi N, Hauser RA, Klepiskaya OS, 
Kreitzman DL, Lew MF, Russell DS, Kadosh S, Litman P, Friedman H, Linvah N,  (2017). A 
randomized trial of a low -dose Rasagiline and Pramipe xole combination (P2B001) in early 
Parkinson's disease. Mov Disord.  , 32 (5), 783 -789. 
Olanow CW, M. F. (2013). Factors Predictive of the Development of Levodopa -Induced. 
Movement Disorders  , 28, 1064 -1071.  
Protocol P2B001/00 3                                                                                                                     CONFIDENTIAL  
Version 3.0   18, November , 2020 
  NCT Number : [STUDY_ID_REMOVED]  
Page 131 of 131 
 
 Olanow W, S. a. (2009). The scientific and clinic al basis for the treatment of Parkinson disease. 
Neurology  , 26;72(21 Suppl 4):S1 -136. 
Perez -Lloret S, R. O. (2010). Dopamine receptor agonists for the treatment of early or advanced 
Parkinson's disease. CNS Drugs  , 24 (11), 941 -968. 
PSG, P. S. (1997). Saf ety and efficacy of pramipexole in early Parkinson disease. J Am Med 
Assoc.  , 278 , 125 -130. 
Rascol PB, R. A. (2010). Efficacy, Safety, and Tolerability of Overnight Switching from 
Immediate - to Once Daily Extended -Release Pramipexole in Early Parkinson’s  Disease for the 
Pramipexole Switch . Movement Disorder Society  , 25 (14), 2326 –2332.  
Shannon KM, B. J. (1997). Efficacy of pramipexole, a novel dpoamine agonist, as monotherapy 
in mild to moderate parkinson's disease. In Neurology  (pp. 724 -728).  
summary, M. (1997). Summary Basis of Approval NDA 20667. Available at: 
http://www.accessdata.f da.gov/drugsatfda_docs/nda/98/020667.cfm  . 
Thebalut JJ, G. M. (2004). Tolerability, safety, pharmacodynamics, and pharmacokinetics of 
rasagiline: a potent, selective, and irreversible monoamine oxidase type B inhibitor. 
Pharmacotherapy  , 24 (10), 1295 -1305 . 
Wright CE, S. T. (1997). Steady -state pharmacokinetic properties of pramipexole in healthy 
volunteers. J Clin Pharmacol.  , 37 (6), 520 -525. 
Wu Y, K. K. (2015). Rasagiline and selegiline suppress calcium efflux from mitochondria by 
PK11195 -induced opening  of mitochondrial permeability transition pore: a novel anti -apoptotic 
function for neuroprotection. J Neural Transm (Vienna).  , 122  (10), 1339 -1407.  
Youdim MB, G. A. (2001). Rasagiline [N -propargyl -1R(+) -aminoindan], a selective and potent 
inhibitor of mi tochondrial monoamine oxidase B. Br J Pharmacol.  , 132  (2), 500 -506. 
 